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ABSTRACT 
 
 Elucidation of the molecular mechanisms of cancers has enabled the development of molecularly 
targeted chemotherapeutics capable of exploiting cancer-specific cellular alterations. Small-molecule 
activation of procaspase-3 represents a particularly promising opportunity, based upon its determinant 
role in the execution of apoptosis and its widespread over-expression across many diverse cancer types.  
PAC-1 is a small-molecule that facilitates procaspase-3 activation by relieving physiological zinc-
mediated inhibition of auto-proteolytic activation.  Activation of procaspase-3 by PAC-1 was previously 
demonstrated to induce apoptosis in cancer cells and be efficacious in select murine tumor models.  
Described herein is the evaluation of PAC-1 in combination with diverse chemotherapeutics, and 
leveraged for the treatment of challenging cancers.   
 Concurrent external development of a second class of mechanistically-distinct procaspase-3 
activating compounds, enabled a proof-of-concept evaluation of dual targeting of a single protein with 
small-molecule activators.  Synergistic enhancement in protein activity, signaling pathway activation and 
in vivo efficacy were observed. This substantiated the hypothesis that when orthogonal mechanisms of 
protein activation were possible, that dramatic enhancements in biologic effect could be observed, thereby 
establishing a novel strategy for combining molecularly targeted chemotherapeutics. 
 Building upon the success of dual targeting of executioner caspases for enhanced apoptotic effect, 
PAC-1 was investigated as a method to broadly enhance diverse pro-apoptotic signals. Excitingly, 
increased anticancer activity was observed broadly in models of increasing complexity and clinical 
relevance (cancer cell lines, murine tumor models, canine cancer patients). Furthermore, co-
administration of PAC-1 with a highly active, but toxicity-limited chemotherapeutic, was demonstrated to 
be both feasible and active in the treatment of a challenging canine cancer.  
 After demonstrating that PAC-1 was capable of enhancing pro-apoptotic signaling initiated by 
diverse cytotoxic chemotherapeutics, the concept was explored for the treatment of brain cancers. PAC-1 
penetrates the blood-brain barrier, suggesting potential for the treatment of brain cancers.  Capitalizing on 
its ability to enhance pro-apoptotic signaling, PAC-1 was explored both as a single agent, and in 
combination with a DNA alkylating agent clinically used for the treatment of glioblastoma. Both 
strategies demonstrated antitumor activity in vivo, suggesting significant clinical utility.   
 This work builds upon the foundation of research of PAC-1 as a single agent and suggests 
numerous exciting clinical pathways. Combination chemotherapy is critical for the management of many 
cancers, thus demonstration of increased anticancer activity in PAC-1-based combinations, and 
establishment of feasibility, will support its clinical development.   
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Chapter 1. Development of procaspase-3 activation as an anticancer strategy 
 
1.1 Introduction 
1.1.1 Apoptosis: a form of programmed cell death critical to cancer 
Apoptosis was the first recognized mechanism of controlled cellular dismantling and remains the 
best characterized. The process is critical to differentiation, development and maintenance of multicellular 
organisms. In response to internal recognition of irreparable damage or external stimulation, apoptosis is 
engaged to remove unwanted, redundant cells in a non-inflammatory way. Activation of the intrinsic 
apoptotic cascade (shown below, Figure 1.1) triggers a cascade of proteolytic activation of caspase family 
proteins. Cancer cells, in order to resist the significantly higher levels of cellular stress (in the form of 
reactive oxygen species, genomic instability, and metabolic stress, among others)1 they face over normal 
cells, must acquire a set of gain-of-function anti-apoptotic alterations and a diminished capacity for pro-
apoptotic signaling (including mutations, amplification and over-expressions).2,3  
The intrinsic apoptotic cascade is activated in response to cellular recognition of damage, signals 
that can occur in the form of irreparable DNA damage or inhibition of microtubule-dynamics (as shown in 
Figure 1.1), among many other signals.  Recognition is mediated by p53, which upregulates transcription 
of pro-apoptotic Bcl-2 family proteins (such as Bim, shown in Figure 1.1), altering the balance between 
pro-apoptotic and anti-apoptotic Bcl-2 family proteins, enabling translocation of cytosolic Bax to the 
mitochondria for oligomerization with Bak, and mitochondrial outer membrane permeablization.4,5  
Permeabilization triggers release of pro-apoptotic proteins, including cytochrome c, which forms the 
apoptosome with Apaf-1 and activated caspase-9.6,7  The apoptosome is subsequently responsible for the 
cleavage of procaspase-3 to caspase-3.  Proteolytic activation of caspase-3, the key executioner caspase, 
then results in cleavage of >300 cellular proteins and the major morphological changes associated with 
apoptosis.8-10  Given the critical role in recognition of cellular damage and initiation of the apoptotic 
cascade, it is not surprising that mutations in p53 are extremely prevalent across many cancer types.11,12  
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Furthermore, alterations in the pro- and anti-apoptotic balance of the Bcl-2 protein family is a common 
feature of many cancers.13,14   
 
Figure 1.1. Schematic representation of the intrinsic apoptotic cascade. In response to recognition of cellular damage 
or stress, the apoptotic cascade is initiated, leading to activation of procaspase-3 caspase-3. Caspase-3 is the key 
executioner of apoptosis and responsible for the proteolysis of >300 cellular substrates.   
 
As strong anti-apoptotic mechanisms represent a hallmark of cancer cells,2,3 it might seem counter-
intuitive that the first successful mechanisms for clinical treatment of cancers relied upon the activation of 
the intrinsic apoptotic cascade, through the use of cytotoxic chemotherapeutics and radiation.15 However, 
the increased cellular stress of cancer cells, requires tonic expression of anti-apoptotic mechanisms. They 
exist closer to the ‘threshold’ for apoptosis than normal cells, and thus are more sensitive to cytotoxic 
assaults, including DNA damage, thereby enabling a therapeutic window for treatment of cancer cells while 
sparing non-cancerous cells.16,17  As such, cytotoxic chemotherapeutics formed the foundation for the early 
clinical management of cancers and remain highly useful today, as discussed in Chapter 3. However, 
increasing knowledge of the mechanisms of oncogenesis and the biology of cancer progression has enabled 
identification of cancer-specific targets that could enable more effective treatments with lower toxicity to 
normal tissues. Some of these targets aim to exploit the intrinsic pathway of apoptosis.  For example, the 
protein MDM2 binds to p53 with high affinity inhibiting its transcriptional activity and is overexpressed in 
MDM2
cleavage of >300 
cellular proteins
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many cancers.18-20  As such, small-molecules capable of inhibiting this protein-protein interaction are being 
developed to enhance the capacity of p53 to initiate apoptosis in cancer cells.21,22 Similarly, inhibitors of 
the anti-apoptotic Bcl-2 protein are capable of competitively releasing bound pro-apoptotic BH3-ony 
proteins, thereby restoring a pro-apoptotic signal.23,24   
 
1.1.2 Procaspase-3 is highly expressed in cancers and is an exciting molecular target 
Activation of procaspase-3 represents an exciting opportunity for a cancer-selective molecular 
target. As shown in Figure 1.1, the activation of procaspase-3 to caspase-3 is the determinant event leading 
to the execution of apoptosis and cleavage of hundreds of cellular proteins. Furthermore, direct activation 
of procaspase-3 bypasses many of the anti-apoptotic mechanisms known to enable oncogenesis, such as 
over-expression of MDM2, mutation of p53, and over-expression of anti-apoptotic Bcl-2 family proteins. 
Procaspase-3 is highly expressed in a wide variety of cancers, including lymphoma and leukemias,25-28 lung 
cancer,29-31 breast cancer,32-35 melanoma,36,37 colon cancer,38-41 pancreatic cancer,42 liver cancer,43 and 
esophageal cancer.44  Importantly, procaspase-3 is rarely mutated in cancer.45 Combined, these data suggest 
that procaspase-3 activation would be highly selective for and effective against a broad range of cancers. 
 
1.2 Small-molecule activators of procapase-3  
1.2.1 Procaspase-3 activating compound – 1 (PAC-1) 
In order to identify a small-molecule procaspase-3 activator, the Hergenrother lab conducted a high 
throughput screen to discover compounds capable of enhancing the in vitro activity of recombinant 
procaspase-3 against a chromogenic substrate (Scheme shown in Figure 1.2A).46 PAC-1 (Figure 1.2B) was 
shown to enhance the activity of procaspase-3 in vitro (EC50 of 0.22 µM), induce apoptosis in cancer cells 
and be efficacious in three murine models of cancer.46 Follow-up studies47,48 revealed the mechanism of 
action of PAC-1 to be due to the capacity of the ortho-hydroxy-N-acylhydrazone moiety to chelate,49-51 and 
the physiological inhibition of procaspase-3 by the labile zinc pool.52,53  As shown in Figure 1.2C, cellular 
populations of procaspase-3 are inhibited from undergoing auto-proteolysis by co-localization with the 
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labile zinc pool.  This loosely bound zinc is sufficient to suppress the low activity zymogen54,55 and prevent 
auto-activation.52,53 PAC-1, as a modest affinity zinc chelator, is able to relieve this inhibition,47 thereby 
generating a pool of primed procaspase-3 molecules that are capable of auto-activation to caspase-3, 
resulting in apoptosis.46,48,56-60 A putative zinc binding site on procaspase-3 has been identified.61 
 
Figure 1.2.  PAC-1 is a small-molecule activator of procaspase-3. (A) Schematic of the high-throughput screen 
conducted to identify small-molecules capable of enhancing the activity of recombinant procaspase-3. (B) Structure 
of PAC-1. (C) PAC-1 activates procaspase-3 by relieving zinc-mediated inhibition, generating a pool of procaspase-
3 proteins capable of auto-activation to caspase-3.  
 
1.2.2 S-PAC-1, B-PAC-1 and WF-210: development of PAC-1 analogues 
 Early in the in vivo evaluation of PAC-1, it was apparent that it was likely penetrating the blood-
brain barrier, based upon the presentation of a neuro-excitatory phenotype in mice shortly after IP or IV 
administration of high doses of PAC-1.58 This phenotype manifested as seizures, that were reversible and 
non-life limiting, but still represented a significant and undesirable toxicity. This is particularly true for 
cancers not requiring a chemotherapeutic to access the brain. Thus, efforts were made to develop a PAC-1-
like molecule that would not be blood-brain barrier penetrant. The resulting compound, a sulfonamide 
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derivative named S-PAC-1 (Figure 1.3), was found to possess similar activity as PAC-1 against cancer cells 
in culture.58 Importantly, evaluation in mice demonstrated that even doses up to 350 mg/kg could be given 
without neurotoxicity. Recognizing the value of canine patients with naturally occurring cancers as an 
excellent model for the human disease (discussed in Section 1.4.5), S-PAC-1 was then evaluated in a 
clinical trial of pet dogs with naturally occurring lymphomas, utilizing two dosing schemes aimed at 
achieving serum levels of S-PAC-1 similar to what was needed to induce apoptosis in culture.  Importantly, 
treatment with S-PAC-1 was shown to be feasible as no hematologic or non-hematologic toxicity was 
observed in any of the six patients. Excitingly, one of six patients showed a partial response, demonstrating 
a 30% reduction in the tumor size. Three of the patients demonstrated stable disease, while the remaining 
two showed disease progression. 
Figure 1.3. Structure of non blood-brain barrier permeable analogue S-PAC-1. 
 Inspired by the success of PAC-1 derivatization to S-PAC-1, a library of 837 analogues was 
synthesized.56 All compounds were screened for their ability to induce apoptosis in U-937 cells treated with 
20 µM compound for 24 h, conditions for which PAC-1 and S-PAC-1 induced ~50% cell death. From this 
screen, six compounds were identified that were more potent, inducing >80% cell death under these 
conditions.  These hits were validated and shown to possess 72 h IC50 values in U-937 cells that were two 
to four-fold more potent than PAC-1 and S-PAC-1. Furthermore, in a 24 h evaluation by Annexin V-FITC 
and PI staining, these compounds, at 7.5 µM, were able to induce substantially higher levels of apoptosis 
than PAC-1(Figure 1.4).  Excitingly, Varsha Gandhi (MD Anderson) and her lab have pursued one of these 
compounds, 3{18, 7}, as a procaspase-3 activator for the treatment of hematological malignancies, 
including leukemias and myeloma (compound now referred to as “B-PAC-1”).62-65 A discussion of 
enhancing in vitro and cell culture potency through the addition of hydrophobic substituents and increased 
molecular weight will follow in Section 1.3.   
S-PAC-1
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Figure 1.4. Evaluation of apoptosis in U-937 cells treated with 7.5 µM of PAC-1 and lead compounds from 837-
member library for 24 h by Annexin V-FITC/propidium iodide staining and flow cytometry. Adapted from literature 
with permission.56 (ACS Comb Sci 2012,14, 44-50.) 
 
 Efforts to increase the potency of PAC-1 have occurred outside of the Hergenrother lab as well. 
Chanfu Wu and Ping Gong of Shenyang Pharmaceutical University sought to improve upon the activity 
and tolerability by retaining the core ortho-hydroxy-N-acylhydrazone moiety, but greatly increasing the 
overall size of the molecule. They have synthesized two lead analogues, termed WF-21066 and a second 
generation compound, WF-20867 (Structures shown in Figure 1.5). Structure expansion from the PAC-1 
core was driven by a desire to understand how extended aromatic regions and increased molecular size on 
both sides of the molecule would alter potency and tolerability. Excitingly, in studying the activity of WF-
210 and WF-208, Wu, Gong and co-workers tested PAC-1 alongside.  WF-210 and WF-208 displayed 
similar capacities to activate procaspase-3 in vitro, with slightly higher potency than PAC-1, and this 
mechanism was based upon chelation of zinc.  Evaluation against a panel of cancer cell lines demonstrated 
that WF-210 efficiently induced cell death with a mean IC50 of 0.88 µM, WF-208 was slightly less potent 
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with a mean IC50 of 1.66 µM, and PAC-1 was the least potent in this panel, with a mean IC50 of 19.4 µM. 
Importantly, all three agents exhibited limited cytotoxicity to normal cell lines (WF-210: 412 µM, WF-208: 
347 µM, PAC-1: 158 µM).  All three agents were shown to induce apoptosis in HL-60 and U-937 cells, 
with Z-VAD-FMK and Z-DEVD-FMK affording significant protection, indicative of procaspase-3 
activation.   Treatment of HL-60 and U-937 cells with all three agents (separately) and analysis by Western 
blot showed that cleavage of procaspase-3 to caspase-3 occurred prior to cleavage of procaspase-8 or -10. 
WF-210 was evaluated in a panel of four xenograft models, and demonstrated efficacy against Hep-3B liver 
cancer, MDA-MB-435 melanoma, and GBC-SD gallbladder cancer.  PAC-1 was also evaluated and 
demonstrated efficacy, though to a lesser degree than WF-210, in the Hep-3B and MDA-MB-435 models.  
Consistent with a procaspase-3-based mode of action, neither compound was efficacious in an MCF-7 
xenograft model, likely due MCF-7 cells not expressing procaspase-3.  WF-208 was evaluated in a PC-3 
prostate cancer xenograft model and was shown to be efficacious at reducing the rate of tumor growth. 
PAC-1 was evaluated alongside, but did not have a significant effect, likely due to the relatively low dosage 
of 2.5 mg/kg.   
 
Figure 1.5. Chemical structures of (A) WF-21066 and (B) WF-208.67 
 
1.2.3 The 1541 series compounds 
The enthusiasm for executioner caspase activation inspired the identification and development of 
a second class of compounds, the 1541 series (structures in Figure 1.6) by James A. Wells at the University 
of California at San Francisco.68 Like PAC-1, 1541 was identified through a high throughput screen for 
small-molecules capable of enhancing the activity of recombinant procaspase-3. Evaluation of a limited 
series of derivatives yielded a procaspase-3 specific molecule (1541B), and an inactive version (1541D).  
Biochemical evaluation with recombinant protein in a zinc-free reducing buffer systems suggested that 
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1541 and 1541B were capable of enhancing the in vitro activity of procaspase-3 to ~70% of full caspase-3 
activity, following a lag phase of ~1 h. Because caspases are known to be dynamic enzymes, capable of 
sampling both “on state” and “off state” conformations,69-72 the Wells group hypothesized that procaspase-
3 might be capable of similar conformational dynamics, and that 1541/1541B was allosterically stabilizing 
a more active proenzyme conformation. Biochemical experiments demonstrated that treatment with 
1541/1541B enhanced both recombinant enzyme activity as well as granzyme B processing of active site 
mutant (C163A) procaspase-3.  This suggested that 1541/1541B was also capable of stabilizing a 
conformation that was more susceptible to proteolysis.  Follow-up experiments in cells demonstrated that 
treatment with 1541/1541B reduced cell viability within 4-5 h, and increased cellular DEVDase activity 
(executioner caspase activity) with similar timing to staurosporine.   
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Figure 1.6. The 1541 series of small-molecule procaspase-3 activators were identified by James Wells at UCSF. (A) 
Chemical structure of 1541, lead hit from high throughput screen for procaspase-3 activators. (B) Chemical structure 
of 1541B, a procaspase-3 specific activator. (C) Chemical structure of 1541D, an inactive derivative. (D) In a reducing, 
zinc-free buffer system, recombinant procaspase-3 is activated by 1541 following a ~2 h lag period to ~70% of the 
activity of caspase-3.  (E) Proteolysis of active site mutant (C163A) procaspase-3 by granzyme B is enhanced in the 
presence of 1541, but not with inactive derivative 1541D.  (F) 1541 reduces the viability of BT-549 cells with similar 
speed as staurosporine (STS), and faster than etoposide. (G) 1541 increases the executioner caspase activity 
(DEVDase) in BT-549 cells with similar speed as staurosporine (STS), but to a diminished level. Panels D-G were 
taken with permission from the literature:68 (Science 2009, 326, 853-858.) 
 
 Upon subsequent evaluation, however, the Wells group recognized that 1541/1541B aggregated in 
solution, with fibrils forming at higher concentrations.73  Thus, they revised their hypothesis to a mode of 
action based upon the premise that procaspase-3 binding to 1541/1541B fibrils increased the local 
concentration of enzyme, thereby enabling auto-proteolysis (Schematic shown in Figure 1.7A).55,73,74  
Evidence supporting this hypothesis is that procaspase-3 molecules can be “pulled down” with 1541/1541B 
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fibrils following co-incubation and centrifugation in a dose-dependent manner (Figure 1.7B). The Wells 
group demonstrated that 1541/1541B can enter cells through the endocytic pathway as fibrils, traffic to 
lysosomes to activate intracellular procaspase-3.74 One consistent feature of experiments performed on 
1541/1541B, however, is that they either occur in zinc-free reducing buffer systems, or in cells. As zinc is 
known to function as a physiological inhibitor of procaspase-3, it was unclear as to how this inhibition 
would alter the activating capacity of 1541/1541B. Although cell culture-based experiments were 
performed (Figure 1.6F, G), the timing and extent of procaspase-3 activation was diminished in comparison 
to in vitro experiments. However, given the exciting nature of 1541/1541B activation of procaspase-3 
through a mechanism distinct from PAC-1, we were eager to examine how the combination of the two 
agents would affect enzymes, cells and tumor bearing animals (to be described in Chapter 2). 1541/1541B 
also served as an important control compound for study with Raptinal (Chapter 5). 
 
Figure 1.7. A revised hypothesis for the mechanism of action of 1541 series small-molecule procaspase-3 activators 
is based upon their ability to self-assemble spontaneously into fibrils. (A) Schematic representation of proposed 
mechanism of 1541 activation based upon a proximity-induced increased local concentration of procaspase-3. (B) 
Procaspase-3 can be “pulled down” and co-precipitate with 1541 and 1541B, but not inactive derivative 1541D. Panels 
A-B were taken with permission from the literature:55 (J. Am. Chem. Soc. 2011, 133, 19630-19633.)   
 
 
1.3 Cell culture potency does not determine clinical value 
1.3.1 Clinical chemotherapeutics vary widely in their potency against cells in culture 
 The overarching goal of preclinical assessment of candidate drug molecules is the selection of a 
small-molecule that is most likely to be efficacious in human patients. In order to have activity in patients, 
sufficient levels of the drug must reach target sites and remain there for a sufficient duration, without 
causing toxicity and side-effects that prevent efficacious doses from being used. Rational selection of a 
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candidate drug likely to succeed is a major challenge, and only a very small number of compounds have 
ever successfully progressed from discovery to clinical evaluation. Furthermore, because only a limited 
number of compounds undergo clinical evaluation, there exists no systematic way of interrogating what 
preclinical parameters are most important for eventual clinical activity. Moreover, these parameters may 
vary based upon the physiochemical properties of a compound, the protein target and the indication.  
 A major assumption driving much of academic and pharmaceutical industry drug development is 
that a small-molecule possessing high potency in vitro and in cell culture assays has a higher likelihood to 
be efficacious in human patients.75 High compound potency is also believed to enable efficacious treatments 
with low doses of compounds. Low doses, in turn, are believed to be less likely to cause generic off-target 
toxicity or accumulation of reactive metabolites. Unfortunately, these assumptions are not supported by 
analysis of preclinical and clinical data; and in some ways they are inherently false.76-78  
 Evaluation of potency in vitro and in cell culture is typically easy, rapid, high throughput, and 
inexpensive. As such, these assays form the foundation for early candidate identification and are frequently 
employed for analysis of structure-activity relationships of candidates. Unfortunately, prioritization of 
compounds by in vitro and cell culture potency can be misleading as potency is only one of many factors 
that contribute to the clinical efficacy of a drug. High potency in in vitro and in cell culture assays can 
frequently be gained at the expense of physiochemical properties associated with good in vivo 
pharmacokinetics.79-81 Increases in molecular weight and lipophilicity are frequently used to enhance pre-
clinical in vitro and cell culture potency, termed “molecular obesity.”77 Many parameters associated with 
increased in vitro potency are also associated with decreased ADMET properties. In a dataset of 
GlaxoSmithKline small-molecules,82 they observed that 15 different ADMET properties were negatively 
affected with increasing molecular weight and lipophilicity. Additionally, increases in lipophilicity can 
increase the level/time that a drug spends in cellular membranes.77 As cellular membranes are home to 
many critical signaling systems, this can increase off-target toxicity of a compound.  
 Although the above discussion focused on how potency of a compound within a given series or 
against a particular target might drive selection away from a compound more likely to be efficacious in 
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patients, the fixation on compound potency also extends to the potential of novel agents. Analysis of 
literature suggests that cell culture potency of a drug does not translate into patient efficacy or significance 
in the clinical management of cancers.76,78 In a retro-analysis of FDA-approved chemotherapeutics and their 
evaluation in the NCI-60 panel, it was determined that high potency (in the form of compounds effective at 
nanomolar concentrations) bore limited relevance to clinical efficacy.76 Furthermore, most major classes of 
cytotoxic chemotherapeutics lack nanomolar potency in cell culture. Of drugs belonging to the class of 
alkylating and DNA damaging agents, only 3/27 drugs demonstrated GI50 values in the nanomolar range, 
with 18/27 possessing GI50 values > 20 µM. Furthermore, the most potent agent, actinomycin D (GI50 = 1.4 
nM) has limited clinical utility due to high levels of toxicity.83 Antimetabolites also frequently lack 
nanomolar potency against the NCI-60 panel (14/19 drugs), though they possess significant clinical utility.76 
The only classes of anticancer drugs that consistently displayed high potency in cell culture were the tubulin 
disrupting agents and the topoisomerase inhibitors.84  
 The ‘potency’ of a given drug in cell culture, is also highly dependent upon the conditions of the 
assay and the metrics of quantification. NCI-60 screening evaluates cells treated with compounds at five 
concentrations for 48 h, and reports the parameters of GI50 (inhibition of 50% of the growth of untreated 
cells), TGI (total growth inhibition, or no net growth of cells over the course of the experiment), and LC50 
(lethality of 50% of the initial number of cells).76 This single value as a description of overall ‘potency’ is 
an inherently flawed representation of the experiment, as well as the potential of the compound to act in 
vivo. Arguments have been made to expand the metrics used in evaluating chemotherapeutic agents in cell 
culture to include parameters such as Emax, Hill slope, and Area Under the Curve (AUC),85 however, even 
an expanded set of parameters to describe the dose response curve still fails to recapitulate the complexities 
of drug activity in vivo. Similar to NCI-60 screening, most cell culture assays assess the activity after 
treatment with the compound for 1-3 days. As will be described in Chapter 5, cytotoxic chemotherapeutics 
can vary widely in their speed to initiation of apoptosis. Furthermore, clinically relevant cytotoxic 
chemotherapeutics vary in their potency, and this potency can be reflective of the time of exposure. This is 
illustrated in Figure 1.8, with six FDA-approved chemotherapeutics evaluated in U-937 human lymphoma 
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cells (Figure 1.8 A, C) and ES-2 human ovarian cancer cells (Figure 1.8 B, D) after a 24 h (Figure 1.8A, B) 
or a 72 h treatment (Figure 1.8 C, D). For example, vincristine is consistently the most potent (by IC50 
value) across the four experiments, whereas the activity of methotrexate is highly dependent upon length 
of treatment (inactive in a 24 h experiment, but demonstrating the second lowest IC50 value in 72 h 
experiments). Furthermore, the chemotherapeutics tested are consistently less potent in the ES-2 ovarian 
cancer cell line than in the U-937 lymphoma line. Figure 1.8 illustrates that clinically used 
chemotherapeutics will vary in potency (by orders of magnitude) and drugs that are more potent in cell 
culture assays are not necessarily more valuable or useful in the treatment of cancer in the clinic. 
Furthermore, as described above, some classes of chemotherapeutics consistently demonstrate low potency 
in cell culture, but are extremely important to the clinical management of cancer. As such, during preclinical 
development it is imperative to consider factors beyond potency in in vitro and cell culture assays. 
Properties predicted to enhance ADMET parameters should be given priority over development of potency 
through enhanced molecular weight and lipophilicity. Furthermore, early incorporation of in vivo 
evaluation in murine models and canine patients (to be described below), can provide more informative 
data on the activity of the compound in vivo and possible clinical utility. For compounds acting on novel 
targets, early evaluation in sophisticated in vivo models and companion animal patients can be imperative 
at determining whether they have clinical potential for the treatment of human disease.    
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Figure 1.8. FDA-approved chemotherapeutics display a wide range of potency that is dependent upon identity of 
chemotherapeutic, time of exposure and cell line. (A, C) U-937 human lymphoma cells were treated for 24 h (A) or 
72 h (C) with a panel of six chemotherapeutic agents. (B, D) ES-2 human ovarian cancer cells were treated for 24 h 
(B) or 72 h (D) with a panel of six chemotherapeutic agents. Cell death was assessed by Alamar Blue.  
  
1.3.2 Utility of a cancer drug is driven by ability to be efficacious at non-toxic dosages  
 The clinical utility of a drug is driven by its ability to be efficacious at dosages that are not 
unacceptably toxic. This ratio can be quantitated as the clinical Therapeutic Index (TI, equation 1.1). 
Although drug safety is required for societal,86 legal,87 and regulatory reasons,88 the level of safety varies 
greatly based upon the intended clinical indication, the extent of clinical need, and the availability of 
alternative options.89,90 As such, there exists no regulatory guidance for a minimum TI, nor are there 
universally accepted TI values believed to be sufficient within the pharmaceutical industry.90,91 Numerous 
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examples exist of withdrawn drugs that were believed to possess sufficient selectivity and activity at plasma 
levels for which toxicity would be unlikely to occur.90  
 
Equation 1.1. Equation for the calculation of the Therapeutic Index, or a quantitative measure of drug safety.   
As a metric, the TI value fails to recapitulate numerous clinical aspects. Namely, drug plasma levels 
in human patients are the only markers of drug levels able to be obtained easily and ethically. However, 
they are only a surrogate for the actual tissue levels. Many drugs, particularly in oncology may possess 
multiple toxicities which occur at different exposure levels, thereby creating multiple TI values. 
Furthermore, substitution of drug dosage for exposure levels in calculation of a TI greatly diminishes the 
prognostic value of TI as drug metabolism, and therefore exposure, may vary greatly based on the 
individual. Furthermore, it is important to recognize that the pharmacokinetic variables that drive efficacy 
may be different than those driving toxicity. For example, the severity of doxorubicin-induced 
cardiotoxicity correlates most closely with peak plasma levels, whereas oncological efficacy appears to be 
driven by the area under the curve of plasma concentration.92,93  
Acceptable toxicity varies greatly based upon the indication of a drug, with more life-threatening 
conditions allowing for higher levels of associated toxicity. As such, many oncology drugs actually possess 
a TI < 1, indicating that toxicity is observed at levels below those required for efficacy. In progressing a 
new drug forward, some forms of toxicity are greatly preferred and believed to be ‘safer’ than others. These 
include toxicities that are reversible, easily monitored, and of low severity for overall fitness. 
A major goal of preclinical and toxicological evaluation of a drug candidate molecule is to 
minimize the risk for unacceptable toxicities (such as inhibition of hERG, which can cause potential fatal 
cardiac arrhythmias),94 as well as identify potential hazards to monitor as a drug progresses through 
development and clinical evaluation. Candidate drug molecules are frequently evaluated against a panel of 
targets with confirmed roles in adverse drug reactions.91,95,96 This enables the identification of potential off-
target toxicities early. These can be subject to attempted mitigation via medicinal chemistry and 
Therapeutic 
Index
= Exposure level at which toxicity occurs
Exposure level at which efficacy occurs
= Safety/Toxicity
Pharmacology
= Median toxic dose
Median effective dose
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comparative structure-activity relationships, and to increased monitoring in preclinical and clinical 
assessment. Furthermore, concurrent evaluation of safety/toxicity in animals used in preclinical evaluation 
can enhance predictive capacities in humans. From a combination of in vitro and animal models, one can 
attempt to predict drug plasma levels needed to be therapeutically effective versus the activity (in vitro and 
in vivo) against known problematic targets. Unfortunately, the currently exists no method to predict the 
ultimate clinical TI in humans, and thus safety-related drug attrition remains a significant challenge in drug 
development.  
 
1.4 Use of murine models and canine patients for the development of novel 
cancer treatment strategies 
1.4.1 Standard murine models: types of mice 
Mice have been used extensively since the 1960’s to investigate strategies to combat cancer, as 
well as to study the molecular mechanisms driving cancer development and progression. Early studies in 
experimental manipulation of murine lymphoma delineated requirements for a “cure,” investigated the 
capacity for drug treatments to kill cancer cells in vivo,97-99 and identified some of the major challenges 
facing human cancer therapy including infiltration of cancer cells into the central nervous system.100,101 As 
models for the study of cancer biology and evaluating treatments in vivo, mice possess many desirable 
attributes. They are small in size (thereby limiting the space needed to house them as well as the quantity 
of a compound needed for evaluation of its in vivo activity), they reproduce rapidly (enabling large sample 
sizes to enhance reliability of experiments), possess extensive physiological and molecular similarities with 
humans (particularly in comparison non-mammalian model species, such as zebrafish, Drosophila and C. 
elegans), and they can be genetically modified to study the role of particular proteins in cancer development 
or response to treatments.84,102-104 Studies in mice enable examination of processes that are not possible in 
cell culture, such as tumorigenesis, angiogenesis and metastasis. Furthermore, they provide evidence as to 
whether or not a potential drug can achieve sufficient bioavailability to be efficacious in vivo, although 
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evidence suggests that there is no strong correlation between a compound’s oral bioavailability profile in 
mice and humans.105 Although mice are unable to faithfully recapitulate all aspects of human cancer biology 
simultaneously, different types of models can be selected based upon the goals of the study. The constraints, 
in terms of technical skill, financial investment and time commitment vary amongst mice and models and 
are summarized at the end of this section in Tables 1.1 and 1.2.  
Mouse models used in the study of cancer and evaluation of potential cancer treatments fall into 
three main types: syngeneic, xenograft and genetically engineered mice (Figure 1.9), to be described below. 
For each type of mouse model, different types of tumor methodology are possible and will be described in 
detail in Section 1.4.2. The type of tumor or metastasis model further dictates the types of monitoring and 
final analysis that are possible, as described in Section 1.4.3. General limitations facing mouse models will 
be discussed in Section 1.4.4.  
Syngeneic models were the first in vivo models of cancer and they utilize cancer cells that were 
developed in a given strain of mouse. Syngeneic models possess many positive attributes including an intact 
immune system, low cost, robust and reproducible phenotypes, and a long history of use and baseline drug 
response data. Syngeneic tumor model experiments can be conducted with meaningful numbers of animals, 
thereby enhancing reproducibility. A major limitation to syngeneic models is that they examine a potential 
cancer treatment’s effect on a murine cancer, rather than a human cancer. Potential drugs interact with 
murine homologs of human proteins. Furthermore, as the cancer cells are implanted back into the native 
host, syngeneic models tend to be extremely fast growing. This results in challenging models from a 
therapeutic standpoint, as well as limits the relevance to slower growing human disease.  
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Figure 1.9. Types of mice commonly used to study the anticancer activity of potential chemotherapeutics. Note: 
syngeneic and xenograft models have been used far more extensively than genetically engineered mice, to date.  
  
Xenograft models were developed with the goal of evaluating potential chemotherapeutics against 
human cancer cells in a small organism, namely the mouse. As the malignant cells are human cells, the 
protein targets are human as well, increasing the relevance of the model to human cancer. Many are highly 
reproducible and have a long history of use, providing baseline drug response data. However, in order to 
prevent recognition of human, non-self, foreign cells, these studies must be performed in immune-
compromised and immune-deficient mice. As the immune system is known to play a significant role in 
human cancer progression, this is a major limitation of the model. Furthermore, although the malignant 
cells are human-derived, their clonal selection in culture prior to implantation means that they lack the 
heterogeneity of human cancers. Additionally, not all human cell lines will readily form tumors in mice and 
even fewer feature robust metastasis. Immune-compromised and immune-deficient mice are more 
expensive than mice used in syngeneic models (by two- to five-fold).  
Patient-derived xenografts (PDX) represent an exciting opportunity for the advancement of 
personalized cancer therapy. In theory, a resected tumor (usually 20-50 mm3) can be implanted into a series 
of mice. The mice can then serve as “avatars” for the human cancer patient and a truly personalized 
treatment, identified through efficacy in the murine avatar, can be selected.106 Implantation of explanted 
fragments of tumor tissue preserves the molecular heterogeneity in the tumor.107 Unfortunately, in practice 
evaluation in these tumors cannot proceed sufficiently rapidly to guide treatment in the human patient. 
PDXs frequently suffer from long latency periods of 2-12 months and engraftment rates can vary 
Syngeneic Xenograft Genetically Engineered Mice
Mouse cancers investigated 
in a native host 
Human cancer cell lines and patient 
tumor samples studied in an 
immuno-compromised murine host
Specific genetic traits are 
engineered into a mouse. Genes 
can be “turned on” in specific 
tissues at certain times.  
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widely.108,109 Thus, at best, evaluation of the murine avatars’ response to chemotherapy regimens can 
provide retrospective rational for the human patient’s response. Patient-derived xenografts also possess 
diminished genetic heterogeneity than the parental tumor and they fail to recapitulate the tumor 
microenvironment, which is known to play a role in cancer progression and response to treatment. If tumors 
are expanded prior to implantation into the immunocompromised mouse, then they are subject to similar 
clonal selection pressures as traditional cancer cell lines. Finally, the transfer of tumors directly from a 
patient into an immunocompromised mouse requires a more advanced skill set, thereby increasing 
associated cost and limiting numbers of animals in a study.  
Genetically engineered mice (GEM) represent a third category of mice sometimes used in tumor 
model evaluations. In GEMs tumors can arise “naturally,” thereby increasing the relevance to human 
cancers and human cancer progression. Specific genetic features can be reversibly controlled at specific 
times and in particular tissues, thereby providing spatial and temporal control for evaluation. However, 
GEMs possess several significant limitations that have prevented their widespread adoption for tumor 
model studies. They are expensive and time consuming to develop. The cost and space required to breed 
and maintain colonies of sufficient size to provide age/sex matched cohorts for experimental studies can be 
prohibitive. Furthermore, the tumors can arise at varying times and in varying tissues. These naturally 
occurring tumors can be difficult to follow. Finally, due to the engineering and sophistication needed for 
creation of a GEM, intellectual property restrictions can hinder widespread use. Due to these substantial 
limitations, GEMs have thus far primarily served to investigate the role of particular genetic trait in the 
development and progression of cancer, rather than as models to study drug efficacy.  
 
1.4.2 Standard murine models: tumor methodology 
In syngeneic and xenograft tumor models, cancer cells (of murine, human, or patient origin) are 
introduced into the mouse. These cells may be implanted subcutaneously beneath the skin, orthotopically 
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at the site of cancer origin, or introduced in such a way to induce development of metastatic disease 
(schemes shown in Figure 1.10).  
Figure 1.10. Schematic of commonly used tumor models for the study of anticancer activity of potential 
chemotherapeutics: subcutaneous, orthotopic and metastasis.  
 
  
Subcutaneous tumor models represent one of the most commonly used strategies for evaluation of 
potential chemotherapeutics and they are possible in both syngeneic and xenograft mouse models. 
Implantation of cells beneath the skin of a sedated mouse is a simple procedure, enabling large numbers of 
animals to be used in a study. Growth of the tumor is easily observable and can be monitored over time via 
caliper measurements. Drug treatments can begin immediately following inoculation to measure the ability 
of a compound to inhibit tumor growth, or tumors can be allowed to develop to a given size and treatment 
can be assessed for the ability to retard tumor growth or induce tumor regression. Large numbers of cells 
can be implanted in these studies and with the appropriate additives, such as the commonly used Matrigel, 
tumor growth is typically robust for many cancer cell lines and some patient tumor samples. However, the 
ease of implantation and monitoring of subcutaneous tumors comes at a significant cost. Tumor 
microenvironment is known to play a significant role in cancer progression and therapeutic response, thus 
implantation in the ectopic subcutaneous space excludes these important aspects. In addition, subcutaneous 
tumors infrequently metastasize (or models do not extend for sufficient time for metastasis to play a role in 
mortality), thereby neglecting a significant aspect of clinical cancer biology.  
Subcutaneous Orthotopic
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tumor piece) at organ of origin
Not easily measurable (though 
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 Furthermore, growth of tumors within the subcutaneous space is not always uniform. Tumor 
volumes are calculated using Equation 1.1 following measurement of tumor length (l) and the width (w) 
with calipers.  
 
Equation 1.2. Prediction of tumor volume based upon the measured length (l) and width (w) of the tumor. 
 
 
Tumor morphology greatly impacts the actual tumor mass (and therefore tumor burden on the 
animal), but may not be well-represented by two-dimensional measurements. An example is described in 
Figure 1.11. In principle, for growing tumors of uniform morphology, a linear correlation should exist 
between tumor volume (calculated from equation 1.2), and mass of extracted tumor. However, the 
measurements may fail to capture the true size of the tumor. Three examples of such discontinuity between 
calculated tumor volume and actual mass of the excised tumor are described here. The first example (shown 
in Figure 1.11A) can be compared to an iceberg. A significant portion of the tumor mass has grown below 
the surface of the skin, inaccessible to the caliper measurements. Thus, although measurements suggested 
that it was the smallest tumor, its actual mass was much larger than expected. The next situations arise due 
to the two-dimensionality of the measurements for tumor volume calculation. If the tumors shown in Figure 
1.11B and 1.11C are compared visually, Tumor B will appear far more bulbous, extending much farther 
into the z-dimension. In contrast, Tumor C will appear flat. Visually their size can be distinguished 
qualitatively, but the measurements of the tumor length (l) and the width (w) do not capture the difference. 
In the same way that a basketball and a frisbee possess similar circumferences, but radically different 
volumes, Tumors B and C possessed highly similar calculated tumor volumes, but were very differently 
sized upon extraction and weighing.  
 
  
Tumor Volume =
l x w2
2
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Figure 1.11. Schematic of challenges and common pitfalls associated with caliper measurements as a method to 
monitor tumor growth. Scatterplot shows the excised tumor mass versus the tumor volume calculated through use of 
caliper measurements. Data obtained from an experiment aimed at identifying a dose of doxorubicin capable of mildly 
reducing tumor size for use in a mouse model assessing the therapeutic utility of PAC-1 in combination with 
doxorubicin. Mice (n=3 per treatment group) were inoculated subcutaneously with 5 million EL4 cells and treated 
with 0, 2.5, 5 or 7.5 mg/kg doxorubicin on Days 3 and 7. Tumors were measured with calipers immediately prior to 
extraction on Day 10. (A) “Iceberg” type tumors demonstrate significant tumor growth beneath the surface of the skin. 
The tumor presence is either unknown, or not easily measured. Thus calculations of overall tumor volume will 
underestimate size. (B) “Basketball” type tumors possess significant three-dimensionality and thus caliper 
measurements underestimate size. (C) “Frisbee” type tumors possess low three-dimensionality and thus caliper 
measurements overestimate size in comparison to standard tumor growth or “basketball”-type tumors. 
 
 Orthotopic tumor models involve implantation of cancer cells at the organ of primary tumor origin 
(ie lung cancer cells will be injected into the lungs of a mouse). Orthotopic models are possible in both 
syngeneic and xenograft mouse models. Studying tumor growth orthotopically avoids a major limitation of 
subcutaneous studies that neglect the role of the tumor microenvironment. Chemotherapeutics have been 
shown to vary in their efficacy in murine tumor models, dependent upon the site of tumor implantation, 
likely due to the critical role of tumor microenvironment.110 Orthotopic tumor models metastasize more 
frequently than subcutaneous tumors, adding support for the importance of the tumor microenvironment. 
However, orthotopic models involve complex surgeries, necessary to access the brain, lungs, ovaries, 
mammary glands, among many other locations. This challenge increases the costs associated with the study 
as well as limits the number of animals that can be used. Despite the complexities of surgery required for 
access, orthotopic locations can be essential for the study of therapeutics that would require access to 
privileged spaces, such as the brain. Unfortunately, orthotopic locations are frequently inaccessible to 
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measurement, meaning that tumor progression or response is difficult to follow. Fluorescently tagged cells 
can enable advanced imaging, but this requires sophisticated equipment.  
 Subcutaneous models primarily study the effect of a treatment on macroscopic disease. Although 
metastasis is more common in orthotopic models, many models exhibit limited propensity for metastasis, 
or do not occur for a duration sufficient for metastatic disease to play a role in mortality. This stands in 
stark contrast to human disease, for which metastasis is thought to be responsible for 90% of cancer 
deaths.111 There exists two main experimental approaches for establishing metastatic disease in mice: 
experimental metastasis (Figure 1.12) and spontaneous metastasis (Figure 1.13). Both models, in theory, 
can be conducted as either syngeneic or xenograft models. Metastatic disease will vary based upon the 
injection site and how the injected cells respond to the challenges associated with establishing a lesion 
following circulation. Syngeneic models of metastasis possess an advantage that the malignant cells, the 
tumor microenvironment, and the host are from the same species. These factors can sometimes promote 
robust metastasis.  
 Experimental metastasis models (scheme in Figure 1.12) are the most widely used murine models 
of metastasis.112 In experimental metastasis models, tumor cells are injected into the lateral tail vein, 
intrasplenically or intracardiacally. The site of injection influences the target organ for the cells, based in 
part on the identity of the first capillary bed the cells face. However, tumor-host interactions can further 
dictate the site and extent of metastases, enabling development of clonally-related variant cell lines with 
different metastatic capacity.113-115 Experimental metastasis models are typically rapid, robust and 
reproducible. They require only an intravenous injection of cells, which is a less complex procedure than 
the surgeries required for models of spontaneous metastasis (described below), thereby enabling large 
numbers of animals. Unfortunately, the rapid speed of the model dictates that important aspects of 
metastatic disease cannot be included. In patients, tumor cells are believed to metastasize within emboli 
that break free of a primary tumor and travel in association with platelets to distant sites. In experimental 
metastasis models, in contrast, high numbers of single cells that were not under selection pressures to 
spontaneously metastasize form lesions on organs simultaneously in a way that could be considered as 
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multiple primary tumors. Experimental metastasis models are challenging to monitor, and thus the primary 
endpoint is typically a change in median survival in response to treatment.  
Figure 1.12. Schematic of experimental metastasis model. 
 
Models of spontaneous metastasis (scheme in Figure 1.13) work to address the main limitations of 
experimental metastasis models. Primary tumors are allowed to grow (in both subcutaneous and orthotopic 
locations), enabling spontaneous metastasis to occur and yielding metastatic lesions at distant organs. For 
some models, these lesions can form in patterns of sites that closely mimic the human disease. 
Unfortunately, growth of the primary tumor is frequently rapid, requiring excision to control morbidity. 
Thus, complex surgery is required for excision of the primary tumor. If the primary tumor was implanted 
orthotopically, then execution of the model requires two complicated surgical procedures. These procedures 
require skill, increase the cost of the model, and limit the number of animals that can be used.  
Figure 1.13. Schematic of spontaneous metastasis model. 
  
Implantation of cancer 
cells subcutaneously (or 
orthotopically).
Tumor grows over a 
period of time.
Metastasis occurs and 
small micro-metastases 
begin to form
Primary tumor is 
surgically resected.
Micro-metastases 
continue to grow into 
macro-lesions
Metastatic disease ultimately 
results in death.
Can include formation of 
metastatic lesions in organ of 
cancer origin  
Surgical tumor 
resection
Cancer cells are 
intravenously injected 
into the tail vein.
Micro-metastases develop 
into macro-lesions 
Can include formation of 
lesions in organ of cancer 
origin.
Metastatic disease ultimately 
results in death.
Can include formation of 
metastatic lesions in organ of 
cancer origin  
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1.4.3 Standard murine models: methods of analysis 
The goal of many murine tumors models is to evaluate the ability of a potential drug to alter tumor 
growth and progression in vivo. The type of tumor model employed impacts the type of analysis possible. 
Analysis can be divided into two main categories: 1) studies that evaluate and measure the average growth 
(or total number of cancer cells) over time (typical analysis shown in Figure 1.14A), and 2) studies that 
evaluate how a potential drug alters the median survival of a population (typical analysis shown in Figure 
1.14B). In order for direct analysis of total cancer burden to be feasible, the cancer must be growing in a 
manner accessible to measurement. This typically takes the form of subcutaneous tumors, which can be 
monitored via caliper measurements, or tumors that are formed using cells that have been experimentally 
altered to possess a fluorescent or luminescent tag that can be imaged. Significant limitations of caliper 
measurements of tumor size were discussed in Section 1.4.2 and thus it is recommended that the final 
measurement also be accompanied by tumor resection and less subjective weight measurement. The 
advantage of models capable of employing direct analysis of tumor burden over time is that treatment can 
be commenced at a given biologically known point, a potential drug can be monitored for both the ability 
to inhibit tumor growth and well as decrease tumor size, and the effects can be quantitated at multiple points 
over the course of the model.  
Direct assessment of tumor burden is not possible in all cases, and thus in such cases an effect must 
be monitored in the form of a change in the median survival of the animal cohort based upon treatment. It 
is important to note that although the measurement is “survival”, appropriate care should be taken in all 
animal experiments to minimize undue suffering. As such, animals should be humanely sacrificed in the 
12-24 h prior to their actual death occurring. Due to the inherent heterogeneity associated with experiments 
performed in vivo, both methods of analysis benefit greatly from large cohorts of animals for each treatment 
group.  
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Figure 1.14. Schematic of commonly used methods to analyze activity in tumor models. (A) Subcutaneous models 
are frequently monitored via caliper measurement, providing information on the activity of a drug over time. (B) When 
tumor burden is not easily monitored, such as in orthotopic and metastasis models, survival curves and an observed 
change in median survival are the primary method used to analyze activity of a drug.  
 
Table 1.1. Comparison of types of mice commonly used to study anticancer activity of potential chemotherapeutics. 
Type of mouse model Advantages Disadvantages 
Syngeneic Low cost 
Highly robust models 
Wide variety of immunocompetent hosts 
Variety of cell lines  
Long history of drug response data 
Easily conducted with meaningful number of animals 
Rodent host may enable more robust metastasis 
Tend to be fast growing 
Study of rodent and rodent target 
Xenograft Wide variety of immunocompromised hosts 
Malignant cells are human cells or human tumor tissues 
Wide variety of cell lines 
More expensive than syngeneic 
Study occurs in immunocompromised setting 
Not all human cell lines or patient tissues will form  
  robust tumors 
Study may not last long enough for metastasis to occur 
Human cell lines lack the heterogeneity, histology and  
  architecture of human tumors  
Genetically engineered 
mice 
Tumors arise “naturally” in host Highly expensive 
Time consuming to develop 
Breeding and maintenance of sufficiently sized colony  
  for age/sex matched cohorts can be challenging 
Tumors can arise at varying times and places 
Tumors can be difficult to follow 
Intellectual property restrictions can hinder use 
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Table 1.2. Comparison of common tumor models for the study of anticancer activity of potential chemotherapeutics. 
Model 
methodology 
Type of mice 
used in model 
Advantages Disadvantages Mode of analysis 
Subcutaneous Syngeneic 
Xenograft  
PDX 
Low cost 
Rapid 
Reproducible 
Wide variety of immunocompetent  
  and immunocompromised hosts 
Wide variety of cell lines available 
Long history of drug response data 
Easily conducted with meaningful  
  number of animals 
Tend to be fast growing 
Lack native tumor 
microenvironment 
Not prone to metastasis 
 
Direct measurement of tumor 
growth over time 
Orthotopic Syngeneic 
Xenograft 
PDX 
Retains native tumor  
  microenvironment 
Wide variety of immunocompetent  
  and immunocompromised hosts 
Require complex surgeries 
Not easily conducted with  
  meaningful number of animals 
May not last long enough for  
  metastasis to occur 
Survival analysis  
Direct measurement possible 
with imaging of labelled 
cancer cells 
Experimental 
metastasis 
Syngeneic 
Xenograft 
Low cost 
Rapid 
Reproducible 
Wide variety of immunocompetent  
  and immunocompromised hosts 
Long history of drug response data 
Easily conducted with meaningful  
  number of animals 
Tend to be fast growing 
Location of metastases a function of  
  intravenous injection location 
Can be considered “multiple  
  primary tumors” 
Survival analysis  
Direct measurement possible 
with imaging of labelled 
cancer cells 
Spontaneous 
metastasis 
Syngeneic 
Xenograft 
Occurs with native tumor   
  microenvironment 
Location of metastases may mimic  
  human disease 
Requires multiple complex surgeries 
Not easily conducted with  
  meaningful number of animals 
Survival analysis  
Direct measurement possible 
with imaging of labelled 
cancer cells 
 
1.4.4 Major limitations of rodent cancer models 
The primary limitation of rodent models of cancer is that they study experimentally induced cancers 
in rodents; cancers that are highly dissimilar in many ways to human clinical cancer. As model organisms, 
mice (and rats) possess many advantages, covered in Section 1.4.1, but they are unable to completely 
replicate human cancers. Evidence of this lack of recapitulation has borne out in the repeated failures of 
exciting preclinical candidates to be translated into successful human clinical trials; an occurrence driven 
primarily by lack of efficacy or unacceptable levels of toxicity.116,117 Rodent models fail to represent some 
of the most challenging aspects of human cancer progression, including long latency periods, genomic 
instability, coupled to significant tumor heterogeneity. Cancers in rodent models are experimentally 
induced and frequently occur in the context of an immunocompromised organism. One could imagine drugs 
that are effective at treating slow-growing, heterogeneous tumors in the context of an intact immune system 
in a canine patient, but that are unable to significantly impact tumor growth in murine models. 
Unfortunately, based upon the current drug development progression, these drugs would likely be discarded 
before they were evaluated successfully against canine cancers. 
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1.4.5 Use of companion animal oncology as a complement to murine models 
Companion animal oncology, the treatment of pets with naturally occurring cancers, offers a 
valuable opportunity to complement experimental rodent models of cancer. Clinical understanding gained 
from the evaluation of potential cancer treatments in pet animals benefits the pets themselves, as a well as 
humans, due to the high level of similarities between their respective cancers. Over 4.2 million dogs are 
diagnosed with cancer in the United States each year,118 and many will go untreated or be euthanized upon 
diagnosis. Canine cancers occur spontaneously and have similar clinical presentation, pathophysiology, 
intact immunity and response to conventional chemotherapy to many human cancers.118-120 Furthermore, as 
they arise naturally, they possess many attributes that are lost in rodent models, including heterogeneity, 
long latency periods and metastasis. Development of cancer in canines is influenced by many of the same 
factors as humans, including age, nutrition, reproductive status and environmental exposure to 
carcinogens.121-124 Although canines possess longer life expectancies than rodents, their lifespans are still 
abbreviated compared to humans. Therefore, treatments can be more rapidly evaluated, and the increased 
physical size of dogs in comparison to rodents makes them more amenable to serial biologic sample 
collection. Interestingly, due to selective breeding and consanguinity practices, some cancers display a 
strong breed-specific risk.125,126 Thus, the restricted genetic variation in dog breeds can represent an 
intermediate in population genetic heterogeneity between inbred mouse strains and the human 
population.127 This breed-specific increased risk for various cancers has been leveraged to identify genes 
associated with both risk and cancer aggressiveness.    
Some cancers are significantly more prominent in the canine population than the human population. 
Osteosarcoma is one such case, a relatively rare cancer in humans, with only ~1,000 new cases in the United 
States each year compared to 75,000 canine diagnoses.128 This strikingly high frequency in canines presents 
an opportunity to investigate and prioritize potential treatments for evaluation in a relatively limited human 
patient set. The low number of human patients has represented a major challenge in the human 
osteosarcoma community, in the form of insufficient patient accrual for clinical trials. Excitingly, genetic 
studies have revealed that canine and human osteosarcomas are extraordinarily similar, further 
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substantiating the use of canine osteosarcoma trials to guide eventual human trials.129 Aiding the 
development of robust comparative oncology clinical trials has been the establishment of the NCI’s 
Comparative Oncology Program and the Comparative Oncology Trials Consortium.120,130 As such, the 
infrastructure now exists, connecting pharmaceutical and biotechnology companies able to sponsor such 
studies with 21 academic veterinary centers. This enables multicenter clinical trials of investigational 
therapeutics. Unlike for human cancers, no gold standards exist for the treatment of canine cancers and 
cancer chemotherapy can be prohibitively costly for many pet owners. This enables the opportunity to test 
novel therapeutics in less heavily pretreated populations than is possible in human clinical trials of drugs.  
 
1.5 Combination chemotherapy in the clinic 
1.5.1 Historical development of combination chemotherapy 
Until the 1960s, surgery and radiotherapy were the dominant, though largely ineffective, methods 
for the treatment of cancer.15  The first true cures of common hematological and solid tumors came from 
treatment of patients with combinations of chemotherapeutics.  However, such combinations necessitated 
the discoveries of the individual chemotherapeutic agents.  These agents had all demonstrated activity, 
though limited, in human cancer patients.  A few of the notable discoveries are described in the following 
paragraph.  
The 1940s discovery that exposure to mustard gas depleted bone marrow and lymph nodes, inspired 
evaluation of similar chemical compounds for anti-lymphoma activity. Nitrogen mustard was found to 
successfully reduce lymphoid tumors in mice, an effect that was also observed in human lymphoma 
patients.131,132 As this was the first instance of a chemical or “chemotherapy” being able to elicit antitumor 
activity in patients, enthusiasm spread for the possibility of drugs capable of curing cancer patients. 
Unfortunately, these nitrogen mustard-induced remissions were brief.  Following the unfortunate discovery 
that folate accelerated leukemias,133 anti-folates were developed and determined to be capable of inducing 
longer remissions.134 5-Fluorouracil (5-FU) was developed following the discovery that rat hepatomas 
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utilized higher levels of uracil than normal tissues, suggesting the possibility that this was a cancer-specific 
pathway that could be inhibited by an appropriate analogue.135 5-FU was determined to be effective in 
treating a range of solid tumor types.  Finally, identification of the vinca alkaloids,136 one of the most potent 
classes of chemotherapeutics, provided what would ultimately be the cornerstone for the first major lasting 
cures in cancer.   
Concurrently to the gradual expansion of chemotherapeutic options was the development of rodent 
models of cancer that were capable of rigorously evaluating experimental hypotheses and testing various 
strategies to determine how dosing, timing and combination therapy might affect antitumor activity.137-139 
Interestingly, combination treatments in mice were seen to be superior to treatment with single agents. 
Although combinations of drugs was not a common medical practice of the time, a radical protocol ‘termed 
VAMP’ was tested in children with leukemia. VAMP treatment employed four agents: vincristine, 
amethopterin, 6-mercaptopurine and prednisone (example schedule shown in Figure 1.15), greatly 
increasing response, and duration of remission.140-142  Inspired by the success of VAMP, a second 
combination scheme based upon vincristine, MOMP (employing vincristine, methotrexate, 
cyclophosphamide and prednisone), was investigated in adults with drug naïve Hodgkin’s Lymphoma 
(schedule shown in Figure 1.16).143 Reflective of the highly experimental nature of combination cancer 
chemotherapy of the time, treatment schedules were frequently varied, altered based upon tolerability and 
anecdotal evidence from other trials. However, evidence began to mount that long-term remissions and 
cures of cancer were possible. This led to a rapid transition from palliative treatment of cancer patients, to 
aggressive treatments with the belief that long term remissions were attainable.144,145  Both rodent and 
human data suggested that the most aggressive therapeutic treatment schedules were typically the most 
effective. Thus, different combinations were investigated, with the goal of maximizing the dose and variety 
of chemotherapeutic agent, within the bounds of the toxicity associated with each chemotherapeutic. In the 
subsequent decades, treatment protocols were tested and compared in large scale controlled clinical trials. 
As they were discovered, novel agents such as doxorubicin and paclitaxel were successfully integrated into 
combination protocols. An important aspect of the historic development of combination chemotherapy 
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regimens is that they were driven exclusively by evidence of activity and non-overlapping toxicity. 
Although it was suspected that chemotherapeutics with different molecular targets might limit the 
development of resistance, or be more effective at killing heterogeneous populations of cells, the primary 
drivers of combination development were activity and avoidance of over-lapping toxicities.   
 
 
Figure 1.15. Schedule of three phases of VAMP protocol for the treatment of pediatric acute lymphoblastic 
leukemia.141  Note: calendar days are presented to illustrate pattern of scheduling, not to imply that treatments only 
occurred on particular days on the week.   
 
Remission Induction 
Vincristine 1.5 mg/m2 IV, once weekly
Prednisone
40 mg/m2 PO, 
daily in 3-4 doses
Mon Tues Wed Thurs Fri Sat Sun
x 4-6 cycles
Methotrexate 10 mg/m2 IV
Mon Tues Wed Thurs Fri Sat Sun Mon Tues Wed Thurs Fri
6-Mercaptopurine 
1 g/m2 IV
Cyclophosphamide 
600 mg/m2 IV
Intensive Chemotherapy Phase
Mon Tues Wed Thurs Fri Sat Sun Mon Tues Wed Thurs Fri Sat Sun
Two week rest/recovery period
Mon Tues Wed Thurs Fri Sat Sun
6-Mercaptopurine 50 mg/m2 PO, daily
Vincristine 1 mg/m2 IV, once weekly
Methotrexate 20 mg/m2 IV, once weekly
Cyclophosphamide 100 mg/m2 IV, once weekly
Continuation Phase
For up to 3 years 
(or until hematologic relapse) 
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Figure 1.16. Schedule of MOMP protocol for the treatment of Hodgkin’s Lymphoma.143 Note: calendar days are 
presented to illustrate pattern of scheduling, not to imply that treatments only occurred on particular days on the 
week. 
 
1.5.2 Modern approaches to combination chemotherapy and integration of molecularly 
targeted agents 
Modern knowledge of genomic alterations associated with and driving cancers have enabled the 
development of small-molecule and antibody based molecularly targeted chemotherapeutic drugs. These 
agents are developed with the goal of exploiting pathogenic oncogene addiction, synthetic lethality and 
other cancer-specific cellular variations, thereby increasing anticancer activity while minimizing toxicity 
to the patient.146,147 However, deep sequencing and analysis of patient tumor samples has concurrently 
identified extraordinary levels of intratumoral heterogeneity, including both de novo and acquired 
resistance to cytotoxic chemotherapeutic and molecularly targeted agents, as well as the simultaneous 
presence of multiple driver mutations.148-150 Thus, similarly to cytotoxic chemotherapeutics, use of these 
agents in combination will be required to achieve lasting activity in patients. Furthermore, with an ever-
growing number of potential agents with which to develop combination chemotherapy regimens, and the 
increasing ability to subdivide cancers based upon their molecular profile, an exponential number of 
possibilities is created.  Thus, prioritization of rational and intelligent strategies to test clinically is 
necessary. 
Mon Tues Wed Thurs Fri Sat Sun
Cyclophosphamide 
600 mg/m2 IV
Methotrexate 
30 mg/m2 intramuscular
Vincristine
1.2 mg/m2 IV
Cyclophosphamide 
600 mg/m2 IV
Methotrexate 
30 mg/m2 intramuscular
Vincristine
1.2 mg/m2 IV
Prednisone
60 mg/m2 PO, daily in 4 doses
Prednisone
60 mg/m2 PO, daily in 4 doses
x 3 cycles 
separated by ≥ 10 days of rest/recovery
Radiotherapy (1000 R/week) x 3-4 weeks was administered between cycles 1 and 2
Mon Tues Wed Thurs Fri Sat Sun
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Hypothesis driven approaches to combining molecularly targeted chemotherapeutic agents have 
focused on three main strategies: 1) Multi-targeted inhibition of a single target in >1 way (such as the 
combination of pertuzumab and Herceptin inhibition of HER2 and HER3),151,152 2) “Vertical” targeting of 
proteins within a single pathway (such as combination of a BRAF inhibitor with a MEK inhibitor),153 and 
3) “Horizontal” targeting of parallel pathways likely to be involved in resistance mechanisms (such as 
combining MEK inhibitors with AKT or PI3K inhibition).154,155  The goal of these strategies is to develop 
“novel-novel” combinations that are able to preemptively overcome known mechanisms of resistance and 
feedback loops with a cell by attacking complementary cancer hallmarks.156-159 As with combinations 
composed of cytotoxic chemotherapies, the success of a given combination requires the ability to combine 
drugs at effective doses without incurring unacceptable side effects. Unfortunately, many molecularly 
targeted agents are plagued by significantly high toxicities, possessing unexpectedly narrow therapeutic 
windows. Clinically this has frequently led to the need for dose reductions for one or more agents.  These 
dose reductions can be particularly problematic in the case of kinase inhibitors, many of which requiring 
>90% inhibition of their target for activity in vivo.160-163  Furthermore, resistance to most kinase inhibitors 
develops extremely rapidly in patients.164-166   
In addition to combinations composed entirely of molecularly targeted agents, many molecularly 
targeted agents have been combined effectively into cytotoxic chemotherapeutic regimes. Examples of 
these include the addition of Herceptin to paclitaxel for the treatment of breast cancer,167 addition of 
rituximab to cyclophosphamide/doxorubicin/vincristine/dexamethasone in Non-Hodgkin’s Lymphoma168 
and lapatinib to capecitabine in breast cancer.169 Agents possessing only modest single agent activity have 
provided significant clinical benefit when used in combination with cytotoxic chemotherapy. Often there 
was no compelling biologic rationale for their inclusion, rather it was based on the pragmatic factors, such 
as tolerability.170,171    
Although molecularly targeted agents such as Gleevec and Herceptin have had a profound impact 
on the treatment of specific cancers, as a whole molecularly targeted chemotherapeutics have not 
revolutionized cancer chemotherapy. Responses to most molecularly targeted agents are typically transient, 
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with resistance occurring within two years.  Furthermore, many of these agents are frequently plagued by 
far higher levels of toxicity than were expected a priori, limiting their ability to be used in combinations. 
As will be described in the subsequent chapters, we believe that activation of procaspase-3 may be a 
particularly unique target for personalized medicine and that PAC-1 may possess unprecedented broad 
utility in the treatment of diverse cancers.  
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Chapter 2. Dual small-molecule targeting of procaspase-3 dramatically 
enhances zymogen activation and anticancer activity 
 
Portions of this chapter are reproduced with permission from literature (Botham, R. C.; Fan, T. M.; Im, I.; 
Borst, L. B.; Dirikolu, L.; Hergenrother, P. J. J. Am. Chem. Soc. 2014, 136, 1312-1319.) Drs. Isak Im, 
Danny Hsu and Howard Roth are acknowledged for contributing the chemical synthesis of PAC-1, PAC-
1a, and 1541B. Prof. Timothy Fan is acknowledged for his assistance with the syngeneic tumor models, 
Prof. Luke B. Borst is acknowledged for pathology analysis, and Prof. Levent Dirikolu is acknowledged 
for pharmacokinetic analysis. 
 
2.1 Introduction 
2.1.1 Combination chemotherapy is the standard clinical management of cancer 
Combination therapy has become standard for treatment of cancer patients.1,2 The goal of drug 
cocktail regimens is to achieve additive or synergistic anticancer effects among chemotherapeutics, thereby 
maximizing summation dose-intensity with resultant enhanced antitumor activities and increased patient 
progression free and overall survival.3-5 Combinations have been identified and developed both through 
unbiased approaches6,7 and by rational design,8,9 and compounds that act on a single biochemical pathway 
are particularly strong candidates for synergy or potentiation.5,10-12 For example, inhibitors of poly(ADP-
ribose)polymerase-1 (PARP-1), an enzyme that facilitates DNA damage repair, potently synergize with 
DNA damaging agents as demonstrated in cell culture and animal models.13-15 Herein we describe an 
approach for potentiation not based on compounds acting on two targets within a single pathway, but rather 
with two compounds acting differentially to activate the same enzyme.   
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During apoptosis, the zymogen procaspase-3 is activated via proteolysis to caspase-3, and this 
active caspase-3 then cleaves scores of cellular substrates, executing the apoptotic program.16  As 
procaspase-3 protein levels are elevated in numerous tumor histologies,17-26 drug-mediated direct activation 
of procaspase-3 has gained significant interest as a selective anticancer strategy. Furthermore, caspase-3 
has been shown to play critical roles in cardiomyocyte hypertrophy, cellular differentiation, and 
remodeling.27-29 Thus development of a strategy to magnify the timing and level of caspase-3 activation in 
a specific and direct manner could greatly aid the study of active caspase-3 in these non-apoptotic processes.  
Figure 2.1. Chemical structures of small-molecule activators of procaspase-3. (A) PAC-1. (B) 1541B. 
 
To date, two major classes of compounds have been disclosed that enhance the activity and auto-
maturation of procaspase-3 in vitro, and induce apoptosis in cancer cells in culture.  Procaspase-activating 
compound-1 (PAC-1, Figure 2.1A) enhances the activity of procaspase-3 in vitro via the chelation of 
inhibitory zinc ions,30 induces apoptosis in cancer cells in culture,31-33 and has shown efficacy in multiple 
murine tumor models.33 More recently, the compound 1541B (Figure 2.1B) was discovered to promote the 
automaturation of procaspase-3 to caspase-3 in vitro and to induce apoptotic death of cancer cells in 
culture.34 Compound 1541B appears to activate procaspase-3 via a binding-induced shift in the on-off state 
equilibrium,34 or through formation of nanofibrils.35,36 PAC-1 and 1541B exert their activating effect on 
procaspase-3 by distinct biochemical mechanisms, suggesting the potential for synergistic effects in cell 
culture and in vivo (Figure 2.2).      
A
PAC-1 1541B
B
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Figure 2.2. Schematic of orthogonal mechanisms of procaspase-3 activating small-molecules PAC-1 and 1541B. 
 
 
In vitro, procaspase-3 has enzymatic activity that is dramatically lower than caspase-3, with 
estimates ranging from reductions of ~200 to 107 fold.36,37 Low micromolar levels of zinc inhibit the activity 
of procaspase-3 and caspase-3 in vitro.30,38-41 Zinc co-localizes with procaspase-3/caspase-3 and inhibits its 
enzymatic activity in the cell.42,43 PAC-1, a moderate affinity zinc chelator that has been shown to chelate 
the labile zinc pool in cells,44 allows procaspase-3 to once again process substrates, including itself.30 
Described herein is the combination use of the two small molecule activators of procaspase-3, PAC-1 and 
1541B. 
 
2.2 Evaluation of procaspase-3 activating compounds in vitro 
2.2.1 PAC-1 and 1541B differ in their ability to activate procaspase-3 under zinc-inhibitory 
conditions 
As zinc co-localizes with cellular procaspase-3/caspase-3,42,43 it was of interest to determine if 
1541B could activate recombinantly expressed procaspase-3 in the presence of zinc; the activating effect 
of 1541B on procaspase-3 in vitro had previously only been evaluated under zinc-free conditions, which 
does not accurately simulated the cellular environment.34 As shown in Figure 2.3A, 1541B does not enhance 
intrinsic procaspase-3 enzymatic activity in zinc-containing buffers, whereas PAC-1 relieves zinc-mediated 
inhibition and induces the anticipated activating effect. The activity of PAC-1 is reliant upon its zinc binding 
ability, as an analogue that does not bind zinc (PAC-1a,30 Figure 2.3B) is not active in this experiment 
PC-3 and Zn2+
Kd = 350 nM 1541B
Primed
Procaspase-3
Caspase-3Inhibited 
Procaspase-3
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(Figure 2.3D). In addition, an inactive derivative of 1541B (compound 1541D,34 Figure 2.3C) has no effect 
in this experiment (Figure 2.3D).  
Figure 2.3. Capacity of procaspase-3 activating compounds and derivatives to increase the activity of recombinantly 
expressed procaspase-3. (A) PAC-1 restores procaspase-3 activity under inhibitory zinc conditions. Procaspase-3 (100 
nM) was incubated with PAC-1 or 1541B in zinc-supplemented caspase activity buffer. Enzymatic activity was 
assessed with Ac-DEVD-AFC after a 30 minute incubation. Data is normalized to procaspase-3 (100 nM) activity in 
zinc-free caspase activity buffer at 100% activity. Error bars represent SEM of three replicates. (B) Structure of non-
zinc binding and inactive PAC-1 derivative PAC-1a. (C) Structure of inactive 1541B derivative, 1541D. (D) PAC-1a 
and 1541D are not capable of relieving zinc-mediated inhibition and restoring procaspase-3 activity. Procaspase-3 
(100 nM) was incubated with PAC-1a or 1541D in zinc supplemented caspase activity buffer. Enzymatic activity was 
assessed with Ac-DEVD-AFC. Data is normalized to procaspase-3 (100 nM) activity in zinc-free caspase activity 
buffer as 100% activity. Error bars represent s.e.m. of three replicates. 
 
2.2.2 PAC-1 restores the capacity of 1541B to activate procaspase-3 under zinc-inhibitory 
conditions 
The orthogonal activity of PAC-1 and 1541B on procaspase-3 (PAC-1 activating zinc-bound 
procaspase-3, 1541B activating procaspase-3 with zinc removed34) suggests synergistic potential, and the 
combination of PAC-1 and 1541B, when incubated with procaspase-3 in vitro, leads to dramatic caspase-3 
activity far exceeding the effect of either compound alone (Figure 2.4A).  Consistent with the established 
structure−activity relationships,31,34 PAC-1a and 1541D as single agents and in combination were unable to 
facilitate procaspase-3 activation in vitro. 
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Figure 2.4. PAC-1 synergizes with 1541B to enhance procaspase-3/caspase-3 activity in vitro. (A) Procaspase-3 (350 
nM) in zinc supplemented caspase activity buffer was incubated 1541B, PAC-1, or 1541B + PAC-1, and enzymatic 
activity was assessed with Ac-DEVD-pNA. Data is normalized to 100% activity = 350 nM caspase-3 in zinc free 
caspase activity buffer. Error bars represent the SEM of three replicates. (B) Inactive analogues of PAC-1 and 1541B 
are unable to activate procaspase-3 as single agents or in combination. Procaspase-3 (350 nM) in zinc supplemented 
caspase activity buffer was incubated with 1541D (25 µM), PAC-1a (50 µM), or 1541D + PAC-1a, and enzymatic 
activity was assessed with AcDEVD-pNA. Data is normalized to 100% activity = 350 nM caspase-3 in zinc-free 
caspase activity buffer. Error bars represent the s.e.m. of three replicates. 
 
2.3 Evaluation of PAC-1 + 1541B for activation of procaspase-3 in cancer cell 
lines in culture 
2.3.1 PAC-1 + 1541B activate procaspase-3 in cancer cell lines in culture 
To examine PAC-1 synergy with 1541B for activation of procaspase-3 in cancer cells in culture, a 
panel of three cancer cell lines were treated with combinations of PAC-1 and 1541B and the caspase-3/-7 
activity of the cell lysates was monitored with the fluorogenic substrate Ac-DEVD-AFC. As seen in Figure 
2.5, co-treatment of U-937 (human lymphoma, A), BT-549 (human breast cancer, B), and A549 (human 
lung cancer, C) cells with PAC-1 and 1541B results in markedly more dramatic and rapid increases in 
caspase-3/-7 activity than treatment with either PAC-1 or 1541B as single agents. The combination 
treatment stimulates caspase-3/-7 activity that rivals or surpasses that induced by staurosporine (STS, 1 
µM), one of the most rapid inducers of cellular DEVDase activity known. Importantly, this effect was 
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shown to to be dose dependent, as increasing concentrations of 1541B, in combination with PAC-1, resulted 
in greater levels of observed caspase-3/-7 activity in A549 cells (Figure 2.5D).   
 
Figure 2.5. PAC-1 + 1541B combinations induce rapid and dramatic procaspase-3 activation in cancer cell lines in 
culture. (A) Cancer cell lines U-937, BT-549 and A549 were treated with PAC-1 (30 µM), 1541B (15 µM), or the 
combination, cells were lysed at various time points, and caspase-3/-7 activity of the lysates was evaluated with the 
fluorogenic Ac-DEVD-AFC substrate. Error bars represent the SEM of three replicates. STS = staurosporine. (B) 
PAC-1 + 1541B combinations induce dose-dependent rapid and dramatic procaspase-3 activation in A549 cancer cells 
in culture. Cell were treated with PAC- 1 (30 µM), 1541B (7.5, 10, 12.5 µM), or PAC-1 + 1541B. Cells were lysed at 
various time points, and caspase-3/-7 activity of the lysates was evaluated with the fluorogenic Ac-DEVD-AFC 
substrate. Error bars represent the s.e.m. of three replicates. 
 
To determine if the elevation of caspase-3/-7 activity was the result of enhanced cleavage of 
procaspase-3 to caspase-3 facilitated by compound co-treatment, cells were treated with PAC-1 and 1541B 
combinations and assessed by Western blotting for the disappearance of procaspase-3 bands and the 
appearance of cleaved active caspase-3 band. Dramatic activation of procaspase-3 to caspase-3 was 
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observed in U-937 (Figure 2.6A), BT-549 (Figure 2.6B), A549 (Figure 2.6C), HL-60 (Figure 2.6D) and 
Hs578T (Figure 2.6E) cells upon treatment with the PAC-1/1541B combinations, as evidenced by the 
appearance of cleaved caspase-3 bands. Conversely low/no procaspase-3 activation was observed with 
1541B or PAC-1 alone at the times and concentrations evaluated.  
 
 
Figure 2.6. PAC-1 + 1541B combinations induce rapid and dramatic procaspase-3 cleavage and maturation in cancer 
cell lines in culture. Cancer cell lines U-937 (A, 3 h treatment), BT-549 (B, 4 h treatment), A549 (C, 8 h treatment), 
HL-60 (D, 5 h treatment), and Hs578T (E, 6 h treatment) were treated with PAC-1 (30 µM), various concentrations 
of 1541B, or the combination, and evaluated by Western blot at time points reflective of maximal caspase activity, as 
observed in the cell lysate caspase activity experiment. Western blots are representative of at least two separate 
experiments. 
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2.3.2 PAC-1 + 1541B induce procaspase-3 activation before cytochrome c release from the 
mitochondria 
Intrinsic pathway mediated apoptosis proceeds via an ordered series of events, with Bcl-2 family 
proteins acting on the mitochondria, stimulating cytochrome c release, formation of the apoptosome and 
concurrent caspase-9 activation, and subsequent cleavage of procaspase-3 to caspase-3.45-47 Caspase-3 then 
cleaves scores of substrates, executing the apoptotic program.16 To examine the sequence of these events 
in cells treated with PAC-1 + 1541B, BT-549 cells were assessed for the timing of procaspase-3 activation 
relative to cytochrome c release from the mitochondria by Western blot of fractionated cell lysate 
(Schematic in Figure 2.7). Analysis of cells treated with PAC-1 + 1541B shows the appearance of cleaved 
caspase-3 bands in the cytosolic fraction before cytochrome c levels diminish in the mitochondria (Figure 
2.8A). At these compound concentrations and relatively short treatment times, 1541B as a single agent is 
considerably less effective at inducing procaspase-3 activation (Figure 2.8B), and PAC-1 is not effective. 
Importantly, as shown in Figure 2.8C, STS induces apoptosis through the canonical intrinsic pathway, with 
clear release of cytochrome c from the mitochondria prior to activation of procaspase-3.  
 
Figure 2.7. Schematic of simplified mitochondrial-mediated intrinsic pathway apoptosis. Yellow arrows indicate 
canonical events capable of distinguishing between mitochondrial mediated apoptosis and apoptosis initiated via direct 
procaspase-3 activation. 
 
 
53 
 
 Figure 2.8. Rapid procaspase-3 activation is observed in cells treated with PAC-1 + 1541B, occurring prior to release 
of cytochrome c from the mitochondria. (A) BT-549 breast cancer cells were treated with PAC-1 (30 µM) and 1541B 
(10 µM) over 8 h and assessed in the cytosol for procaspase-3 activation, and in the mitochondria for cytochrome c 
levels. (B) BT-549 cells treated with 1541B (10 µM) and assessed for 8 h. (C) BT-549 cells treated with STS (1 µM) 
and assessed for 10 h. Western blots are representative of at least two separate experiments. 
 
BT-549 cells were assessed by phase contrast microscopy and monitored for the phenotypic 
changes associated with caspase activation and apoptosis (Figure 2.9). Consistent with the Western blot 
and caspase activity data, only the combination of PAC-1 and 1541B demonstrated substantial 
morphological changes indicative of apoptosis, such as blebbing. 
 
2.3.3 PAC-1 + 1541B synergize to potently induce apoptosis of cancer cell lines in culture  
The combination of PAC-1 and 1541B was evaluated for the capacity to induce apoptotic death in 
a variety of cancer cell lines in culture using Annexin V-FITC and propidium iodide staining, following by 
analysis by flow cytometry. These experiments were performed at short incubation times of 6 hours, 
reflective of the timing of caspase activation observed in Figure 2.5 and 2.6 and where neither compound 
exerts a significant effect as a single agent. PAC-1 significantly synergizes with 1541B for potent 
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proapoptotic activity in U-937 (Figure 2.10A), BT-549 (Figure 2.10B), A549 (Figure 2.10C), HL-60 
(Figure 2.10D), Hs578T (Figure 2.10E), and U-87 cells (Figure 2.10F); the dashed horizontal lines in each 
graph mark levels of cell death that would be observed from a strictly additive effect of PAC-1 and 1541B.  
 
Figure 2.9. PAC-1 + 1541B combinations induce dramatically enhanced cellular blebbing. Human breast cancer BT-
549 cells were treated for up to 8 hours with PAC-1 (30 µM), 1541B (10 µM) or the combination and morphology 
was assessed by phase contrast microscopy. Images are representative of two or more images per treatment and time 
point.  
 
Flow cytometry analysis with AnnexinV-FITC and PI staining of U-937 cells demonstrated that 
the combination produced significant populations of cells stained positively with Annexin V-FITC (Figure 
2.11). This indicated that combination of PAC-1 and 1541B induced rapid cell death via apoptosis.   
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Figure 2.10. PAC-1 and 1541B synergize to induce rapid apoptotic cell death in cancer cell lines. (A-F) Cancer cell 
lines (A – U-937; B – BT-549; C – A549; D – HL-60; E – Hs578T; F – U-87) were treated with the indicated 
concentrations of PAC-1 (0, 15, and 30 µM) and 1541B (0, 7.5, 10 µM) for 6 hours, and apoptotic death was assessed 
using flow cytometry with Annexin V-FITC/propidium iodide staining. Error bars represent the SEM of three 
replicates. The dotted horizontal lines represent the level of cell death expected from a mere additive effect. of PAC-
1 and 1541B for each drug combination. 
 
While the non-blood-brain barrier permeable analogue S-PAC-132,44 (Figure 2.12A) possesses a 
comparable capacity for synergy as PAC-1 (Figure 2.12B), synergy was not observed when inactive 
analogues of PAC-1 (PAC-1a) or 1541B (1541D) were used in combination with 1541B or PAC-1, 
respectively, following either 6 or 24 hours of co-treatment (Figure 2.12C-F).  
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Figure 2.11. U-937 cells were treated with the indicated concentrations of PAC-1 and/or 1541B for six hours, and 
assessed via Annexin V-FITC/propidium iodide staining and flow cytometry. Histograms shown are representative of 
three experiments. 
 
Further assessment (in U-937 cells) of a broad range of concentrations for both compounds clearly 
shows the dramatic synergy between these two agents. Shown in Figure 2.13 is the cell death induced by 
the compound matrix, with synergy apparent from simple comparisons of the percent cell death induced by 
the single agents versus the combinations; this is true at both short (6 h, Figure 2.13A) and long (24 h, 
Figure 2.13C) time points. Synergism is frequently quantified in such experiments though calculation of 
Combination Indices (CI) using the Chou and Talalay method.48-50 Combinations describing synergistic 
interactions possess CI values 1; additive effects when the CI value equals 1.  Thus, the lower the CI value, 
the stronger the synergy. When U-937 cells were treated with a range of PAC-1 and 1541B compound 
concentrations in combination, synergistic interactions were observed broadly, with several combinations 
considered strongly synergistic (Figure 2.13B, D).  
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Figure 2.12. S-PAC-1 and 1541B synergize to induce rapid apoptosis in U-937 cancer cells, but inactive derivatives 
PAC-1a and 1541D do not. (A) Structure of S-PAC-1. (B) Apoptosis is induced rapidly by S-PAC-1 and 1541B 
combinations. Cells were treated with the indicated concentrations of S-PAC-1 and 1541B for 6 h and apoptotic death 
was assessed using flow cytometry with Annexin V-FITC/propidium iodide staining. Error bars represent the s.e.m. 
of three replicates. The dotted horizontal lines represent the level of cell death expected from a mere additive effect 
of each S-PAC-1 and 1541B drug combination. (C-D) Inactive derivative PAC-1a and 1541B do not synergize in U-
937 cancer cells. Cells were treated with the indicated concentrations of PAC-1a and 1541B for 6 h (C), or 24 h (D) 
and apoptotic death was assessed using flow cytometry with Annexin V-FITC/propidium iodide staining. (E-F) PAC-
1 and inactive derivative 1541D do not synergize in U-937 cancer cells. Cells were treated with the indicated 
concentrations of PAC-1 and 1541D for 6 h (E), or 24 h (F) and apoptotic death was assessed using flow cytometry 
with Annexin V-FITC/propidium iodide staining. Error bars represent the SEM of three replicates. 
 
The proapoptotic effect of the PAC-1/1541B combination was markedly reduced with the pan-
caspase inhibitor Q-VD-OPh, consistent with the involvement of caspases in the mode of cell death (Figure 
2.14A). To further investigate the connection between activation of procaspase-3 and the apoptotic cell 
death induced by the drug combination, the MCF-7 isogenic cell lines pair was used. MCF-7 cells do not 
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express procaspase-3,51 thereby enabling analysis of the role of procaspase-3 via comparison with a 
matched cell line transfected to express procaspase-3 (Figure 2.14B). The combination of PAC-1/1541B 
has minimal effect on MCF-7 cells transfected with control plasmid (MCF-7 VRL), but dramatically 
induces apoptosis in procaspase-3 expressing MCF-7 cells (MCF-7 C-3) (Figure 2.14C). This cell-line 
dependent apoptosis is consistent with analysis of the MCF-7 C3 cells by Western blot, which demonstrated 
that the PAC-1/1541B combination induced the appearance of cleaved caspase-3 bands (Figure 2.14D). 
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Figure 2.13. PAC-1 and 1541B synergize to induce rapid cell death in a human lymphoma cell line (U-937). (A, C) 
Percent cell death observed after 6 h (A) and 24 h (C) treatment of U 937 cells with PAC-1 + 1541B combinations in 
matrix format. Values are heat mapped with white equal to 0% cell death and red equal to 100% cell death. Error 
represents the SEM of three replicates. (B, D) Combination Index values calculated for each combination with 
Combosyn software (<1 indicates synergistic interaction with values <0.3 indicating strong synergism). Values are 
heat mapped with lowest values in green and highest values in red. (B) Combination Index values for 6 h treatment. 
(D) Combination Index values for 24 h treatment.   
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Figure 2.14. PAC-1 and 1541B induce rapid caspase-dependent cell death in cancer cell lines. (A) The pan-caspase 
inhibitor Q-VD-OPh (25 µM) protects against PAC-1 + 1541B-mediated cell death in U-937 cells (6 h treatment). 
Error bars represent the SEM of three replicates. (B) Western blot analysis of MCF-7 cells transformed with empty 
plasmid (MCF-7 VRL) and MCF-7 cells transformed with a plasmid containing the gene for procaspase-3 (MCF-7 C-
3). (C) MCF-7 VRL and MCF-7 C-3 cells were treated with the indicated concentrations of PAC-1 and 1541B (for 6 
h) and apoptotic death was assessed using flow cytometry with Annexin V-FITC/propidium iodide staining. Error 
bars represent the SEM of three replicates. The dotted horizontal lines represent the level of cell death expected from 
a mere additive effect of PAC-1 and 1541B for each drug combination. (D) Western blot of MCF-7 C-3 cells treated 
for 6 h with combinations of PAC-1 (30 µM) and 1541B. 
 
2.4 Evaluation of PAC-1 + 1541B in vivo 
2.4.1 Assessment of toxicity of 1541B as a single agent and in combination with PAC-1 in mice  
To explore the therapeutic utility of the dual procaspase-3 activation strategy, the combination of 
PAC-1 and 1541B was assessed in vivo. HPβCD was used as vehicle, and compounds were administered 
via IP injection. Prior to beginning efficacy studies, the tolerability and toxicity of 1541B as a single agent 
was first established (Table 2.1).  Based on these findings, the maximum tolerable dose (MTD) of 1541B 
for repeated doses is 20 mg/kg (Table 2.1). Prior work with PAC-1 as a single agent had determined that 
roughly 200 mg/kg daily, for ten days, is well-tolerated (T. Fan, unpublished work). With this knowledge, 
the MTD of the combination of these two compounds, in combination was systematically evaluated (Table 
0
20
40
60
80
100
15 µM PAC-1 +
12.5 µM 1541B
30 µM PAC-1 +
12.5 µM 1541B
%
 A
po
pt
os
is
15 µM 
PAC-1 + 
12.5 µM 
1541B
30 µM 
PAC-1 + 
12.5 µM 
1541B
(-) Q-VD-OPh
(+) Q-VD-OPh
0
20
40
60
80
100
0 µM PAC-1 15 µM PAC-1 30 µM PAC-1
MCF-7 VRL
0 µM 1541B
10 µM 1541B
0
20
40
60
80
100
0 µM PAC-1 15 µM PAC-1 30 µM PAC-1
MCF-7 C3
0 µM 1541B
10 µM 1541B
%
 A
po
pt
os
is
0 15 30
[PAC-1] (µM)
0 15 30
[PAC-1] (µM)
A C
DB
PC-3
VRL    C3
β-Actin
PC-3
C-3
β-Actin
1541B (µM) 0 7.5 10 12.5 15
PAC-1 (30 µM) - + - + - + - + - +
61 
 
2.2).  At dosages up to 125 mg/kg PAC-1 and 17.5 mg/kg 1541B, mice tolerated the treatment well and 
were completely asymptomatic by visual inspection and behavioral analysis. On the basis of these results, 
a maximum combination dosage of 125 mg/kg of PAC-1 followed by 17.5 mg/kg of 1541B was chosen for 
the efficacy model.  
 
Table 2.1. MTD studies of 1541B (formulated at 0.5 mg/ml in HPβCD), administered by intraperitoneal injection in 
female C57BL/6 mice.   
1541B dosage 
(mg/kg,) 
Number of 
consecutive daily 
treatments 
Result 
5 5 3/3 mice asymptomatic 
10 5 3/3 mice asymptomatic 
15 5 3/3 mice asymptomatic 
20 5 3/3 mice asymptomatic 
25 3 2/3 mice survived treatment with 20% weight loss 
50 1 3/3 mice survived treatment with 10% weight loss after 24 h. Mice were symptomatic for 48 h post-treatment 
 
 
Table 2.2. MTD studies of PAC-1 (formulated at 12.5 mg/ml in HPβCD) and 1541B (formulated at 0.5 mg/ml in 
HPβCD), administered by intraperitoneal injection in female C57BL/6 mice.   
Fraction of 
MTD 
PAC-1 
dosage 
(mg/kg) 
1541B 
dosage 
(mg/kg) 
Result 
1/10 20 2 3/3 mice asymptomatic 
1/6 33.3 3.3 3/3 mice asymptomatic 
1/3 66.7 6.7 3/3 mice asymptomatic 
1/2 100 10 3/3 mice asymptomatic 
3/4 150 15 3/3 mice survived treatment and demonstrated toxicity for 24 h 
‘sub-toxic 
level’ 125 17.5 3/3 mice asymptomatic 
 
To more comprehensively investigate the biochemical, hematologic and non-hematologic toxicity 
of PAC-1 and 1541B combination treatment, mice were treated for three consecutive days and sacrificed 
for analysis (IP administrations of HPβCD, PAC-1, 1541B, or combination (PAC-1 + 1541B)). Analysis of 
blood revealed no clinically significant evidence for myelosuppression, renal injury, or hepatic toxicity was 
identified in any of the treatment cohorts (Table 2.3). For mice receiving HPβCD, PAC-1, or 1541B alone, 
62 
 
all collected target organs were devoid of histologic evidence for inflammation and necrosis. In mice 
receiving combination PAC-1 and 1541B, pathologic changes were noted in the lung parenchyma of 2 out 
of 3 mice. These mice had eosinophilic and histiocytic perivascular and peribronchiolar infiltrates, which 
were mild to moderate in severity. The clinical significance of this finding is unclear, as mice in these 
groups were asymptomatic and did not demonstrate weight loss compared to controls.  
 
Table 2.3. Hematologic Toxicity of PAC-1 and 1541B.  No clinically significant evidence for myelosuppression, renal 
injury or hepatic toxicity was identified in any of the treatment groups.   
 HPbCD PAC-1  (125 mg/kg) 
1541B  
(17.5 mg/kg) 
PAC-1 (125 mg/kg) 
+ 1541B (17.5 
mg/kg) 
WBC 
(cells/µL) 7193.3 ± 1628.4 11483.3 ± 2815.3 12723.3 ± 3401.9 10976.7 ± 3090.2 
Neutrophil 
(cells/µL) 1653 ± 1347.1 2405.3 ± 2697.4 2477.9 ± 2506.6 2142.3 ± 1085.8 
Lymphocyte  
(cells/µL) 5345.1 ± 1047.7 8692.5 ± 1975.5 9398.2 ± 2367.2 7711.9 ± 2845.6 
Hematocrit 
(%) 42.3 ± 1.9 42.2 ± 0.8 41.9 ± 5.6 44.0 ± 0.8 
Platelets 
(cells/µL) 
601666.7 ± 
439496.7 1038000 ± 173225.3 872666.7 ± 78360.3 
985333.3 ± 
121022 
Creatinine 
(mg/dl) 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 
BUN 
(mg/dl) 25 ± 2.6 30.3 ± 6.0 27.3 ± 6.8 27.3 ± 1.5 
Albumin 
(g/dl) 3.1 ± 0.2 3.5 ± 0.1 3.3 ± 0.2 3.6  ± 0.1 
ALP 
(U/L) 89.7  ± 17.5 134 ± 23.6 64.3 ± 22.7 85.3 ± 5.9 
ALT 
(U/L) 23.3 ± 1.5 36.7 ± 5.8 47 ± 51.3 27.3 ± 17.2 
T. Bilirubin 
(mg/dl) 0.2 ± 0.1 0.2 ± 0.0 0.2 ±  0.1 0.2 ± 0.0 
 
The pharmacokinetic parameters of each compound were then determined (Table 2.4). Following 
a single IP injection at a dose of 125 mg/kg, PAC-1 in HPβCD was rapidly absorbed and achieved a 
maximal plasma concentration of 32720.0 ng/mL within 20 min post-injection. PAC-1 was distributed 
quickly throughout the body with a mean distribution half-life of 20 min and a mean terminal elimination 
half-life of 4.2 h. Likewise, 1541B in HPβCD was absorbed and reached a maximal plasma concentration 
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of 2699.9 ng/mL within 20 min of intraperitoneal administration. The distribution half-life of 1541B was 
20 min and the terminal elimination half-life was 5.4 h.  
 
Table 2.4. Pharmacokinetic parameters of PAC-1 (125 mg/kg) and 1541B (17.5 mg/kg) solubilized in HPβCD 
following single intraperitoneal injection in female C57BL/6 mice assuming 100% bioavailability following injection 
(Based upon average body weight of 20 g). 
Parameter PAC-1   (mean ± SD) 
1541B  
 (mean ± SD) 
t1/2 α (h) 0.3 ± 0.06 0.3 ± 0.04 
t1/2 β (h) 4.2 ± 0.5 5.4 ± 0.4 
Cmax (ng/ml) 32720.0 ± 2995.2 2699.9 ± 491.0 
Cls (ml/h) 158.2 ± 10.6 468.3 ± 32.0 
Vdss (ml) 88.2 ± 3.9 1420.0 ± 196.6 
Vdc (ml) 76.8 ± 7.4 1095.9 ± 152.1 
AUC0-inf (ng x h/ml) 15823.8 ± 1094.9 1868.3 ± 127.7 
 
2.4.2. PAC-1 + 1541B is efficacious in a murine model of lymphoma  
The EL4 syngeneic murine lymphoma model was chosen to explore the therapeutic utility of PAC-
1 and 1541B combinations, as PAC-1 and 1541B synergize to induce dramatic activation of procaspase-3 
and cell death versus this cell line (Figure 2.15A, B), and it is a challenging treatment model due to its rapid 
doubling time (less than 24 h)52 and uniformly high tumor formation rate (100%) when inoculating greater 
than 1 × 106 cells subcutaneously in C57BL/6 mice.53 PAC-1 was chosen over S-PAC-1 for the combination 
studies as it has greater activity versus the EL4 cell line in culture.32 C57BL/6 mice implanted with EL4 
cells were treated with PAC-1 alone (125 mg/kg), 1541B alone (17.5 mg/kg), or sequential treatments of 
PAC-1 + 1541B (125 mg/kg and 17.5 mg/kg, respectively) once-a-day for three days, formulated in 
HPβCD. Once tumors in vehicle treated mice had reached their maximum allowed size of 1500 mm3 (8 
days), all mice were sacrificed, and tumors were excised and weighed. As shown in Figure 2.15C, 1541B 
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treatment had no effect, and PAC-1 had a small but statistically significant effect on tumor growth in this 
model. However, the combination of PAC-1 and 1541B dramatically retarded tumor growth (Figure 2.15C). 
 
 
Figure 2.15. PAC-1 and 1541B are efficacious against EL4 murine lymphoma in cell culture and in vivo. (A) PAC-1 
+ 1541B combinations induce rapid and dramatic procaspase-3 cleavage and maturation in EL4 cells in culture. Cells 
were treated with PAC-1 (30 µM), various concentrations of 1541B, or the combination, and evaluated by Western 
blot after 4 h. (B) EL4 cells were treated with the indicated concentrations of PAC-1 and 1541B and apoptotic death 
was assessed using flow cytometry with Annexin VFITC/propidium iodide staining. Error bars represent standard 
error across three replicates. The dotted horizontal lines represent the level of cell death expected from a mere additive 
effect of PAC-1 and 1541B for each drug combination. (C) EL4 cells were injected subcutaneously into C57BL/6 
mice (10 million cells per mouse), the animals were split into four groups and treated once-a-day for three days via IP 
injection with vehicle (2-hydroxypropyl-β cyclodextrin, HPβCD), 1541B (17.5 mg/kg in HPβCD), PAC-1 (125 mg/kg 
in HPβCD), or 1541B + PAC-1 (17.5 and 125 mg/kg, respectively, in HPβCD). After eight days the mice were 
sacrificed and the tumors excised and weighed. n = 6−7 mice per group. P-values are relative to vehicle control; *, P 
< 0.005; **, P < 5 × 10−6. 
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2.5 Conclusions 
2.5.1 Dual small-molecule targeting of procaspase-3 enables activation that is more rapid and 
efficient than either molecule can achieve alone   
 While there is clear benefit to anticancer strategies utilizing combinations of drugs that act on 
different targets, the work described herein demonstrates that dramatic synergy can be observed with 
compounds that act through orthogonal mechanisms on the same biological target. This multi-targeting 
approach may have particular advantages when activation of an enzyme is sought. Rational deseing of 
‘novel-novel’ combinations of molecularly targeted agents frequently target ‘vertical’ inhibition of a 
pathway, or ‘horizontal’ inhibition of parallel signaling pathways, with the goal of preemptively 
overcoming known resistance mechanisms and feedback loops.9 However, the dual inhibition of a single 
target via orthogonal mechanisms has also been successful with the combination of Herceptin and 
pertuzumab.54,55 Herceptin binds to HER2, but a known mechanism of resistance is continued HER2/HER3 
dimerization. Pertuzumab, in contrast, binds to an alternate site on HER2, to inhibit dimerization. However, 
as many small-molecule inhibitors target the active site of the protein in similar ways, this approach has not 
become widespread. Furthermore, as many inhibitors require tonic suppression of their target in vivo for 
activity, dual inhibition of a single target may have limited value. Furthermore, many small-molecule 
molecularly targeted agents possess greater than expected toxicity.  Thus, dual inhibition of a single protein 
may possess only limited utility as a clinical strategy.  In contrast, activation of a protein target presents an 
opportunity to greatly increase the overall biologic effect. This may be particularly true for enzymes that 
possess auto-catalytic activity. PAC-1 chelates the labile inhibitory zinc from procaspase-3 and caspase-3, 
thus priming the enzyme for robust and efficient activation by 1541B. In cell culture at conditions where 
neither compound significantly induces death at 6−12 h, dramatic enhancement of apoptotic cell death (over 
the additive effect) is observed with the PAC-1 + 1541B combination. This cell death is tied to the ability 
of the PAC-1 + 1541B combination to induce a rapid conversion of procaspase-3 to caspase-3, as shown 
by the Western blots and the caspase-3/-7 enzymatic activity in cell lysates. PAC-1 is safe in mice and 
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dogs,56 and a derivative of PAC-1, S-PAC-1, showed promising activity in a phase I clinical trial of pet 
dogs with lymphoma,32 thus the observed synergy with 1541B could have clinical significance. PAC-1 has 
been utilized as a tool for studying direct procaspase-3 activation in various systems,27,57 and data presented 
herein suggest that the PAC-1 + 1541B combination will also be valuable as a tool for rapidly activating 
procaspase-3. As interest in activating enzymes with small molecules is increasing rapidly and has 
considerable medicinal potential,58-62 our data suggest that targeting strategies using two small molecules 
with different activation mechanisms could be a general approach for dramatic enhancement of the intended 
biological effect. 
  
2.6 Materials and methods 
General 
All antibodies were purchased from Cell Signaling Technology: β-actin (9542), pro- and active 
caspase-3 (9662), cytochrome c (4272), and COX IV (5247). RIPA lysis buffer was prepared (50 mM Tris 
base, 150 mM NaCl, 1% TritonX-100, 0.5% Na-deoxycholate, 0.1% SDS, pH7.4) and a 1:100 dilution of 
Protease Inhibitor Cocktail Set III (CalBioChem) was added immediately prior to use. Annexin V-FITC 
conjugate was obtained from SouthernBiotech. Propidium iodide was obtained from Sigma Aldrich.  
 
In Vitro Activation of Procaspase-3  
Procaspase-3 and caspase-3 were expressed as follows (adapted from33) A 20 mL volume of an 
overnight culture of Rosetta E. coli containing the procaspase-3 (wild-type) expression plasmid was seeded 
into 2 L of LB media containing ampicillin. The culture was grown to an OD600 = 1.0, at which point protein 
expression was induced via addition of IPTG (to 1 mM); the culture was allowed to grow for 30 additional 
minutes. Cells were then harvested (10 minute spins at 10,000xg and re-suspended in NTA binding buffer 
(300 mM NaCl, 50 mM Tris, 10 mM imidazole, pH 8.0). The cells were lysed on ice via sonication. The 
cell lysate was then clarified at 35,000xg for 35 min. The supernatant was decanted and 1 mL of nickel-
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NTA resin was added. The cell lysate was incubated with gentle agitation for 45 minutes at 4°C. The resin 
was loaded on a column, washed with 10 mL NTA binding buffer followed by 10 mL NTA wash buffer 
(300 mM NaCl, 50 mM Tris, 50 mM imidazole, pH 8.0). The proteins were eluted in 0.5 mL fractions with 
10 mL of NTA elution buffer (300 mM NaCl, 50 mM Tris, 500 mM imidazole, pH 8.0). Fractions 
containing protein were pooled and further purified3 to remove any contaminating zinc by applying the 
protein to a PD-10 column (GE Healthcare) charged with Caspase Activity Buffer that had been treated 
with Chelex ® resin. The resulting concentration was determined using the Edelhoch method and the molar 
absorptivity of procaspase-3 of 26150 M−1 cm −1. Protein stocks were flash-frozen in liquid nitrogen and 
stored at -80°C and purified with Qiagen nickel-NTA resin. Increasing concentrations of PAC-1, 1541B, 
PAC- 1a and 1541D were assessed for their capacity to enhance activity of 100 nM procaspase-3 in an 
inhibitory zinc-based system (2 µM ZnSO4, 50 mM HEPES, 50 mM KCl, 1.5 mM TCEP, 0.1% CHAPS, 
pH 7.6). Compounds were added to zinc-inhibited PC-3, incubated for 30 min, and activity was assessed 
by cleavage of Ac-DEVD-AFC (50 µM) and was normalized to 100 nM procaspase-3 in zinc-free caspase 
activity buffer (50 mM HEPES, 50 mM KCl, 1.5 mM TCEP, 0.1% CHAPS, pH 7.6). 1541B (20 and 25 
µM) and PAC-1 (25 and 50 µM) were evaluated separately and in combination for their capacity to activate 
350 nM procaspase-3 over time in a mildly inhibitory zinc-based system (750 nM ZnSO4, 50 mM HEPES, 
50 mM KCl, 5 mM TCEP, pH 7.6, 0.1% TritonX-100). At designated time points aliquots were assessed 
by cleavage of Ac-DEVD-pNA (200 µM). 350 nM caspase-3 in a zinc-free caspase activity buffer (50 mM 
HEPES, 50 mM KCl, 5 mM TCEP, pH 7.6, 0.1% TritonX-100) was used for 100% caspase-3 activity. 
 
Cell Culture Conditions 
All cells were grown in RPMI 1640, DMEM or EMEM media supplemented with 10% FBS, 1% 
penicillin-streptomycin and incubated at 37 ºC in 5 % CO2, 95% humidity incubator. 
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Caspase Activation in Cell Lysate.  
U-937 (50,000 cells per well), BT-549 (10,000 cells per well) and A549 (10,000 cells per well) 
were plated in 96-well plates, allowed to adhere overnight (BT-549 and A549), and incubated with 1 µM 
Staurosporine (STS), 1541B (7.5, 10, 12.5, or 15 µM), PAC-1 (30 µM), 1541B (7.5, 10, 12.5, or 15 µM) 
and PAC-1 (30 µM) or DMSO (final concentration 1%) in phenol-red free RPMI media. Plates were 
assessed for executioner caspase activity via addition of a 4X bifunctional lysis activity buffer (200 mM 
HEPES, 400 mM NaCl, 40 mM DTT, 0.4 mM EDTA, 1% TritonX-100, 20 µM Ac-DEVD-AFC). 
Fluorescence was measured after a one-hour incubation. Activity is expressed as normalized to minimal 
and maximal activity observed within the assay. 
 
Western Blot Assessment of Procaspase-3 Cleavage to Caspase-3  
For Western analysis one million suspension (U-937, HL- 60 and EL4) or adherent cells at 75% 
confluency in 6-well plates were treated with increasing concentrations from 7.5 to 12.5 µM 1541B in the 
presence or absence of 30 µM PAC-1 for a duration reflective of near maximal caspase activity as seen in 
the cell lysate experiment. At the conclusion of treatment, the medium and Trypsin-aided detached cells 
were pelleted, lysed on ice in RIPA buffer (50 mM Tris base, 150 mM NaCl, 1% TritonX-100, 0.5% Na-
deoxycholate, 0.1% SDS, pH7.4, with a 1:100 dilution of Protease Inhibitor Cocktail Set III), and clarified, 
and protein content was normalized by BCA Protein Assay reagent (Pierce). Samples were denatured, 
separated by SDS-PAGE (4−20%), and transferred to a membrane for Western blot analysis of pro- and 
active caspase-3 (Cell Signaling 9662). Blots were stripped and reprobed for β-Actin (Cell Signaling 4970) 
as a loading control. 
 
Western Blot Assessment of Procaspase-3 Activation and Cytochrome c Release Timing 
 BT-549 cells at 75% confluency (allowed to adhere for >24 h) in 6-well plates were treated with 
10 µM 1541B and 30 µM PAC-1, 10 µM 1541B or 1 µM STS for up to 10 h. At each time point, medium 
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and Trypsin-aided detached cells were pelleted, washed in PBS and suspended in cold digitonin 
permeabilization buffer (75 mM NaCl, 1 mM sodium phosphate monobasic, 8 mM sodium phosphate 
dibasic, 250 mM sucrose, 200 µg/mL of digitonin, protease cocktail inhibitor, pH 7.5) and placed on ice for 
5 min. Permeabilized cells were centrifuged (14 000 rcf, 5 min), and the supernatant (cytosolic fraction) 
was saved. The pellet (mitochondrial fraction) was washed with digitonin permeabilization buffer, lysed in 
RIPA buffer, and clarified. Protein content for all samples was normalized (Pierce BCA Protein Assay). 
Samples were denatured, separated by SDS-PAGE and transferred to a membrane for Western blot analysis 
probed for the presence of pro- and active caspase-3 (Cell Signaling 9662), and cytochrome c (Cell 
Signaling 4272). Western blots were stripped and reprobed for β-Actin (Cell Signaling 4970) and COX IV 
(Cell Signaling 5247) as loading controls. 
 
Induction of Apoptosis 
The induction of apoptosis was measured by Annexin V-FITC/Propidium iodide staining and flow 
cytometry. Either 1,000,000 suspension (U-937, HL-60, EL4) cells or adherent cells at 75% confluency 
in 6-well plates were treated with combinations of PAC-1 and 1541B (final concentration of DMSO <1%). 
The entire contents of each well was then transferred to flow cytometry tubes, pelleted, and suspended in 
450 µL of Annexin VFITC binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, 1% BSA, pH 
7.4), premixed with Annexin V-FITC and Propidium iodide dyes. Staining was assessed by flow cytometry 
(10 000 events per sample). The Annexin V-FITC (−)/Propidium iodide (−) population was confirmed to 
be greater than 90% viable and normalized as the live control. Percent apoptosis was determined as 100% 
minus the viable quadrant. The role of caspases in the induction of apoptosis was assessed by cotreatment 
with 25 µM Q-VD-OPh (CalBioChem). 
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1541B and PAC-1 + 1541B MTD 
All experimental procedures were reviewed and approved by the University of Illinois Institutional 
Animal Care and Use Committee. 6−8 week old C57BL/6 mice were used in all experiments (Charles 
River). The maximum tolerated dose (MTD) of 1541B was determined. Beginning at 5 mg/kg, (formulated 
at 0.5 mg/mL in HPβCD, pH 5.5) mice (groups of three) were treated for 5 consecutive days and monitored 
for signs of toxicity. MTD was the highest dosage for which all mice survived and acceptable (<20%) 
weight loss was observed. The MTDs of PAC-1 (200 mg/kg) and 1541B (20 mg/kg) were used as the base 
unit for determining the combined MTD. Beginning with 1/10 of each MTD (20 mg/kg PAC- 1 + 2 mg/kg 
1541B), mice were treated with PAC-1, followed by 1541B one hour later. Groups of 3 mice were treated 
with 1/10, 1/6, 1/4, 1/3, 1/2 and 3/4 of each single agent’s MTD. Given the tolerability of 1/2 and the 
toxicity of 3/4, an additional treatment of 125 mg/kg PAC-1 + 17.5 mg/kg 1541B was evaluated and 
determined to be the combined MTD. 
 
Toxicity Assessment 
Ten week old, C57BL/6 female mice (n = 3/cohort) were administered three consecutive daily 
intraperitoneal injections of hydroxypropyl-β-cyclodextrin (vehicle), PAC-1 (125 mg/ kg), 1541B (17.5 
mg/kg), or PAC-1 + 1541B (125 mg/kg +17.5 mg/ kg, respectively), and then humanely sacrificed 24 h 
later. Heparinized whole blood was collected for assessment of total white blood cells, neutrophils, 
lymphocytes, hematocrit, platelets, creatinine, blood urea nitrogen, albumin, alanine aminotransferase, 
alkaline phosphatase, and total bilirubin. Mice were necropsied, and heart, lung, kidney, liver, spleen, 
gastrointestinal tract and brain were collected for histopathology. Tissue samples were fixed overnight in 
10% neutral buffered formalin, processed, and paraffin embedded for histopathology using routine 
methods. Tissue blocks were sectioned into 3 µm tissue sections and stained with hematoxylin and eosin. 
All slides were systematically evaluated by a single board certified veterinary pathologist (LBB) for 
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evidence of acute or chronic inflammation and toxicity. All lesions were characterized, recorded, and scored 
for severity (minimal = 1, mild = 2, moderate = 3, and severe = 4). 
 
Pharmacokinetics 
Ten week old, C57BL/6 female mice were administered a single intraperitoneal dose of PAC-1 at 
125 mg/kg or 1541B at 17.5 mg/kg, and sacrificed in cohorts of 3 at predetermined time points (0, 10, 20, 
30, 40, 60, 120, 240, 360, 720, and 1440 min). Blood was collected and centrifuged, and plasma separated 
for quantification of PAC-1 or 1541B by HPLC methods (UIUC Metabolomics Center, Urbana, IL). 
Pharmacokinetic analyses were performed, using a nonlinear regression program (Winnonlin, version 5.1, 
Pharsight Corporation, Cary, NC). 
 
EL4 Syngeneic Tumor Model  
Ten million EL4 cells were prepared in HBSS and injected subcutaneously on the right flank of 
sedated (ketamine/xylazine) mice (day 0). By three hours postinjection the injection bleb was no longer 
evident, and soft tumors appeared the following morning. Mice were randomized into four treatment 
groups: vehicle, 1541B alone, PAC-1 alone, and 1541B + PAC-1. Mice were treated on days 1, 2, and 3. 
Compounds were formulated in HPβCD (1541B at 0.5 mg/mL at pH 5.5 and PAC-1 at 12.5 mg/mL at pH 
5.5). All mice received two treatments, one hour apart: vehicle (HPβCD + HPβCD), 1541B (HPβCD + 
1541B), PAC- 1 (PAC-1 + HPβCD) and 1541B + PAC-1 (PAC-1 + 1541B). After 8 days the largest tumors 
had achieved maximal size; mice were sacrificed, and tumors were excised and weighed. 
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Chapter 3. Survey and evaluation of PAC-1 in combination with diverse 
chemotherapeutics 
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3.1 Introduction 
3.1.1 Role of cytotoxic chemotherapeutics in the early treatment of cancer and their modern 
utility 
Cytotoxic chemotherapy formed the foundation of historical cancer treatments, and despite 
concerted efforts to understand and exploit molecular mechanisms driving cancer growth, cytotoxic 
chemotherapies remain essential to numerous frontline and salvage treatment protocols.1-6 Patients are 
treated with cytotoxic chemotherapies when targeted agents have not been developed for their malignancy, 
when they do not respond to targeted therapies, or upon the development of resistance.7 Despite the 
enthusiasm for personalized medicine in oncology, the majority of these molecularly targeted therapeutics 
are not curative when used as single agents;8-10 moreover, molecularly targeted agents have been 
successfully integrated into a number of combination chemotherapy regimens.11-13 Pre-clinically and 
clinically, many targeted agents have demonstrated the ability to dramatically enhance the activity of 
cytotoxic chemotherapies;14-17 thus, a molecularly targeted therapeutic that broadly synergizes with 
traditional cytotoxic chemotherapeutics would have potential for enormous clinical impact.  
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3.1.2 Rational combination of PAC-1 with cytotoxic chemotherapeutics  
As described thoroughly in Chapter 1, procaspase-3, the zymogen form of the key executioner of 
apoptosis, caspase-3, is over-expressed in numerous cancers.18 As unrestricted caspase-3 activity is lethal 
to cells, mechanisms exist that directly inhibit both procaspase-3 activation and caspase-3 activity, 
including protein inhibitors of caspase-3 (XIAP and survivin) and the labile zinc pool.19-21 Labile zinc co-
localizes with procaspase-3 within cells22,23 and inhibits both procaspase-324 and caspase-321,25,26 activity. 
By chelating the labile zinc pool,27 PAC-1 is able to achieve single agent anticancer activity by facilitating 
the auto-activation of procaspase-3 to caspase-3,24,28,29 thereby inducing apoptosis.  
As most classical cytotoxic chemotherapeutic agents achieve their anticancer activity through the 
induction of apoptosis, we questioned whether facilitation of the final cleavage event of the apoptosis-
initiating caspase cascade (activation of procaspase-3 to caspase-3), could broadly enhance the activity of 
the apoptosis-inducing chemotherapeutics (schematic in Figure 3.1). Based upon the ubiquitous over-
expression of procaspase-3 in diverse cancer types, and the common mode of cytotoxic chemotherapeutic-
induced cell death, we hypothesized that PAC-1 would enable synergy with diverse cytotoxins in a range 
of cancer types. Furthermore, the widespread clinical usage of cytotoxic chemotherapeutics, suggests a 
molecularly targeted agent capable of broadly synergizing with traditional cytotoxic chemotherapeutics 
would have potential for enormous clinical impact.  
Interestingly, in select studies, PAC-1 has shown the ability to potentiate targeted agents,30-32 
including 1541B, as described in Chapter 2. Even more excitingly, limited studies have suggested that PAC-
1 may synergize with select conventional chemotherapeutics (paclitaxel, cisplatin).33,34 Thus, our objective 
was to perform a comprehensive study of PAC-1 in combination with a broad range of FDA-approved 
chemotherapeutics. Unfortunately, a major limitation to the clinical utility of many cytotoxic 
chemotherapeutic agents and combination treatments is significant and often overlapping toxicity profiles. 
Therefore, a significant aim of this project was to examine the feasibility of combining PAC-1 with 
cytotoxic chemotherapeutics, without compounding toxicity.  
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Figure 3.1. PAC-1 facilitates the activation of procaspase-3 to caspase-3, the final step in intrinsic pathway mediated 
apoptosis.  
 
3.2 Survey of PAC-1 in combination with 15 FDA-approved cytotoxic 
chemotherapeutic drugs 
3.2.1 Combination of PAC-1 and cytotoxic chemotherapeutics in five murine cancer types 
The ability of PAC-1 to induce cell death in combination with common cytotoxic 
chemotherapeutics was assessed in five diverse solid and hematopoietic cancer types (osteosarcoma, 
lymphoma, melanoma, breast cancer, and lung cancer) that are commonly treated with such cytotoxic drugs. 
As a single concentration of any given agent would not allow for effective measures of broad synergy, the 
PAC-1/drug combinations were examined in a matrix format. The 3x6 matrices (schematic in Figure 3.2) 
were designed such that the two PAC-1 concentrations induced ~10 to 20% cell death during the 24-hour 
treatment, whereas five concentrations for chemotherapeutic agents used induced up to 50% cell death. The 
Chou-Talalay method35 was used to quantify the effects, and Combination Index (CI) values were 
calculated for each combination, resulting in ten CI values per chemotherapeutic agent (schematic in Figure 
3.2).  
Proteolysis of 
~100 proteins
Zn2+
PAC-1
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Figure 3.2. Schematic of treatment of cancer cells in culture with matrix combinations of PAC-1 plus approved 
chemotherapeutics. For each cell line, each of fifteen chemotherapeutics was evaluated for the ability to induce cell 
death at 6 concentrations in combination with 3 concentrations of PAC-1. The CI value was calculated for cell death 
induced by each PAC-1 + chemotherapeutic combination (10 CI values per cell line, per chemotherapeutic). 
 
Murine cancer cell lines (K7M2, EL4, B16-F10, 4T1, and 3LL) representing each of the five cancer 
types were used for these initial experiments, as a prelude to the in vivo syngeneic models (below), and the 
most promising combinations were followed up in human cancer cell lines. As is true with most cancer cell 
lines, these murine cell lines have robust expression of procaspase-3 (Figure 3.3).  
 
Figure 3.3. Procaspase-3 is overexpressed in cancerous murine cell lines. (A) The expression of procaspase-3 in 
murine embryonic fibroblasts and cancerous cell lines was determined by immunoblotting. (B) Quantification of 
relative procaspase-3 expression compared to β-actin for murine embryonic fibroblasts and cancerous cell lines. 
 
The complete results of the combination experiments are shown in Figures 3.4-3.8. Quantification 
of the combination experiments is depicted in Figure 3.9, with median CI values shown for each PAC-1 
drug combination. CI values of <1 indicate a synergistic interaction, with lower values demonstrating 
stronger synergy. 35-37  
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Figure 3.4. The combination of PAC-1 and conventional chemotherapeutics was evaluated for the ability to 
synergistically induce cell death in K7M2 murine osteosarcoma cells. In the survey, combinations were evaluated in 
3x6 concentration matrices, and each was quantified for synergy using the Chou-Talalay combination index method 
(CI values). Three independent biologic replicates were performed, the average of those is shown. Calculation of CI 
values is only possible when agents induce positive and increasing levels of cell death across a range of increasing 
concentrations. 
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Figure 3.5. The combination of PAC-1 and conventional chemotherapeutics was evaluated for the ability to 
synergistically induce cell death in EL4 murine lymphoma cells. In the survey, combinations were evaluated in 3x6 
concentration matrices, and each was quantified for synergy using the Chou-Talalay combination index method (CI 
values). Three independent biologic replicates were performed, the average of those is shown. Calculation of CI values 
is only possible when agents induce positive and increasing levels of cell death across a range of increasing 
concentrations. 
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Figure 3.6. The combination of PAC-1 and conventional chemotherapeutics was evaluated for the ability to 
synergistically induce cell death in B16-F10 murine melanoma cells. In the survey, combinations were evaluated in 
3x6 concentration matrices, and each was quantified for synergy using the Chou-Talalay combination index method 
(CI values). Three independent biologic replicates were performed, the average of those is shown. Calculation of CI 
values is only possible when agents induce positive and increasing levels of cell death across a range of increasing 
concentrations. 
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Figure 3.7. The combination of PAC-1 and conventional chemotherapeutics was evaluated for the ability to 
synergistically induce cell death in 4T1 murine breast cancer cells. In the survey, combinations were evaluated in 3x6 
concentration matrices, and each was quantified for synergy using the Chou-Talalay combination index method (CI 
values). Three independent biologic replicates were performed, the average of those is shown.   
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Figure 3.8. The combination of PAC-1 and conventional chemotherapeutics was evaluated for the ability to 
synergistically induce cell death in 3LL murine lung cancer cells. In the survey, combinations were evaluated in 3x6 
concentration matrices, and each was quantified for synergy using the Chou-Talalay combination index method (CI 
values). Three independent biologic replicates were performed, the average of those is shown. Calculation of CI values 
is only possible when agents induce positive and increasing levels of cell death across a range of increasing 
concentrations. 
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Figure 3.9. PAC-1 exhibits broad synergy with conventional chemotherapeutics in procaspase-3 overexpressing cell 
lines. For each cell line, each of fifteen chemotherapeutics was evaluated for the ability to induce cell death at 6 
concentrations in combination with 3 concentrations of PAC-1. The CI value was calculated for cell death induced by 
each PAC-1 + chemotherapeutic combination (10 CI values per cell line, per chemotherapeutic). The median CI values 
for each PAC-1/chemotherapeutic combination for each cell line are shown for instances when the CI values are 
between 1.5 (near additive effect) and 0 (very strong synergy). Instances with less that 5 markers shown for a given 
chemotherapeutic indicate that either the median CI value was >1.5 or it was not able to be calculated. Calculation of 
Ci values is only possible when agents induce positive and increasing levels of cell death across a range of increasing 
concentrations.   
 
As shown in Figure 3.9, PAC-1 synergizes with many different cytotoxins to potently induce death 
in these cell types; combinations with paclitaxel, vincristine, carmustine, mitomycin C, irinotecan, 
etoposide, and doxorubicin were particularly effective across all cancer types. Although many of these 
combinations are intriguing and potentially useful, the combinations of PAC-1 with doxorubicin, and PAC-
1 with mitomycin C were selected for further investigation, as these combinations displayed uniformly low 
CI values and was capable of inducing high levels of death across the five cancer cell lines (Figure 3.10). 
Importantly, the design and timing of the survey unquestionably impacted which 
chemotherapeutics demonstrated the greatest synergy with PAC-1. Cell death was evaluated following a 
24 h co-treatment as most commonly used chemotherapeutics are capable of initiating cell death during that 
time period,38 and it was predicted that PAC-1, by facilitating caspase activation, would increase the speed 
and magnitude of cell death. However, pro-apoptotic chemotherapeutics are not universally capable of 
initiating cell death during this time span, an effect observed with methotrexate, chlorambucil and 
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temozolomide in many of the cell lines. As quantification by CI value required positive and increasing cell 
death induced by increasing concentrations of compounds, it was not feasible in all cases. This does not 
mean that PAC-1 is unable to enhance the activity of these chemotherapeutics in these cell lines, simply 
that an effect was not observed under these circumstances. It is highly possible that should cell death be 
examined at later time points for combinations with slower acting chemotherapeutics that synergy with 
PAC-1 would be observed.  
 
 
3.2.2 Confirmation of observed synergy between PAC-1 and doxorubicin in human and 
murine cancer cell lines 
Doxorubicin (structure in Figure 3.10A) is an anthracycline natural product widely used as both a 
single agent and as the backbone of many combination chemotherapy regimens. It is included in the World 
Health Organization List of Essential Medicines and is commonly used to treat a variety of cancers, 
including leukemias, lymphomas, osteosarcomas, soft tissue sarcomas, and cancers of the breast, lung, and 
ovaries.39-42 The diverse cancers for which doxorubicin has demonstrated activity, coupled to the extensive 
overexpression of procaspase-3 in these cancers, suggests that synergistic PAC-1 and doxorubicin 
combinations would possess broad clinical utility. The proapoptotic activity of doxorubicin is due to its 
ability to intercalate DNA, as well as bind topoisomerase II (Top2), stabilizing the ternary Top2-
doxorubicin-DNA cleavage complex and thereby inhibiting the process of replication.43 Unfortunately, 
treatment with doxorubicin is accompanied by significant toxicity in the form of cardiomyopathy, leading 
to congestive heart failure. This is due to the ability of doxorubicin to inhibit the cardiomyocyte specific 
Top2b isoform, leading to apoptosis and the generation of reactive oxygen species.44 In order to attenuate 
the risk of congestive heart failure, a maximum lifetime cumulative dose of 450-550 mg/m2 for adults is 
recommended.39,45 Identification of a molecularly-targeted agent that could increase the in vivo activity of 
doxorubicin without compounding the associated toxicity would significantly increase the clinical utility 
of this indispensable chemotherapeutic.  
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Figure 3.10. PAC-1 synergistically induces cell death with (A) doxorubicin and (B) mitomycin C in procaspase-3 
overexpressing cell lines. Results of the cell death induced by PAC-1 combinations evaluated in the 3x6 matrix, and 
corresponding quantification of synergy with CI values. Three independent biologic replicates were performed, the 
average of those is shown. 
 
As shown above, the panel of five cancer cell lines treated with combinations of PAC-1 and 
doxorubicin demonstrated significantly enhanced cell death at multiple concentrations in the 3x6 matrix 
(Figure 3.10). This combination was further examined in each murine cell line and two human cell lines for 
each cancer type, evaluating the agents in expanded 8x8 matrices. As shown in Figures 3.11 - 3.15, the 
PAC-1/doxorubicin combination induces highly synergistic cell death in both murine and human cancer 
cell lines. For each combination the murine cancerous cell line was evaluated in the expanded 8x8 matrices, 
as well as an additional two human cell lines of the same cancer. Strong synergy was universally observed 
for PAC-1/doxorubicin in 8x8 matrices.  
 It is important to note is that although cancers such as melanoma, breast cancer and lung cancer are 
now initially treated with molecularly targeted agents based upon their B-raf V600E mutation status 
(melanoma), epidermal growth factor receptor mutations (lung cancer), and estrogen, progesterone and 
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human epidermal growth factor 2 receptor status (breast cancer), resistance frequently occurs rapidly. Upon 
the emergence of resistance, these cancers are treated primarily with cytotoxic chemotherapeutics. As such, 
human cell lines were not chosen specifically to represent a given subtype, but rather to support the strong 
and ubiquitous synergy observed during the survey in murine cell lines. Furthermore, many advanced, 
metastatic and resistant cancers are treated with a ‘Physician’s Choice’ regimen, frequently designed based 
upon anecdotal evidence of activity or a particular side-effect profile. For instance, mitomycin C is the most 
commonly used cytotoxic chemotherapeutic for the treatment of non-muscle-invasive bladder cancer, but 
is only approved by the FDA for treatment of gastric and pancreatic cancers.46,47 As such, synergistic 
combinations were considered to be of possible future clinical relevance even if a given chemotherapeutic 
was not approved for use in a cancer. However, with an aim towards rapid clinical encorporation, only 
chemotherapeutic/cancer type pairs currently used clinically were selected for in vivo evaluation.  
Figure 3.11. The combination of PAC-1 and doxorubicin shows strong synergistic activity for the induction of death 
of osteosarcoma cancer cells in culture. The cell death and CI value quantification are shown for 8x8 matrices of PAC-
1 and doxorubicin treatment in murine (K7M2) and human (HOS, 143B) osteosarcoma cell lines. 
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50 1.8 11.8 9.7 16.3 26.2 34.3 38.2 49.5
100 19.6 24.5 22.5 30.6 41.2 50.7 53.9 68.9
250 33.2 41.9 36.1 48.0 55.2 62.0 65.2 71.9
500 42.1 46.6 45.2 51.5 60.2 66.7 67.5 76.7
1000 41.6 47.1 45.3 55.8 59.5 66.6 69.3 77.1
2500 64.5 65.1 64.9 69.8 71.5 79.2 81.7 85.7
0 1 2.5 5 10 20 30 50
0 - - - - - - - -
10 - 0.31 0.80 0.63 0.72 0.48 0.69 0.61
50 - 0.78 1.54 0.92 0.57 0.51 0.54 0.39
100 - 0.42 0.57 0.39 0.27 0.21 0.23 0.12
250 - 0.35 0.51 0.29 0.22 0.18 0.17 0.14
500 - 0.55 0.60 0.45 0.30 0.23 0.24 0.15
1000 - 1.06 1.17 0.70 0.60 0.43 0.38 0.24
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50 4.7 8.7 21.5 24.5 33.9 50.7 63.1 67.1
100 16.4 23.1 34.0 44.0 46.2 62.8 70.9 84.5
250 52.8 58.5 56.3 61.5 59.5 69.5 79.8 92.1
500 66.9 67.3 70.3 71.2 69.7 74.8 83.3 92.1
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2500 81.1 80.8 83.5 84.5 83.0 90.6 94.4 102.3
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10 1.3 6.5 9.5 27.8 30.0 39.3 42.7 48.3
50 2.7 9.8 11.5 35.9 40.2 49.6 55.7 63.2
100 21.4 28.6 33.2 57.9 55.7 60.9 64.8 68.0
250 39.9 45.5 53.6 62.7 62.6 65.8 70.8 79.1
500 61.1 62.7 61.7 68.9 68.3 72.0 76.1 82.6
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250 - 0.53 0.41 0.30 0.34 0.36 0.32 0.24
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250 - 0.46 0.50 0.46 0.53 0.45 0.33 0.17
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Figure 3.12. The combination of PAC-1 and doxorubicin shows strong synergistic activity for the induction of death 
of lymphoma cells in culture. The cell death and CI value quantification are shown for 8x8 matrices of PAC-1 and 
doxorubicin treatment in murine (EL4) and human (Daudi, CA46) lymphoma cell lines. 
 
 
Figure 3.13. The combination of PAC-1 and doxorubicin shows strong synergistic activity for the induction of death 
of melanoma cells in culture. The cell death and CI value quantification are shown for 8x8 matrices of PAC-1 and 
doxorubicin treatment in murine (B16-F10) and human (SK-MEL-5, UACC-62) melanoma cell lines. 
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50 5.2 -1.9 9.7 11.0 14.5 34.3 53.1 76.5
100 6.2 2.4 11.7 13.1 18.6 37.9 54.4 76.1
250 17.3 12.6 18.2 19.3 21.1 41.2 55.2 76.4
500 25.4 19.3 28.5 27.7 30.6 48.7 62.6 79.1
1000 30.2 28.6 37.2 38.7 40.8 60.3 70.5 81.2
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500 23.7 25.0 27.3 37.0 40.1 44.5 47.8 57.0
1000 31.4 32.8 31.0 40.5 44.5 48.9 55.0 63.8
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10 12.5 14.4 17.3 15.1 21.0 28.6 22.6 23.5
50 13.1 16.0 16.7 22.7 22.9 29.0 29.6 32.4
100 21.6 27.9 23.2 27.6 34.7 38.6 36.6 58.8
250 45.7 50.1 53.3 52.3 58.2 61.1 58.4 76.4
500 61.0 63.4 61.7 63.1 66.5 69.8 62.2 85.7
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0 1 2.5 5 10 20 30 50
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10 13.6 15.7 23.7 25.6 30.0 36.6 43.6 42.9
50 20.6 28.4 35.0 34.7 40.0 48.1 58.9 68.1
100 31.9 41.9 46.1 52.5 55.5 63.6 73.0 83.6
250 41.7 46.3 52.6 57.7 61.1 69.5 78.7 87.1
500 51.5 53.8 58.8 62.2 70.4 83.4 87.9 93.9
1000 57.7 58.9 62.0 69.8 76.7 89.9 94.1 98.9
2500 76.3 77.9 81.4 84.0 91.3 95.6 91.6 94.8
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50 2.4 12.6 8.7 13.7 21.5 39.9 44.8 60.3
100 19.2 31.7 32.2 31.7 45.4 56.9 64.8 83.1
250 36.6 40.1 34.5 44.5 52.2 64.9 73.6 87.3
500 56.4 55.0 54.0 59.0 68.8 81.6 87.5 98.1
1000 65.2 65.5 59.8 69.9 86.8 97.2 102.3 106.7
2500 86.8 89.2 88.5 90.5 92.0 96.6 95.3 101.7
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Figure 3.14. The combination of PAC-1 and doxorubicin shows strong synergistic activity for the induction of death 
of breast cancer cells in culture. The cell death and CI value quantification are shown for 8x8 matrices of PAC-1 and 
doxorubicin treatment in murine (4T1) and human (BT-549, MDA-MB-436) breast cancer cell lines. 
 
 
Figure 3.15. The combination of PAC-1 and doxorubicin shows strong synergistic activity for the induction of death 
of lung cancer cells in culture. The cell death and CI value quantification are shown for 8x8 matrices of PAC-1 and 
doxorubicin treatment in murine (3LL) and human (H460, H1993) lung cancer cell lines. 
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100 - 1.53 0.98 1.02 0.66 0.59 0.60 0.67
250 - 0.74 0.55 0.52 0.33 0.38 0.35 0.45
500 - 0.74 0.61 0.48 0.39 0.32 0.38 0.38
1000 - 0.82 0.58 0.56 0.56 0.47 0.53 0.56
2500 - 1.14 1.16 1.06 1.17 0.88 0.84 0.67
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0 0.0 0.6 8.5 9.3 22.6 41.4 48.1 42.9
10 1.5 3.2 8.4 13.3 24.6 47.3 50.4 52.7
50 2.6 2.6 8.4 13.2 25.2 46.9 49.6 53.4
100 8.0 7.9 14.8 18.8 36.4 52.7 61.4 69.7
250 25.0 28.7 38.1 44.2 62.9 69.0 76.4 79.4
500 43.0 43.7 50.6 58.9 68.5 77.9 79.0 84.2
1000 57.1 58.1 67.2 69.2 71.4 78.4 79.2 82.2
2500 69.3 71.3 71.2 73.6 72.6 79.5 81.5 86.6
0 1 2.5 5 10 20 30 50
0 - - - - - - - -
10 - 0.49 0.70 0.63 1.75 0.72 0.71 0.58
50 - 0.74 0.89 0.53 0.69 0.53 0.45 0.34
100 - 0.36 0.34 0.33 0.44 0.34 0.22 0.13
250 - 0.45 0.46 0.43 0.49 0.39 0.24 0.12
500 - 0.66 0.63 0.69 0.51 0.40 0.23 0.10
1000 - 1.09 1.09 0.82 0.75 0.58 0.30 0.19
2500 - 1.08 1.21 1.10 1.02 0.69 0.73 0.14
0 1 2.5 5 10 20 30 50
0 0.0 6.9 7.7 10.3 7.4 21.4 24.0 42.5
10 3.8 10.2 11.0 15.8 12.0 27.7 33.2 44.3
50 6.7 17.7 17.2 26.3 26.7 37.0 44.6 56.2
100 34.1 38.9 41.0 43.3 41.1 50.4 62.3 74.4
250 46.6 51.7 51.7 53.9 52.8 59.4 69.6 81.9
500 56.1 58.0 59.0 57.7 63.9 69.4 78.6 88.2
1000 57.6 61.5 61.7 67.1 68.8 73.5 82.8 87.8
2500 72.4 77.0 75.4 76.8 78.0 83.1 82.5 94.6
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0 0.0 3.4 2.5 4.7 8.3 10.1 12.1 12.9
10 15.2 18.5 14.9 18.6 21.8 30.2 35.1 43.8
50 28.6 31.9 31.9 41.7 37.8 39.3 50.4 61.6
100 38.7 46.6 41.9 51.8 51.1 61.4 65.7 75.3
250 54.0 54.7 54.6 58.5 59.4 64.9 65.7 75.9
500 62.8 65.3 60.5 69.5 69.7 71.2 73.3 79.7
1000 65.3 67.1 66.2 68.1 72.5 73.2 74.1 79.4
2500 73.8 73.4 73.4 76.2 76.2 78.6 78.8 83.1
0 1 2.5 5 10 20 30 50
0 - - - - - - - -
10 - 0.72 1.22 0.76 0.57 0.29 0.22 0.15
50 - 0.87 0.87 0.39 0.55 0.51 0.22 0.10
100 - 0.52 0.75 0.35 0.37 0.17 0.12 0.05
250 - 0.69 0.69 0.51 0.48 0.31 0.29 0.11
500 - 0.58 0.86 0.40 0.39 0.34 0.28 0.14
1000 - 0.99 1.07 0.91 0.60 0.56 0.52 0.29
2500 - 1.37 1.37 1.03 1.03 0.79 0.77 0.45
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0 0.0 -2.0 16.7 18.3 30.9 41.0 41.6 52.1
10 5.3 8.5 26.7 33.8 44.3 53.7 48.0 58.9
50 -9.8 0.8 22.2 32.2 39.3 55.5 52.2 60.2
100 7.8 14.9 30.6 37.8 45.5 53.6 55.1 65.1
250 16.4 33.3 35.2 43.2 49.0 57.5 53.5 65.0
500 47.6 55.7 55.4 59.8 62.4 68.8 63.5 71.6
1000 57.6 62.1 63.2 66.4 67.6 72.0 72.4 74.7
2500 79.8 86.0 84.4 89.9 92.1 93.0 100.4 102.6
0 1 2.5 5 10 20 30 50
0 - - - - - - - -
10 - 0.28 0.22 0.32 0.46 0.71 1.24 1.53
50 - 4.73 0.38 0.42 0.59 0.71 1.14 1.50
100 - 0.60 0.38 0.43 0.56 0.79 1.10 1.33
250 - 0.53 0.58 0.56 0.66 0.83 1.28 1.42
500 - 0.45 0.50 0.50 0.60 0.71 1.11 1.26
1000 - 0.68 0.69 0.68 0.76 0.85 1.04 1.32
2500 - 0.51 0.59 0.40 0.36 0.39 0.00 0.00
0 1 2.5 5 10 20 30 50
0 0.0 -0.2 4.0 8.2 20.1 25.1 37.1 52.3
10 13.3 14.0 14.7 20.0 34.5 45.5 53.4 64.0
50 15.0 21.6 20.9 30.0 48.8 60.4 60.0 73.8
100 36.5 40.8 47.1 52.6 56.0 64.6 70.4 84.9
250 55.2 57.8 57.1 60.9 64.2 71.7 79.0 84.4
500 74.1 73.9 73.4 78.7 80.3 83.1 84.0 89.3
1000 83.4 84.0 83.2 84.3 86.7 87.2 88.6 94.2
2500 86.2 88.3 84.9 87.0 85.7 87.6 89.9 95.2
0 1 2.5 5 10 20 30 50
0 - - - - - - - -
10 - 0.68 0.82 0.76 0.56 0.63 0.67 0.72
50 - 1.47 1.68 1.06 0.53 0.48 0.65 0.52
100 - 0.90 0.69 0.58 0.58 0.52 0.49 0.29
250 - 0.92 0.98 0.84 0.77 0.61 0.45 0.40
500 - 0.72 0.76 0.54 0.51 0.46 0.47 0.34
1000 - 0.65 0.71 0.65 0.53 0.54 0.49 0.24
2500 - 1.02 1.49 1.20 1.41 1.18 0.91 0.37
0 1 2.5 5 10 20 30 50
0 - - - - - - - -
10 - 0.33 1.28 0.43 0.49 0.61 1.42 1.71
50 - 0.54 0.88 0.51 0.52 0.55 1.12 1.12
100 - 0.40 0.66 0.42 0.39 0.42 0.67 0.70
250 - 0.62 0.89 0.63 0.54 0.50 0.52 0.54
500 - 0.85 0.97 0.78 0.57 0.59 0.67 0.66
1000 - 0.96 1.20 0.94 0.89 0.91 0.89 0.85
2500 - 1.51 1.62 1.39 1.48 1.29 1.27 0.82
0 1 2.5 5 10 20 30 50
0 0.0 2.9 -1.5 7.5 14.5 18.3 19.6 27.7
10 -0.1 4.0 2.0 11.8 19.2 27.8 19.0 24.9
50 1.2 5.7 5.0 13.9 22.0 33.2 25.0 35.7
100 7.9 15.4 11.0 23.2 33.3 44.2 39.7 50.1
250 19.4 23.2 17.3 28.0 38.3 49.4 54.8 62.8
500 29.6 33.1 30.3 38.9 52.6 56.8 57.7 65.1
1000 49.8 51.6 44.3 53.8 57.3 59.9 63.2 69.0
2500 65.3 66.6 64.5 69.6 68.3 73.3 74.7 85.1
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3.2.3 Confirmation of observed synergy between PAC-1 and Mitomycin C in human and 
murine cancer cell lines 
 Mitomycin C (MMC, structure in Figure 3.10B) possesses a much less significant role than 
doxorubicin in the modern clinical management of cancer. MMC was discovered in the 1950s from 
fermentation cultures of Streptomyces caespitosus.48-50 Upon reduction of the quinone, the molecule 
undergoes a spontaneous transformation yielding an unstable vinylogous quinone methide, with a high 
alklylating reactivity; when this reacts with DNA, a second alkylating center develops, which can be 
attacked by another DNA nucleophile to yield a DNA crosslink.50 This cross-linking of complementary 
strands of DNA is extremely lethal and responsible for the induction of apoptosis observed anticancer 
activity. MMC was approved in 1974 for the treatment of cancers of the head and neck, lungs, breast, cervix, 
colon, hepatic cell carcinoma, melanoma, stomach and pancreatic cancer. However, due to concerns 
regarding activity, these indications were revised in 1975 to only include use in advanced gastric and 
pancreatic cancers.39,51 Despite limited approved indications, MMC continues to be prescribed for some 
advanced cancers that are not responsive to more commonly used chemotherapeutic agents. It is possible 
that the ability of PAC-1 to enhance the anticancer activity of MMC, coupled to its limited use, might 
facilitate a more prominent clinical role. Patients might be unlikely to have been previously treated with 
MMC, thereby reducing the potential for pre-existing resistance to the drug.  
The combination of PAC-1 and MMC was further examined in the solid tumor cancer types: 
osteosarcoma, melanoma, breast and lung cancer. For each cancer type, the murine cell line and two human 
cell lines were evaluated in expanded 8x8 matrices. As shown in Figures 3.16 - 3.19, the PAC-1/MMC 
combination induces highly synergistic cell death in both murine and human cancer cell lines. Strong 
synergy was observed universally.  
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Figure 3.16. The combination of PAC-1 and MMC shows strong synergistic activity for the induction of death of 
osteosarcoma cells in culture. The cell death and CI value quantification are shown for 8x8 matrices of PAC-1 and 
MMC treatment in murine (K7M2) and human (HOS, 143B) osteosarcoma cell lines. 
 
 
Figure 3.17. The combination of PAC-1 and MMC shows strong synergistic activity for the induction of death of 
melanoma cells in culture. The cell death and CI value quantification are shown for 8x8 matrices of PAC-1 and 
MMC treatment in murine (B16-F10) and human (SK-MEL-5, UACC-62) melanoma cell lines. 
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Figure 3.18. The combination of PAC-1 and MMC shows strong synergistic activity for the induction of death of 
breast cancer cells in culture. The cell death and CI value quantification are shown for 8x8 matrices of PAC-1 and 
MMC treatment in murine (4T1) and human (BT-549, MDA-MB-436) breast cancer cell lines. 
 
Figure 3.19. The combination of PAC-1 and MMC shows strong synergistic activity for the induction of death of 
lung cancer cells in culture. The cell death and CI value quantification are shown for 8x8 matrices of PAC-1 and 
MMC treatment in murine (3LL) and human (H460, H1993) lung cancer cell lines. 
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50 -3.9 3.4 22.5 32.3 32.8 49.9 52.5 62.3
100 1.3 10.7 23.5 33.4 38.6 53.2 57.1 65.0
250 9.6 16.6 26.1 36.9 38.5 50.9 56.3 64.9
500 16.5 24.4 27.9 45.8 49.2 55.3 60.5 68.7
1000 19.8 26.8 33.2 47.9 49.1 54.1 61.3 69.0
2500 37.6 41.1 52.4 56.2 56.0 59.0 62.8 71.5
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0 0.0 3.1 6.5 12.6 26.5 37.5 40.0 48.8
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50 19.1 15.5 24.9 29.9 44.2 53.2 57.2 75.1
100 29.0 35.6 44.7 52.0 54.3 59.3 64.5 86.3
250 50.0 56.2 56.7 61.0 61.4 65.5 69.8 85.1
500 63.2 67.3 67.3 71.0 70.6 73.2 78.4 88.7
1000 69.3 72.8 73.2 75.3 75.8 79.0 80.5 87.9
2500 83.8 85.7 84.8 87.4 84.4 88.3 87.0 93.7
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0 - - - - - - - -
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100 9.0 13.3 9.4 24.0 25.7 33.5 55.7 60.1
250 18.0 18.5 20.5 28.6 37.6 42.9 65.8 71.9
500 31.4 33.4 32.0 39.7 48.6 53.3 71.4 75.7
1000 48.5 47.1 42.0 53.9 57.3 62.0 71.8 78.9
2500 65.2 67.2 66.9 71.0 68.5 72.9 71.9 80.6
0 1 2.5 5 10 20 30 50
0 - - - - - - - -
10 - 1.15 1.40 0.44 0.62 0.84 0.73 0.91
50 - 1.21 0.94 0.59 0.59 0.85 0.67 0.71
100 - 0.64 1.09 0.45 0.58 0.63 0.36 0.47
250 - 1.01 0.95 0.68 0.56 0.61 0.31 0.34
500 - 0.89 0.99 0.75 0.59 0.60 0.33 0.35
1000 - 0.99 1.24 0.80 0.74 0.69 0.50 0.41
2500 - 1.07 1.09 0.91 1.06 0.91 1.00 0.69
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3.3 Evaluation of mechanism of PAC-1 and doxorubicin synergy in cancer 
cell lines 
3.3.1 PAC-1 and doxorubicin combinations synergistically induce apoptosis and enhance 
executioner caspase-3 activity 
The synergistic effect and mode of cell death induced by the PAC-1/doxorubicin combination were 
further assessed for apoptosis (by flow cytometry) and for activation of procaspase-3 and cleavage of 
caspase-3 (by Western blot and caspase activity assay), as shown for each cell line in Figure 3.20. Biomass 
remaining after the treatments analyzed for apoptosis was visualized by cell fixation and staining with 
sulforhodamine B dye. Treatment of the cells with the PAC-1/doxorubicin combination followed by 
Annexin V/PI staining reveals that the majority of the cells are Annexin V positive and PI negative, 
indicative of apoptosis. Western blot analysis of cells after PAC-1/doxorubicin treatment reveals cleavage 
of procaspase-3 and PARP-1. Analysis of executioner caspase-3/-7 activity of treated cells over time 
indicates that co-treatment with PAC-1 greatly increases the extent to which a given concentration of 
doxorubicin is capable of activating executioner caspases. A structurally related but inactive PAC-1 
analogue (called PAC-1a)24 was unable to potentiate doxorubicin (Figure 3.21), further supporting the 
importance of procaspase-3 activation to this synergy.  
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Figure 3.20
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Figure 3.20. (cont.) The combination of PAC-1 and doxorubicin induces apoptosis in cancer cell lines. Cancer cell 
lines (A) K7M2, (B) EL4, (C) B16-F10, (D) 4T1, and (E) 3LL were treated with vehicle, PAC-1, doxorubicin, or the 
combination of PAC-1 + doxorubicin, and evaluated for the induction of apoptosis by Annexin V-FITC and propidium 
iodide staining, by Western blot analysis for cleavage of markers of apoptosis procaspase-3 and PARP-1, and 
evaluated for caspase-3/-7 activity with the fluorogenic substrate Ac-DEVD-AFC. Plots and Western blots are 
representative of three independent biologic experiments. (A) K7M2 cells were treated with 30 µM PAC-1 and 1.5 
µM doxorubicin and evaluated overtime (caspase-3/-7 activity assay), or at 48 h (analysis of apoptosis by flow 
cytometry and Western blot; stained biomass). (B) EL4 cells were treated with 15 µM PAC-1 and 1 µM doxorubicin 
and evaluated overtime (caspase-3/-7 activity assay), or at 24 h (analysis of apoptosis by flow cytometry and Western 
blot). (C) B16-F10 cells were treated with 10 µM PAC-1 and 0.75 µM doxorubicin and evaluated overtime (caspase-
3/-7 activity assay), or at 48 h (analysis of apoptosis by flow cytometry and Western blot; stained biomass). (D) 4T1 
cells were treated with 7.5 µM PAC-1 and 1 µM doxorubicin and evaluated overtime (caspase-3/-7 activity assay), or 
at 48 h (analysis of apoptosis by flow cytometry and Western blot; stained biomass). (E) 3LL cells were treated with 
10 µM PAC-1 and 1 µM doxorubicin and evaluated overtime (caspase-3/-7 activity assay), or at 24 h (analysis of 
apoptosis by flow cytometry and Western blot; stained biomass). 
 
Figure 3.21. PAC-1 synergizes with doxorubicin in EL4 murine lymphoma cells, but inactive derivative PAC-1a does 
not synergize with doxorubicin in EL4 murine lymphoma cells (A) Structure of PAC-1a. (B) Cells were treated with 
the indicated concentrations of PAC-1a and doxorubicin for 24 hours and apoptotic cell death was assessed by flow 
cytometry with Annexin V-FITC and propidium iodide staining. Three independent biologic replicates were 
performed, the average of those is shown. Error bars show the s.e.m. (C) Structure of PAC-1. (D) Cells were treated 
with the indicated concentrations of PAC-1a and doxorubicin for 24 hours and apoptotic cell death was assessed by 
flow cytometry with Annexin V-FITC and propidium iodide staining. Three independent biologic replicates were 
performed, the average of those is shown. Error bars show the s.e.m. 
 
3.4 Evaluation of PAC-1 and doxorubicin in murine models of cancer 
3.4.1 PAC-1 and doxorubicin combinations synergistically extend survival in a syngeneic 
murine model of metastatic osteosarcoma 
The PAC-1/doxorubicin combination was evaluated in syngeneic murine models of osteosarcoma 
and lymphoma. The first model investigated was an experimental metastases osteosarcoma model, with the 
K7M2 murine cell line, with survival as an experimental endpoint. This model enables evaluation of the 
PAC-1PAC-1a
N
N
N
N
H
O
A
B
-20
0
20
40
60
80
100
0 12.5 25 50
%
 C
el
l D
ea
th
0 nM Dox
100 nM Dox
500 nM Dox
1000 nM Dox
1500 nM Dox
-20
0
20
40
60
80
100
0 5 10 15
%
 C
el
l D
ea
th
0 nM Dox
250 nM Dox
500 nM Dox
1000 nM Dox
1500 nM Dox
C
D
[PAC-1a] (µM) [PAC-1] (µM)
97 
 
PAC-1/doxorubicin combination against microscopic metastatic disease of the type that is often present 
immediately after tumor resection and/or limb amputation. The K7M2 model results in numerous 
metastases to the lungs, representative of human disease progression and metastasis.52 In this model two 
different dosing strategies were evaluated. In the first experiment, mice were treated with vehicles, PAC-1 
(100 mg/kg, oral, on days 7 and 14), doxorubicin (5 mg/kg, IV, on days 7 and 14), or the combination. As 
shown in Figure 3.22A, under these conditions PAC-1 and doxorubicin are not effective as single agents,  
 
Figure 3.22. The combination of PAC-1 and doxorubicin has efficacy in murine model of metastatic osteosarcoma. 
(A) Experimental metastatic K7M2 cancer was initiated in BALB/c mice via tail vein injection of 1 million K7M2 
cells and inoculated mice were treated with PAC-1 (Days 7 and 14, 100 mg/kg, oral, in HPβCD), with doxorubicin 
(Days 7 and 14, 5 mg/kg, IV, in 0.9% saline) or with vehicles. Remaining mice were sacrificed after 55 days. n = 8 
mice per group. (B) Stained lungs from vehicle and PAC-1 + doxorubicin treated animals demonstrate substantial 
differences in tumor burden. Experiment performed by Timothy M. Fan. 
 
but, the combination extends the median survival, with 25% of mice surviving until the end of the 
experiment. After 55 days, the surviving mice were sacrificed, and the lungs were examined for tumor 
nodules. As shown in Figure 3.22B, pulmonary metastases were clearly visible in vehicle control mice 
sacrificed on day 18, and markedly fewer lesions were observed in the lungs of the long-term survivors 
from the combination treatment.  
 In the second metastatic K7M2 model, the ability of daily PAC-1 treatments to improve survival 
was evaluated as a single agent and in combination with doxorubicin. As seen in Figure 3.23, when mice 
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were treated with PAC-1 as a single agent (125 mg/kg, PO, daily from days 1-15), a significant extension 
in median survival was observed, from 31 to 43.5 days (P=0.0194, compared to vehicle). As a single agent, 
slightly higher doses of doxorubicin than those used previously (7.5 mg/kg, IV, days 5 and 10) also extended 
median survival from 31 to 58 days (P=0.0002, compared to vehicle). When mice were treated with both 
PAC-1 and doxorubicin, a further increase in median survival was observed to 79 days (P<0.0001, 
compared to vehicle; P=0.0017, compared to doxorubicin) with 20% of mice surviving to study termination 
at 100 days.  
 
Figure 3.23. The combination of PAC-1 and doxorubicin has efficacy in murine model of metastatic osteosarcoma. 
(A) K7M2 inoculated mice were treated with PAC-1 (Daily from days 1 and 15, 125 mg/kg, oral, in HPβCD), with 
doxorubicin (Days 5 and 10, 7.5 mg/kg, IV, in 0.9% saline) or with vehicles. n = 8-10 mice per group. (B) Stained 
lungs from vehicle and PAC-1 + doxorubicin treated animals demonstrate substantial differences in tumor burden. 
Experiment performed by Timothy M. Fan. 
 
3.4.2 PAC-1 and doxorubicin combinations synergistically reduce tumor burden in a 
syngeneic subcutaneous model of murine lymphoma  
The PAC-1/doxorubicin combination was then evaluated in a subcutaneous syngeneic model of 
lymphoma, using the EL4 cell line. Tumor-bearing mice were treated with vehicles, PAC-1 as a single 
agent (100 mg/kg, IP, daily for 9 days), doxorubicin as a single agent (7.5 mg/kg, IP, on days 3 and 7), or 
the combination of PAC-1 and doxorubicin. Mice were sacrificed 10 days following tumor cell inoculation, 
when the caliper measurements of the tumors on vehicle-treated mice exceeded 1500 mm3 (Figure 3.24). 
Upon sacrifice, tumors were extracted and weighed. Vehicle-treated mice bore an average tumor burden of 
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1.96 ± 0.08 g, whereas the PAC-1 treatment group trended towards modestly smaller tumors at 1.75 ± 0.09 
g (P=0.1). Treatment with doxorubicin significantly reduced tumor burden by approximately a third to 1.27 
± 0.15 g. Co-treatment with PAC-1 and doxorubicin further reduced the tumor burden to approximately 
half of vehicle-treated mice, 1.05 ± 0.16 g (P<0.0005, compared to vehicle).  
 
 
Figure 3.24. The combination of PAC-1 and doxorubicin has efficacy in a subcutaneous murine lymphoma model. 
Subcutaneous EL4 lymphoma tumors were established in C57BL/6 mice (5 million cells per mouse) and inoculated 
mice were treated with PAC-1 once-a-day (Days 1-9, 100 mg/kg, IP, in HPβCD), with doxorubicin (Days 3 and 7, 7.5 
mg/kg, IP, in 0.9% saline) or with vehicles. n = 8 mice per group. (A) Tumor burden was monitored daily by caliper 
measurement, beginning when tumors reached ~100 mm3. (B) After ten days the mice were sacrificed and the tumors 
excised and weighed.  
 
Recognizing that the half-life of PAC-1 in mice is extremely short, 25 ± 0.9 minutes, compared to 
2.1 ± 0.3 hours in dogs,53,54 we investigated whether increased frequency of dosing would increase the 
activity of PAC-1 as a single agent and in combination with doxorubicin; this study served as a prelude for 
the treatment of canine cancer patients. The EL4 subcutaneous model was repeated, and mice were treated 
with vehicles, PAC-1 (100 mg/kg, IP, three times daily for 9 days), doxorubicin (7.5 mg/kg, IP, on days 3 
and 7), or the combination of PAC-1 and doxorubicin (Figure 3.25). Repeated daily dosing significantly 
improved the activity of PAC-1 as a single agent and in combination with doxorubicin. In this experiment, 
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the tumor size of vehicle and doxorubicin treated mice were consistent with the previous result (Figures 
3.24 and 3.25), measuring 1.85 ± 0.17 g and 1.25 ± 0.09 g, respectively. Thrice daily dosing with PAC-1 
reduced the tumor size to 0.75 ± 0.06 g (P<0.0005, compared to vehicle). The thrice daily dosing of PAC-
1 in combination with two treatments with doxorubicin further reduced the tumor burden to 0.31 ± 0.04 g 
(P<0.00005, compared to vehicle). The images of the extracted tumors visually demonstrate the significant 
antitumor effect (Figure 3.26). 
 
Figure 3.25. The combination of PAC-1 and doxorubicin has efficacy in a subcutaneous murine lymphoma model. 
Subcutaneous EL4 lymphoma tumors were established in C57BL/6 mice (5 million cells per mouse) and inoculated 
mice were treated with PAC-1 thrice-daily (Days 1-9, 100 mg/kg x 3 treatments, IP, in HPβCD), with doxorubicin 
(Days 3 and 7, 7.5 mg/kg, IP, in 0.9% saline) or with vehicles. n = 7-8 mice per group. (A) Tumor burden was 
monitored daily by caliper measurement, beginning when tumors reached ~100 mm3. (B) After ten days the mice 
were sacrificed and the tumors excised and weighed. 
 
 
 
Dox Dox
A B
PAC-1 (3X daily)
0
500
1000
1500
2000
0 2 4 6 8 10 12
C
al
cu
la
te
d 
Tu
m
or
 V
ol
um
e 
(m
m
3 )
Time (days)
Vehicle
100 mg/kg PAC-1 (3X)
7.5 mg/kg Dox
PAC-1 (3X) + Dox
1.85 ±
0.17
0.75 ±
0.06
1.25 ±
0.09
0.31 ±
0.04
Tumor 
Weight (g):
0
0.5
1
1.5
2
2.5
3
Vehicle PAC-1 Dox PAC-1 +
Dox
Tu
m
or
 W
ei
gh
t (
g)
P < 0.0005
P < 0.05
P < 0.00005
P < 0.0005
P < 0.000005
3X daily
101 
 
Figure 3.26. The combination of PAC-1 and doxorubicin has efficacy in a subcutaneous murine lymphoma model. 
Subcutaneous EL4 lymphoma tumors were established in C57BL/6 mice (5 million cells per mouse) and inoculated 
mice were treated with PAC-1 thrice-daily (Days 1-9, 100 mg/kg x 3 treatments, IP, in HPβCD), with doxorubicin 
(Days 3 and 7, 7.5 mg/kg, IP, in 0.9% saline) or with vehicles. n = 7-8 mice per group. After ten days the mice were 
sacrificed and the tumors excised and weighed. 
 
3.5 Evaluation of PAC-1 and doxorubicin in canine patients with naturally 
occurring cancers 
 
3.5.1 Canine osteosarcoma is highly reflective of human pediatric osteosarcoma and is an 
unmet medical need  
While murine tumor models enable facile in vivo evaluation of potential anticancer drugs and 
combinations, they frequently fail to predict clinical success in human patient populations. Reasons for this 
include the abbreviated murine life span, homogeneity of the tumors due to clonal selection in cell line 
growth, lack of long periods of cancer latency, frequent absence of micro- and macro-metastases, and 
species differences in drug exposure, among many others.55,56 The evaluation of anticancer drugs in pets 
with spontaneous cancers represents an opportunity to compliment induced murine models with naturally-
occurring cancers. Pet dogs are large mammals, more similar in size and physiology to humans. Many 
canine cancers are very similar to their human counterparts at the molecular level.57,58 For example, canine 
osteosarcoma has a gene expression profile indistinguishable from human osteosarcoma,59-61 and canine 
lymphomas also possess many similarities to the human disease; dogs typically present with aggressive 
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high-grade multicentric lymphoma, which is similar to human non-Hodgkin lymphoma.62 Canine and 
human lymphomas share similar genetic features, including alterations to MYC, Bcl-2 and RB1 genes.63  
To further assess the potential of PAC-1 as a clinically useful molecularly targeted agent for use in 
combination with cytotoxic chemotherapeutics, the feasibility and activity of the PAC-1/doxorubicin 
combination was evaluated in canine cancer patients. Canine patients with metastatic osteosarcoma are 
typically treated with either doxorubicin or a platinum drug (cisplatin or carboplatin), but with minimal 
efficacy: partial responses are observed in only 5% of patients.61,64 Canine lymphoma patients, similarly to 
human non-Hodgkins lymphoma patients are typically treated with the CHOP protocol 
(Cyclophosphamide, Hydroxydaunorubicin – also known as doxorubicin, Oncovin – also known as 
vincristine, and Prednisone, see Figure 3.27)65 and/or with doxorubicin as a single agent. These treatments 
are more effective; 7-10 month remissions and survival of greater than one year are observed in 
approximately 50% of patients.66,67  
 
Figure 3.27. Schedule of CHOP protocol for the treatment of diffuse large B-cell lymphoma.65 
 
Day 1 2 3 4 5 6 7
15 16 17 18 19 20 21
Cyclophosphamide 
750 mg/m2 IV
Doxorubicin 
50 mg/m2 IV
Vincristine
1.4 mg/m2 IV
Prednisone
40 mg/m2/day PO
8 9 10 11 12 13 14
x 8 cycles
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The expression of procaspase-3 in canine lymphomas and had been previously noted in lymph node 
aspirates taken from canines with both T-cell and B-cell lymphomas.68 As a prelude to our clinical study, 
the presence of the procaspase-3 target was analyzed in canine osteosarcoma, and the data reveal that 
procaspase-3 is overexpressed in malignant canine osteoblasts compared to normal osteoblasts (Figure 
3.28).  
Figure 3.28. Procaspase-3 is overexpressed in osteosarcoma. (A) The expression of procaspase-3 in canine osteoblasts 
and cancerous cell lines was determined by immunoblotting. (B) Quantification of relative procaspase-3 expression 
compared to β-actin for canine osteoblasts and cancerous cell lines. Experiment performed by Alison P. Book.  
 
3.5.2 Bolus PAC-1 and doxorubicin is efficacious in the treatment of canine metastatic 
osteosarcoma 
Evaluation of PAC-1 plus doxorubicin was initiated in canines with naturally occurring metastatic 
osteosarcoma. Pet dogs presented at or referred to the Small Animal Clinic at the University of Illinois at 
Urbana-Champaign College of Veterinary Medicine were considered for enrollment in the clinical trial. 
The first cohort of patients (Table 3.1, Patients 1-3) were treated with 50 mg/kg PAC-1 (oral), followed by 
20-30 mg/m2 doxorubicin (IV) four hours later. Both drugs were administered once-every-two-weeks, with 
all animals receiving at least three cycles. Due to overall disease stabilization and reduction in the size of 
small lesions, Patient 2 continued to receive the PAC-1/doxorubicin combination treatment for nine cycles. 
As shown in Figure 3.29, Patient 2’s tumors were rapidly progressing when treated with carboplatin 
(microscopic and Pre1-3 RECIST scores). Overall tumor growth ceased upon treatment with PAC-1 and 
doxorubicin, with the three smaller lesions decreasing in size over the course of treatment. Growth of the 
largest lesion stabilized, resulting in an overall 17% reduction in total tumor burden.  
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Table 3.1. Canine metastatic osteosarcoma patients treated with bolus PAC-1 + Dox. 
        Treatment  
Patient Breed Sex Age (y) 
Weight 
(kg) 
Location 
of 
primary 
tumor 
Metastases Prior therapy 
PAC-1 
(mg/kg) 
Dox1 
(mg/m2) 
Out-
come 
1 Labrador retriever FS 11 31 
L distal 
femur Pulmonary 
PD on 
carboplatin 75 30 PD 
2 Golden retriever FS 5 37 
R 
proximal 
humerus 
Sub-
cutaneous 
PD on 
carboplatin 75 
302 
(25, 20) SD 
3 Shepherd mix MC 12 27 
L distal 
ulna Pulmonary 
PD on 
carboplatin 75 
30 
(25, 25) PR 
1Values in parentheses indicate dosage of dox for 2nd and 3rd treatment.  
2Patient received a total of 9 cycles of PAC-1 + dox treatments. Treatments 4 – 9 occurred with the dox dosage given in the 3rd treatment (20 
mg/m2).  
Abbreviations: FS, female spayed; MC, male castrated; MI, male intact; L, left; R, right; PD, progressive disease; SD, stable disease; PR, partial 
response; CR, complete response.  
 
Figure 3.29. The combination of PAC-1 and doxorubicin is well tolerated and has efficacy in a canine patient with 
naturally occurring osteosarcomas. A pet dog (Patient 2) presented with rapidly growing, carboplatin-resistant 
osteosarcoma, with four measurable masses. Patient 2 was treated with 50 mg/kg PAC-1 (oral), followed by 20-30 
mg/m2 doxorubicin (IV) four hours later. Treatments were administered every 14 days, for 9 cycles. Clinical 
evaluation performed by Timothy M. Fan. 
 
 
3.5.3 Daily oral PAC-1 treatments in combination with biweekly doxorubicin is efficacious in 
the treatment of canine metastatic osteosarcoma 
Recognizing the success of repeated PAC-1 dosing observed in the murine models, the feasibility 
of treating patients with lower doses of daily oral PAC-1 in combination with biweekly IV treatments of 
doxorubicin was explored. Three patients were treated daily with PAC-1 (10-12.5 mg/kg), and doxorubicin 
(25 mg/m2 on days 1, 14 and 28) (Table 3.2, Patients 4-6). Patient 4, a drug naïve osteosarcoma patient, 
presented with three macro metastases in the lungs; 2 of 3 lesions decreased in size following treatment 
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with PAC-1 + doxorubicin (see Figure 3.30 for quantified tumor measurements and Figure 3.31 for chest 
films of masses). Patient 5 was admitted to the study with progressive osteosarcoma following treatment 
with rapamycin. All three of Patient 5’s lesions decreased in size with treatment of PAC-1 and doxorubicin 
(see Figure 3.32 for quantified tumor measurements and Figure 3.33 for chest films of masses). 
 
Table 3.2. Canine metastatic osteosarcoma patients treated with metronomic PAC-1 + bolus Dox. 
1Doxorubicin was administered as an IV bolus on days 1, 14 and 28 
Abbreviations: FS, female spayed; MC, male castrated; MI, male intact; L, left; R, right; PD, progressive disease; SD, stable disease; PR, partial 
response; CR, complete response.  
 
 
Figure 3.30. Activity of metronomic PAC-1 and bolus doxorubicin in a pet dog with metastatic osteosarcoma. Patient 
4 presented with rapidly growing, drug-naïve osteosarcoma, with three measurable masses. Patient 4 was treated daily 
with 11.5 mg/kg PAC-1 (PO), and 25 mg/m2 doxorubicin on days 1, 14 and 28. Masses R1 and R2 decreased in size 
upon treatment with PAC-1 and dox. Overall tumor growth slowed to an 8% increase in 42 days (July 7 to August 
17), compared to a 54% increase when the Patient went untreated for 27 days (June 10 to July 7). See Figure 3.31 for 
chest films. Clinical evaluation performed by Timothy M. Fan. 
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Figure 3.31. Metronomic PAC-1 and bolus doxorubicin achieves a partial response in a pet dog with metastatic 
osteosarcoma. Patient 4 presented with rapidly growing, drug-naïve osteosarcoma, with three measurable masses 
Patient 4 was treated daily with 11.5 mg/kg PAC-1 (PO), and 25 mg/m2 doxorubicin on days 1, 14 and 28. Masses 
R1 and R2 decreased in size upon treatment with PAC-1 and dox. Overall tumor growth slowed to an 8% increase in 
41 days (July 7 to August 17), compared to a 54% increase when the Patient went untreated for 27 days (June 10 to 
July 7). See Figure 3.30 for quantitation of mass size. Clinical evaluation performed by Timothy M. Fan. 
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Figure 3.32. Activity of metronomic PAC-1 and bolus doxorubicin in a pet dog with metastatic osteosarcoma. Patient 
5 presented with rapidly growing, rapamycin-resistant (107% increase in tumor burden) osteosarcoma, with three 
measurable masses. Patient 5 was transferred to the PAC-1 + dox protocol and treated daily with 12.5 mg/kg PAC-1 
(PO), and 25 mg/m2 doxorubicin on days 1, 14 and 28. All three masses (R1, L1 and L2) decreased in size upon 
treatment with PAC-1 and dox. Overall tumor was reduced by 27% in 42 days (May 18 to June 29), compared to a 
54% increase when the Patient went untreated for 10 days (May 8 to May 18). See Figure 3.32 for chest films. Clinical 
evaluation performed by Timothy M. Fan. 
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Figure 3.33. Metronomic PAC-1 and bolus doxorubicin achieves a partial response in a pet dog with metastatic 
osteosarcoma. Patient 5 presented with rapidly growing, rapamycin-resistant osteosarcoma, with three measurable 
masses. Patient 5 was treated daily with 12.5 mg/kg PAC-1 (PO), and 25 mg/m2 doxorubicin on days 1, 14 and 28. 
All three masses (R1, L1 and L2) decreased in size upon treatment with PAC-1 and dox. Overall tumor was reduced 
by 27% in 42 days (May 18 to June 29), compared to a 54% increase when the Patient went untreated for 10 days 
(May 8 to May 18). See Figure 3.32 for quantitation of mass size. Clinical evaluation performed by Timothy M. 
Fan. 
 
3.5.4 Bolus PAC-1 and doxorubicin is efficacious in the treatment of canine lymphoma 
The combination of PAC-1 and doxorubicin was also evaluated in canines with naturally occurring 
lymphomas (Table 3, Patients 7-10). As canine lymphomas are commonly treated with the CHOP therapy 
regimen and doxorubicin is known to be efficacious as a single agent,69 the main priority of these studies 
was to confirm the feasibility of combining PAC-1 (oral) with doxorubicin (IV) in canine lymphoma 
patients. Three patients received PAC-1 (75 mg/kg PO), followed by doxorubicin (30 mg/m2, IV) four hours 
A
R1 R1
L2
L1 L2
L1
R1 R1
L2
L1
L2
L1
At presentation
(Day 0)
Post treatment with 
Rapamycin (Day 24)
No treatment
(Day 34)
Post treatment with 
PAC-1 + Dox (Day 76)
107%
Increased total tumor mass 
post-treatment with Rapamycin
(24 days)
54%
Increased total tumor mass 
without treatment
(10 days)
27%
Decreased total tumor mass 
post-treatment with PAC-1 + Dox
(42 days)
B C D
109 
 
later. Complete responses were observed in 2/3 patients, with Patient 7 demonstrating a partial tumor 
regression. A fourth canine lymphoma patient, Patient 10, was treated with PAC-1 (100 mg/kg, oral) and 
doxorubicin (30 mg/m2, IV). The treatment was well-tolerated and a partial response was observed.  
 
Table 3.3. Canine lymphoma patients treated with bolus PAC-1 + Dox. 
      Treatment  
Patient Breed Sex Age  (y) 
Weight 
(kg) 
Prior 
therapy 
PAC-1 
(mg/kg) 
Dox1 
(mg/m2) Outcome 
7 Golden retriever MC 7 45 Naïve 75 30
 PR 
8  Golden retriever FS 6 44 Naïve 75 30 CR 
9 Mixed breed MC 14 22 Naïve 75 30 CR 
10 Golden retriever MI 11 39 Naïve 100 30 PR 
 
1Doxorubicin was administered as an IV bolus on days 1, 14 and 28. Each dog received 3 treatments.  
Abbreviations: FS, female spayed; MC, male castrated; MI, male intact; PR, partial response; CR, complete response.  
 
 
3.6 PAC-1 does not compound doxorubicin-associated toxicity  
3.6.1 Experimental analysis of PAC-1 and doxorubicin toxicity in mice 
A significant objective of these experiments was to assess the tolerability of combining PAC-1 with 
doxorubicin in vivo. Of particular interest was to determine whether PAC-1 treatment would compound the 
cardiomyopathy induced by doxorubicin. As the major limitation to patient treatment with doxorubicin is 
the lifetime cumulative dose limit, in order for a molecularly targeted agent to be suitable for combination, 
it must not induce cardiotoxicity as a single agent, or increase the toxicity induced by doxorubicin.  
To experimentally examine the cardiotoxicity PAC-1 and doxorubicin treatments, mice were 
treated with PAC-1 as a single agent (125 mg/kg, PO, daily from days 1-15), doxorubicin (7.5 mg/kg, IV, 
days 5 and 10), or the two agents in combination (the dosing scheme used in the K7M2 metastatic 
osteosarcoma model, Figure 3.23). As the cumulative dosage of doxorubicin administered in the in the span 
of a week equaled 15 mg/kg, mice were expected to demonstrate cardiomyopathy.44,70,71 As expected, 
treatment with doxorubicin induced a reduction in the average body weight of the cohort (Figure 3.34), but 
importantly, that reduction was not further enhanced by daily treatments with PAC-1. 
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Figure 3.34. PAC-1 does not enhance doxorubicin-mediated toxicity in vivo. (A) BALB/C mice were treated with 
PAC-1 (Daily from days 1 and 15, 125 mg/kg, oral, in HPβCD), with doxorubicin (Days 5 and 10, 7.5 mg/kg, IV, in 
0.9% saline) or with vehicles. n = 6-8 mice per group. Mice were sacrificed on Day 16 and body mass was determined.  
 
3.6.2 Analysis of canine patients treated with PAC-1 and doxorubicin 
 All canine patients were evaluated for toxicity induced by treatment with oral PAC-1 and IV 
doxorubicin via serial complete blood counts and serum chemistry panels. The hematologic and 
biochemical parameters support the feasibility of safely combining the agents. None of the treated dogs 
showed significant signs of toxicity beyond what is expected for doxorubicin treatments alone. 
Additionally, an EKG was performed on all patients immediately prior to each doxorubicin treatment. As 
the patients received ³3 treatments with doxorubicin, EKG results were obtained 14 days after each 
treatment (with the exception of the final treatment with doxorubicin). No evidence of cardiac arrhythmias 
was observed, suggesting that co-treatment with PAC-1 did not enhance doxorubicin-induced 
cardiomyopathy in canine patients. 
 
3.7 Conclusions  
3.7.1 PAC-1 is capable of synergistically enhancing the activity of diverse cytotoxic 
chemotherapeutic drugs 
 Cytotoxic anticancer drugs retain a major role in the treatment of cancer, even in the era of targeted 
therapy. This continued reliance on cytotoxins is largely due to the limitations of many molecularly targeted 
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agents, most notably the frequent emergence of rapid resistance. Thus, development of a molecularly 
targeted agent with the ability to be used in combination with cytotoxic chemotherapeutics in treatment of 
many cancers (rather than a highly limited subset) could have a profound clinical impact. Procaspase-3 is 
a molecular target overexpressed in numerous cancers and a critical node in the induction of cell death. 
Described herein is the evaluation of synergy of a procaspase-3 activating compound, PAC-1, in 
combination with cytotoxic drugs. Marked synergy was observed with diverse classes of chemotherapeutic 
drugs, and further studies with the PAC-1/doxorubicin combination showed its tremendous promise in cell 
culture, mouse models, and pet dogs with metastatic osteosarcoma and lymphoma. Excitingly, the PAC-
1/doxorubicin combination was only one of many intriguing clinically relevant combinations. When PAC-
1 was combined with the antimitotic agents paclitaxel and vincristine, strong synergy was observed across 
the five cancer types. Paclitaxel is prescribed extensively in the treatment of metastatic breast cancer, and 
enhancement of activity through combination with PAC-1 could be of high clinical relevance. Furthermore, 
PAC-1 demonstrated strong synergy with less commonly used agents, such as MMC, with strong synergy 
observed in all four solid tumor types assessed. Revival of these agents in a more potent PAC-1-potentiated 
form could be particularly useful in patients as they would be unlikely to have been treated with the drug 
previously. As the strong synergy between PAC-1/doxorubicin observed in the survey translated into 
activity in murine models of cancer and canine cancer patients, optimism exists that other combinations 
would translate with similar efficiency into complex clinically relevant settings.  
Osteosarcoma was selected for evaluation of the PAC-1/doxorubicin combination because patients 
with relapsed or metastatic disease represent a significant unmet clinical need. Osteosarcoma, a relatively 
rare cancer, has a global incidence of 1-3 cases per million annually.72 The current standard of care for this 
disease is complete surgical resection, followed by combinatorial chemotherapy based upon methotrexate, 
doxorubicin and cisplatin (MAP protocol - Methotrexate, Adriamycin – also known as doxorubicin, 
Cisplatin, Figure 3.35)73, and results in long-term survival of ~70% of patients.74 Despite numerous clinical 
trials aimed at identifying more effective strategies for the treatment of osteosarcoma, doxorubicin remains 
the backbone of the therapy and is believed to be the most effective agent.75 Unfortunately, survival of 
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patients with relapsed and metastatic osteosarcoma has remained unchanged over the past 30 years, with 
an overall 5-year survival rate at 20%.76 This is largely due to the challenge of treating recurrent 
macroscopic metastases in the lungs or other anatomic sites less amendable to surgical resection.  
 
Figure 3.35. Schedule of MAP protocol for the treatment of osteosarcoma.73  
 
Pulmonary macroscopic metastases represent a major challenge in the treatment of canine 
osteosarcoma as well. Approximately 15% of patients present with these lesions upon diagnosis, although 
estimations suggest that occult metastatic disease is present in ~90% of dogs at diagnosis.77 Canine macro-
metastatic lesions are extremely resistant to therapeutic intervention, with less than 10% of patients 
demonstrating a biologic response to conventional systemic chemotherapies. Pulmonary metastases in 
human patients are similarly challenging to treat, and no standard has been established as an effective 
second-line chemotherapeutic agent. Thus, strategies that elicit a response in canine patients could also 
prove useful for human patients with the poorest prognosis. The high number of patients for which PAC-
1/doxorubicin was able to elicit a biologic response, even in this small trial, suggests that the combination 
could be effective in treating recurrent macroscopic metastatic disease not amendable to surgical resection, 
an unmet clinical need.  
 Toxicological assessment of both high-dose intermittent PAC-1 and low-dose metronomic PAC-1 
revealed no significant toxicity when used in combination with doxorubicin. Importantly, treatment with 
the PAC-1/doxorubicin combination did not induce increased myelosuppression relative to doxorubicin 
alone. This result suggests that PAC-1 may be combined effectively with other clinically useful agents or 
combination regimes without intensifying toxicity. As doxorubicin is a prominent member of numerous 
chemotherapy regimens for the treatment of diverse cancers, addition of PAC-1 to treatment protocols for 
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the many procaspase-3 overexpressing cancers deserves further exploration. Furthermore, the risk of 
doxorubicin-induced cardiotoxicity is known to be enhanced in certain patient populations, including 
children, the elderly, those with liver disease, and those possessing a BRCA2 mutation,78,79 substantiating 
the need to develop well-tolerated agents capable of enhancing the activity of doxorubicin. The 
cardiotoxicity associated with cancer chemotherapeutics has even necessitated the emergence of the field 
of onco-cardiology to study, manage and minimize this severe side effect, while still enabling effective 
anticancer activity.80  
 A common misconception surrounding combination chemotherapy treatment regimens is that the 
drugs of a given protocol are administered concurrently, simultaneously treating cancer cells with multiple 
chemotherapeutic agents, and thereby establishing a basis for enhancement in anti-tumor activity. In reality, 
as discussed in Chapter 1, most combination cancer regimens were developed with the goal of maximizing 
the frequency or intensity of cancer treatments with chemotherapies known to be active against a cancer, 
while minimizing over-lapping toxicities. Thus, although chemotherapy protocols may frequently include 
³ 3 cytotoxic agents, they are rarely administered simultaneously. The protocols described in this Thesis 
illustrate this (VAMP, Figure 1.15; MOMP, Figure 1.16; CHOP, Figure 3.27; MAP, Figure 3.35). For 
example, in the VAMP intensive chemotherapy phase, methotrexate (8 treatments), 6-mercaptopurine (3 
treatments) and cyclophosphamide (1 treatment) are administered daily as single agents over the course of 
twelve consecutive days. Similarly, patients treated with MAP receive doxorubicin and cisplatin semi-
concurrently (72 h and 4 h infusions, respectively), but treatment with high-dose methotrexate is not 
administered until two weeks later. These protocols also contain recommendations for increased delays 
between cytotoxic chemotherapy treatments based upon the time required for hematological markers to 
recover. Thus, the discovery that PAC-1 is capable of enhancing the activity of doxorubicin via 
simultaneous same day administration is both unique and exciting for a rational designed combination 
chemotherapy protocol. Co-administration, in theory, enables true synergy between chemotherapeutic 
agents to occur as cells are treated simultaneously. As PAC-1 facilitates procaspase-3 activation, the 
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determinant step of cytotoxin-induced apoptosis, it is particularly exciting that simultaneous administration 
with chemotherapeutics is feasible.  
In conclusion, we have identified PAC-1 plus doxorubicin as a well-tolerated combination that is 
effective in both murine models of cancer and in canine patients with naturally occurring cancers. Due to 
the important role of doxorubicin in the treatment of numerous cancers and the widespread over-expression 
of procapsase-3, we anticipate that the combination may be broadly effective.  
 
3.8 Materials and methods 
Cell lines and reagents 
K7M2, EL4, LLC, B16-F10, 4T1, Daudi, CA46, HOS, 143B, H1993, H460, BT-549, MDA-MB-
436, and SK-MEL-5 cells were obtained from the American Type Culture Collection. UACC-62 cells were 
obtained from the Developmental Therapeutics Program, National Cancer Institute, NIH (Frederick, MD) 
Cells were maintained at low passage number and were cultured in in RPMI 1640, DMEM or EMEM 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, as specified by ATCC and 
grown at 37°C and 5% CO2.  
PAC-1 and PAC-1a were synthesized as previously described.81 Paclitaxel, cisplatin, 
Chlorambucil, Carmustine, Etoposide, 5-Fluorouracil, 6-Mercaptopurine and gemcitabine were purchased 
from Sigma Aldrich. Vincristine, Oxaliplatin, and Irinotecan were purchased from Selleck. Mitomycin C, 
Temozolomide, methotrexate and Ac-DEVD-AFC were purchased from Cayman Chemical. Doxorubicin 
was purchased from OChem Incorporation. Chemotherapeutics, with the exception of cisplatin and 
gemcitabine, were prepared as 10 mM DMSO stocks, aliquoted, and stored at -20°C until use. Cisplatin 
was prepared immediately prior to use in 0.9% saline to a concentration of 2 mM. Gemcitabine was 
prepared was prepared immediately prior to use in 0.9% saline to a concentration of 10 mM. 
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Immunoblotting 
For Western blot analysis one million suspension cells or adherent cells at 75% confluency in 6-
well plates (150,000 to 300,000 cells) were used. At the conclusion of treatment, the medium and Trypsin-
aided detached cells were pelleted, lysed on ice in RIPA buffer (50 mM Tris base, 150 mM NaCl, 1% 
TritonX-100, 0.5% Na-deoxycholate, 0.1% SDS, pH 7.4, with a 1:100 dilution of Protease Inhibitor 
Cocktail Set III), and clarified, and protein content was normalized by BCA Protein Assay reagent (Pierce). 
Samples were denatured (10 minutes, 95°C), separated by SDS-PAGE (4−20%), and transferred to a 
membrane for Western blot analysis. Antibodies for procaspase-3 and caspase-3 (9662), PARP-1 (9542) 
and β-Actin (4970) were purchased from Cell Signaling and used as directed. 
 
Cell death survey of PAC-1 combinations with classical chemotherapeutics 
All cell death experiments were performed with cells treated in 96-well plates, in 100 µL total 
volume, and 1% DMSO. Survey plates were prepared as follows: 49 µL of complete growth media was 
added, then each well received 0.5 µL of PAC-1 stock solution in DMSO at three concentrations selected 
to induce between 10 and 20% cell death, and 0.5 µL of chemotherapeutic stock solution in DMSO at six 
concentrations, up to but not exceeding 100 µM. For cisplatin and gemcitabine, chemotherapeutics prepared 
in 0.9% saline, the volume of complete growth medium was reduced to accommodate a larger volume of 
chemotherapeutic stock if necessary. 0.5 µL of DMSO was added to each well to ensure all treatments 
occurred at 1% DMSO. To each well, 50 µL of a suspension of cells at 800,000 cells/mL (suspension cells) 
or 100,000 to 120,000 cells/mL (adherent cells) were plated into the wells, for a final density of 40,000 
suspension or 5,000 to 6,000 adherent cells per well, respectively. Additionally, each plate had three wells 
receiving 1 µL of the positive death control Raptinal38 (final concentration 10 µM), and three wells receiving 
1 µL DMSO as a negative control. The plates were incubated at 37°C with 5% CO2 for 24 hours. At the 
conclusion of treatment, the plates were analyzed by Alamar Blue.82 For larger 8x8 matrix evaluations of 
cell death in murine and human cell lines, similar procedures as described above were used. All cell death 
experiments were performed with three independent biologic replicates. 
116 
 
Assessment of apoptosis by flow cytometry.  
The induction of apoptosis was measured by Annexin V-FITC/Propidium iodide staining and flow 
cytometry. Either 250,000 suspension (EL4) cells or adherent cells at 75% confluency in 6-well plates 
(125,000 to 200,000 cells) were treated with combinations of PAC-1 and doxorubicin for 24 to 48 h at 37 
ºC, 5% CO2. At the conclusion of treatment, the cells (adherent cells detached with trypsin), medium and 
debris were transferred to flow tubes and pelleted via centrifugation (500 x g for 2 min) and resuspended 
in 450 µL Annexin V Binding Buffer (10 mM HEPES, 2.5 mM CaCl2, 140 mM NaCl, 0.1% BSA, pH 7.4). 
Buffer was prepared with dyes such that each sample would receive 3 µL of FITC-conjugated Annexin V 
(Southern Biotech) and 0.25 µL of a 1 mg/mL solution of propidium iodide (Sigma). Samples were 
protected from light and stored on ice until assessment. Cell populations were analyzed on a Becton 
Dickinson LSR II cell flow cytometer. 10,000 events per sample were recorded. 
 
Caspase Activation in Cell Lysate.  
Cells (10,000 per well) were plated in 96-well plates, allowed to adhere, and incubated with 10 µM 
Raptinal,38 PAC-1, doxorubicin or DMSO (final DMSO concentration normalized across wells and <1%) 
in phenol-red free RPMI media. Cells were treated with the concentrations of PAC-1 and doxorubicin used 
in the flow cytometry and Western blot analyses for apoptosis (K7M2: 30 µM PAC-1, 1.5 µM dox; EL4: 
10 µM PAC-1, 1 µM dox; B16-F10: 10 µM PAC-1, 0.75 µM dox; 4T1: 7.5 µM PAC-1, 1 µM dox; 3LL: 
10 µM PAC-1, 1 µM dox). Plates were assessed for executioner caspase activity via addition of a 4X 
bifunctional lysis activity buffer (200 mM HEPES, 400 mM NaCl, 40 mM DTT, 0.4 mM EDTA, 1% 
TritonX-100, 50 µM Ac-DEVD-AFC). Fluorescence was measured over time for 30 minutes. Activity is 
expressed as normalized to the vehicle activity at the earliest time point and maximal activity is defined as 
the activity induced by 10 µM Raptinal at 5 h. 
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EL4 subcutaneous syngeneic tumor models 
All experimental procedures were reviewed and approved by the University of Illinois Institutional 
Animal Care and Use Committee. 8-10 week old mice were used in all experiments (Charles River). Five 
million EL4 cells were prepared in HBSS and injected subcutaneously on the right flank of sedated 
(ketamine/xylazine) C57BL/6 mice (day 0) in a 100 µL volume. Mice were randomized into four treatment 
groups: vehicle, PAC-1 alone, doxorubicin alone, and PAC-1 + dox. PAC-1 was formulated in HPβCD 
(13.3 mg/mL in 200 mg/ml HPβCD at pH 5.5). Doxorubicin was formulated in 0.9% saline (0.5 mg/ml). 
Mice were treated one or three times daily on days 1-9 with 100 mg/kg PAC-1 as an IP injection. Mice 
were treated with doxorubicin on days 3 and 7 with 7.5 mg/kg doxorubicin as an IP injection. All mice 
within a model received an equal number of treatments, with HPβCD or saline vehicles substituted for mice 
not receiving active drug. After 10 days, the largest tumors had achieved maximal size, >1500 mm3; mice 
were sacrificed, and tumors were excised and weighed. 
 
K7M2 metastatic tumor models 
1,000,000 K7M2 cells were prepared in HBSS and intravenously injected into the tail vein of 
BALB/c mice (day 0) in a 100 µL volume. Mice were randomized into four treatment groups: vehicle, 
PAC-1 alone, doxorubicin alone, and PAC-1 + dox. PAC-1 was formulated in HPβCD (10 mg/mL in 200 
mg/ml HPβCD at pH 5.5). Doxorubicin was formulated in 0.9% saline (2 mg/ml). For the low dose model, 
mice were treated with 100 mg/kg PAC-1 orally, followed 4 hours later by 5 mg/kg IV doxorubicin on day 
7 and day 14. For the chronic dosing model, mice were treated daily from days 1-15 with 125 mg/kg PAC-
1 orally, and with 7.5 mg/kg doxorubicin on days 5 and 10.  
 
Anticancer assessment of PAC-1 and doxorubicin in dogs with lymphoma or osteosarcoma 
Inclusion Criteria 
The inclusion criteria for eligible patients were the following: histologically or cytologically 
confirmed multicentric lymphoma or osteosarcoma, measurable tumor burden, favorable performance 
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status, a life expectancy of >4 weeks, and no significant co-morbid illness including renal or hepatic failure, 
history of congestive heart failure, or clinical coagulopathy. Pet owners signed a written informed consent 
form prior to study entry according to university guidelines.  
Canine patients receiving biweekly dosing of bolus high dose PAC-1 received 75-100 mg/kg of 
PAC-1 (oral), which was followed by 20-30 mg/m2 doxorubicin (IV) four hours later. Canine patients 
receiving daily dosing of PAC-1 received between 10-13 mg/kg of PAC-1 (oral) daily, and 25 mg/m2 
doxorubicin (IV) every 14 days.  
Tumor size was monitored via computed tomography (CT) scans and caliper measurement when 
possible. Measurement was performed according to the Response Evaluation Criteria in Solid Tumors 
(RECIST) method. Briefly, the longest linear length measurement was recorded for each tumor, with the 
summation of these values giving a RECIST score. 
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Chapter 4. Use of PAC-1 in the treatment of brain cancers 
 
We acknowledge Vanquish Oncology and Dr. Howard Roth for contributing the chemical synthesis of 
PAC-1. This work has been conducted as a collaboration between the laboratories of Paul Hergenrother, 
Gregory Riggins (Johns Hopkins University), and Timothy M. Fan (University of Veterinary Clinical 
Medicine).  
 
4.1 Introduction 
4.1.1 Brain cancers (particularly glioblastoma) are an unmet clinical need 
Malignant gliomas are the most common type of malignant primary brain tumor, with ~17,000 new 
cases each year in the United States.1 The classification of malignant gliomas includes both World Health 
Organization grade IV tumors (glioblastomas) and grade III tumors (anaplastic astrocytomas, 
oligodedrogliomas and oligoastrocytomas), with grade IV glioblastomas possessing a greater level of un-
differentiation and aggressiveness.2 Glioblastomas, formerly referred to as glioblastoma multiforme for the 
varying size and shape of their pleomorphic tumors,3 account for ~80% of all malignant gliomas.4 These 
glioblastoma tumors are highly heterogeneous and invasive, infiltrating the surrounding parenchyma of the 
brain. Molecularly, malignant gliomas are highly heterogeneous tumors.5 Unfortunately these tumors are 
also rapidly progressing and uniformly lethal, with standard-of-care treatment (described below) yielding 
a 2-year survival rate of 27% and a 5-year survival of <5%.6  
 
4.1.2 Current standard-of-care treatment for glioblastoma 
Upon diagnosis, typically achieved through MRI imaging with a gadolinium contrast agent, 
patients undergo complete surgical resection of the tumor. Surgical resection aims to achieve three goals: 
relief of neurologic symptoms caused by the mass of the tumor within the brain, massive reduction in the 
overall tumor cell number, and enabling of tissue for molecular characterization. Following surgery, 
125 
 
patients are then treated with radiotherapy (60 Gy in 30 fractions) and concomitant chemotherapy with the 
DNA alkylating cytotoxic agent temozolomide (TMZ, structure in Figure 4.1, mechanism of action 
described below), and an adjuvant course of TMZ. This regimen was supported by a landmark clinical trial, 
demonstrating that the addition of TMZ extended the median patient survival from 12.1 months with 
radiation alone, to 14.6 months.6,7  
TMZ is a small lipophilic prodrug synthesized in England in the 1970s and whose activity was first 
described in 1987.8,9 A Phase I clinical trial primarily composed of melanoma patients demonstrated 
anecdotal, but remarkable responses in two glioblastoma patients.10 Following confirmatory Phase II and 
III trials, TMZ, in combination with surgical resection and radiation, was rapidly adopted as the new 
frontline standard-of-care therapy for the treatment of glioblastoma.6,7 TMZ functions by spontaneously 
converting at slightly basic physiological pH to MTIC (is also derived enzymatically from the 
chemotherapeutic dacarbazine). MTIC then spontaneously converts to 4-amino-5-imidazole-carboxamide 
and a methyldiazonium cation, the true active species. Interaction of methyldiazonium cation with DNA 
causes a transfer a methyl group to the O6 position of guanine (mechanism in Figure 4.1). This prompts 
incorporation of thymine during replication, instead of the native cytosine residue. The resultant guanine-
thymine pair initiates a pause in the DNA replication fork, triggering the DNA mismatch repair pathway 
and cell cycle arrest. Frequently the cell is unable to keep up with the DNA mismatch repair, and after futile 
cycles of DNA mismatch repair, apoptosis is triggered.  
 
Figure 4.1. At physiological pH TMZ converts to a reactive methyldiazonium cation that is capable of methylating 
DNA. Methylated DNA will either trigger the cell to undergo apoptosis, or will be repaired by the suicide DNA-repair 
enzyme MGMT, enabling cell survival.  
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4.1.3 Major challenges in the treatment of glioblastoma 
Due to the deadliness, rapid progression, and lack of effective chemotherapeutics for the treatment 
of glioblastoma, even early diagnosis and aggressive treatment do not improve outcomes. The lack of 
available chemotherapeutic options is due primarily to the existence of the blood-brain barrier (BBB). The 
BBB is formed by the brain capillary endothelium and was evolved to protect the brain from toxic entities, 
but unfortunately it prevents most chemotherapeutics from gaining access the site of the glioblastoma 
tumor.11 In fact, since the emergence of chemotherapy in the 1950s, nearly every class of drug has been 
tested and proved ineffective in the clinical management of glioblastoma.12 
One method developed to bypass the BBB is the use of biodegradable polymers, such as Gliadel, 
impregnated with a chemotherapeutic agent, and placed at the site of surgical resection. Developed at John 
Hopkins University by Henry Brem, Gliadel wafers are infused with the nitrosourea alkylating agent 
carmustine.13 Due to the modest activity of carmustine and severity of side effects (in the form of 
myelosuppression and pulmonary fibrosis), it was posited that the local delivery would lead to higher local 
concentrations, thereby enhancing efficacy while limiting side effects.14,15 While a Phase 3 clinical trial 
demonstrated modestly efficacy of the Gliadel wafers, severe toxicities (in the form of brain edema, 
infections and associated seizures) limits its utility in the clinical management of glioblastoma.16  
As described in the above statistics, glioblastoma is a universally lethal cancer. However, 
approximately ~40% of all patients possess methylation in the promoter region of DNA repair enzyme 
MGMT, suppressing the expression of the enzyme and enabling treatment with TMZ to be more effective, 
an effect that is seen in the difference in higher median survival following treatment with TMZ (21.7 months 
compared to 15.3 months).17 MGMT is a suicide DNA repair enzyme that is capable of reversing the 
alkylation by TMZ, in a one-to-one stoichiometry. Thus, patients expressing MGMT derive little to no 
benefit from treatment with TMZ. Efforts have been made to exploit the suicide repair mechanism, 
including dose-dense treatment schedules to deplete the protein population,18 and development of small-
molecule MGMT inhibitors of its activity.19,20 Unfortunately, limited success in these areas has been 
observed. Because TMZ is orally bioavailable and possess limited side-effects, it is prescribed universally, 
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though it is only effective in less than half of the patient population. Therefore, novel chemotherapeutics 
that are capable of penetrating the BBB and initiating apoptosis in glioblastoma cells, regardless of MGMT 
status, are desperately needed. 
 
4.1.4 Rationale for the use of PAC-1 in the treatment of glioblastoma and other brain cancers 
 Greater than 98% of small-molecules do not penetrate the blood-brain barrier, including most 
cytotoxic chemotherapeutics.11 However, early in the development of PAC-1 it was discovered that it did 
penetrate the BBB, a discovery made due to a transient and non-life limiting neuroexcitation following IV 
administration of high doses of the drug.21 When explored quantitatively, PAC-1 was shown to distribute 
between the brain and the blood of a mouse with a 30:70 ratio.22 The maximum ratio of such a distribution 
for a non-concentrating compound would be 50:50. Even TMZ only penetrates to a 17:83 ratio between the 
cerebral spinal fluid and the blood in a human.23 PAC-1, as a single agent, is capable of inducing apoptosis 
in cancer cells and has shown tremendous potential to synergize with diverse cytotoxic chemotherapeutics 
(as described in Chapter 3). When this activity is coupled to its somewhat unique ability to penetrate the 
BBB, PAC-1 has the potential to have a remarkable clinical impact in the treatment of glioblastoma and 
other brain tumors.  
 
4.2 Cell culture evaluations of PAC-1 and TMZ for the treatment of 
glioblastoma and brain cancers 
4.2.1 Evaluation of suitability of procaspase-3 as a molecular target for the treatment of 
glioblastoma 
 The potential of procaspase-3 activation as an anti-brain cancer strategy is provocative as the 
cellular concentrations of procaspase-3 in glioblastoma patient samples have been quantified in the single 
digit micromolar range, elevated well above what is typically found in normal tissues.24 Furthermore, a 
heightened latent (though sub-apoptotic) level of caspase-3 activity has been observed in glioblastoma 
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patient samples and this has been linked to an increased malignant invasion.25 This mild level of caspase-3 
activity is insufficient for the execution of apoptosis, but suggests that PAC-1 may be particularly effective 
in this partially primed pool of procaspase-3/caspase-3, thereby providing the greatest therapeutic benefit 
to patients with the most severe disease.  
 To further investigate and validate the presence of procaspase-3 in brain cancer tumors, the 
Repository for Molecular Brain Neoplasia Data (REMBRANDT) provided by the National Cancer Institute 
(NCI) was used to analyze expression of the CASP3 gene in brain tumor samples and non-tumor controls.26 
Analysis of REMBRANDT Affymetrix gene expression data demonstrates that elevated expression of 
CASP3 correlates with tumor grade (Figure 4.2A). Non-tumor tissues have the lowest relative expression 
of CASP3, whereas glioblastomas have the highest expression from CASP3 (p<0.0001). Low-grader 
astrocytomas and oligodendrogliomas expressed intermediate levels of CASP3. In addition to examining 
gene expression levels in clinical samples, the protein procaspase-3 levels in 10 glioblastoma cell lines were 
analyzed by immunoblotting. All glioblastoma cell lines demonstrate robust expression of procaspase-3 
(Figure 4.2B). 
Figure 4.2. Procaspase-3 is expressed in brain tumors. (A) Analysis of CASP3 expression in the NCI REMBRANDT 
database demonstrates that CASP3 is more highly expressed in brain tumors compared to non-tumor tissues (p<0.0001 
for pair wise comparison between non-tumor and glioblastomas or astrocytomas or oligodendrogliomas). Highest 
expression of CASP3 was observed in glioblastoma, compared to lower expression in low-grade astrocytomas and 
oligodendrogliomas. Pair wise comparison. (B) Immunoblotting demonstrates the presence of high protein levels of 
procaspase-3 in glioblastoma cell lines. Analysis and experiment performed by the Gregory Riggins lab (JHU). 
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4.2.2 High expression of the CASP3 gene correlates with poor survival in glioblastoma 
patients 
Given that preliminary reports have suggested a correlation between procaspase-3 levels and 
activity and increased malignancy, we performed a comprehensive retrospective survey to determine if 
increased CASP3 expression affected prognosis. The REMBRANDT database from the NCI was used to 
analyze how the survival of glioblastoma patients correlates with the expression of caspase genes involved 
in the apoptosis pathway. Expression levels of executioner caspase genes (CASP3, CASP6 and CASP7 for 
the procaspase-3, -6, and -7 proteins, respectively) and initiator caspase genes (CASP8, CASP9 and CASP10 
for the procaspase-8, -9, and -10 proteins, respectively) were analyzed. Kaplan-Meier analysis 
demonstrated a consistent trend that high expression of caspase genes was usually associated with decreased 
survival in GBM patients (Figure 4.3). Interestingly, expression of CASP9 was highly consistent across the 
GBM patients, with only one patient out of 181 exhibiting high CASP9 expression (Figure 4.3E). This 
analysis revealed that glioblastoma patients with higher expression of CASP3 (p=0.0001; Figure 4.3A) had 
significantly shorter survival compared to patients with lower CASP3 expression. The correlation between 
CASP3 gene expression and survival was of greater significance (p=0.0001) than the correlation of any 
other caspase gene and prognosis. This suggests that a compound that directly activates procaspase-3, a 
protein shown to be over-expressed in Figure 4.2A, could have selective antitumor activity, and could 
potentially have the most benefit in the patients with the poorest survival. 
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Figure 4.3. Kaplan Meier analysis of the expression of apoptosis-related caspase genes as prognostic factors for 
survival in glioblastoma patients. (A)-(C) Executioner caspases: CASP3, CASP6, and CASP7. (A) Glioblastoma 
patients with high expression of CASP3 survived significantly shorter (n=107; median=12.5 months) compared to 
those with intermediate CASP3 levels (n=74; median 20.3 months; p=0.0001). (B) High expression of the CASP6 gene 
correlated with poor prognosis at a level of mild significance (p= 0.045). (C) Expression of CASP7 did not correlate 
with survival. (D)-(F) Initiator caspases: CASP8, CASP9, and CASP10. (D) Glioblastoma patients with high CASP8 
expression survived significantly shorter (n=116; median=13 months) compared to those with intermediate CASP8 
levels (n=65; median 18 months; p=0.0082). (E) Expression of CASP9 was primarily unchanged across the GBM 
patients except one patient out of 181 exhibiting high caspase 9 expression and a shortened survival (p=0.14). (F) 
High expression of the CASP10 gene correlated with poor prognosis at a level of mild significance (p=0.023). Analysis 
performed by the Gregory Riggins lab (JHU).  
 
A small panel of other proteins involved in the intrinsic and extrinsic apoptotic pathways were also 
analyzed (Figure 4.4), but their expression did not reach or surpass the significance of CASP3 expression. 
Kaplan Meier survival analysis demonstrated that high expression of FADD and TRADD correlated with 
poor survival in GBM patients whereas no such correlation was found in case of MCL1 and BCL2L1. 
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Figure 4.4. Kaplan Meier analysis of selected apoptosis pathway genes in glioblastoma patients. Analysis for 
apoptosis pathway genes are correlated with poor survival to a mild significance, whereas intrinsic apoptosis pathway 
genes (BCL2L1, MCL1) expression does not predict survival using a Log rank test. (A) Glioblastoma patients with 
high FADD tend to survive shorter (n=51; median=13.3 months) compared to those with intermediate FADD levels 
(n=130; median 15.4 months; p=0.052). (B) Glioblastoma patients with high TRADD survived significantly shorter 
(n=38; median=10.35 months) compared to those with intermediate TRADD levels (n=142; median 15.8 months; 
p=0.0091). Comparison of survival in glioblastoma patients on the basis of expression of genes involved in intrinsic 
apoptosis pathway such as (C) BCL2L1 (p = 0.37) and (D) MCL1 (0.79) did not demonstrate a correlation with 
survival. Analysis performed by the Gregory Riggins lab (JHU).  
 
 
4.2.3 PAC-1 induces death of brain cancer cells in culture  
To assess the potential of procaspase-3 activation with PAC-1 treatment to induce death of brain 
cancer cells, we determined the 72 h IC50 values of PAC-1 in a panel of cell lines, composed of both serum 
grown and oncosphere lines. PAC-1 demonstrated a range of 72 h IC50 values of 1 – 16 µM in serum grown 
lines, while glioblastoma oncosphere cells were killed with IC50 values in range of 17 – 26 µM (Table 4.1). 
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Table 4.1. Cytotoxicity of small-molecules against brain cancer cell lines. 
   Abbreviations: H, human; R, rat; M, mouse 
 
4.2.4 PAC-1 in combination with TMZ synergistically induces apoptosis in glioblastoma cells 
in culture 
After establishing that PAC-1 was cytotoxic as a single agent in brain cancer cell lines, we were 
interested in determining if PAC-1 would be capable of enhancing the activity of the standard-of-care for 
the treatment of glioblastoma, TMZ.  PAC-1 was thus evaluated in combination with TMZ in a small panel 
of glioblastoma cells in culture, including human (U87 and D54) and rat (9L). Excitingly, a supra-additive 
synergistic response was observed (Figure 4.5A-C).  
 
  
Cell line Cancer type MGMT Expression 
PAC-1 72 h 
IC50 (µM) 
TMZ 72 h 
IC50 (µM) 
Carmustine 72 
h IC50 (µM) 
U87 (H) Glioblastoma - 15.2 ± 2.8 >100 111.3 ± 13 
D54 (H) Glioblastoma - 5.5 ± 0.4 65.9 ± 20 41.7 ± 6.9 
U118-MG (H) Glioblastoma Low/+ 27.2 ± 2.6 >100 80.9 ± 7.0 
9L (R) Glioblastoma - 5.7 ± 0.5 >100 21.3 ± 1.6 
GL261 (M) Glioblastoma - 1.3 ± 0.2 >100 29.7 ±1.8 
020913 (H) Glioblastoma (oncosphere) 
 17.7 >1000 ND 
JHH-079 (H) Glioblastoma (oncosphere) 
 18.0 >1000 ND 
JHH136 (H) Glioblastoma (oncosphere) 
 25.8 ND ND 
JHH10168 (H) Glioblastoma (oncosphere) 
 25.2 ND ND 
IOMM-lee (H) Meningioma - 2.2 ± 0.1 11.8 ± 1.3 ND 
KT21MG1 (H) Meningioma  2.5 ± 0.1  13.4 ± 1.8 ND 
STTG1 (H) Astrocytoma  15.3 ± 7.8 >300 ND 
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Figure 4.5. PAC-1 and TMZ induce synergistic cell death in glioblastoma cells. (A)-(C) Glioblastoma cells human 
(A: U87, human; B: D54, human; C: 9L, rat) were treated for 72 h with combinations of PAC-1 and TMZ (assessed 
by Alamar Blue). The horizontal dashed lines represent the level of cell death expected from a mere additive effect of 
compounds. 
 
Additional characterization of synergy between PAC-1 and TMZ in cell culture was evaluated in 
the 9L cells, as a prelude to in vivo studies. Treatment of 9L cells with a combination of PAC-1 and TMZ 
induced apoptosis to a significantly higher degree as compared to either compound alone, as determined by 
Annexin-V-FITC and propidium iodide staining (Figure 4.6A). Furthermore, Western blot analysis of these 
cells demonstrated the presence of substantial cleavage of procaspase-3 and PARP-1, both characteristic 
markers of apoptosis (Figure 4.6B). The PAC-1 and TMZ combination was also assessed for the ability to 
impact the clonogenic potential of 9L cells and a significant decrease in clonogenic survival was observed 
(Figure 4.6C).  
Figure 4.6. PAC-1 and TMZ synergistically induce apoptotic cell death in 9L glioblastoma cells and reduce their 
clonogenic potential. (A) The ability of PAC-1 and TMZ to induce apoptosis was assessed by flow cytometry with 
AnnexinV-FITC and propidium iodide staining after a 48 h treatment. A substantial apoptotic population (FITC + / 
PI -) was observed with the combination treatment. (B) 9L cells treated with PAC-1 and TMZ were analyzed via 
Western blot for the presence of traditional markers of apoptosis: procaspase-3 activation and PARP-1 cleavage, after 
a 48 h treatment with compounds. (C) Combination treatments of PAC-1 and TMZ were assessed for their ability to 
impact the clonogenic potential of 9L cells. Cells were treated for 12 h and then clonogenic growth was assessed after 
7 days. 
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4.3 In vivo evaluations of PAC-1 and TMZ for the treatment of glioblastoma 
and brain cancers 
4.3.1 PAC-1 does not induce off-target activation of procaspase-3 in neurons and glial cells 
As a prelude to evaluations of PAC-1 efficacy in murine models of brain cancers, it was first 
imperative to determine if PAC-1 was damaging to neurons. As a small-molecule capable of both 
penetrating the BBB and inducing apoptosis in cancer cells, there was concern that PAC-1 might be toxic 
to neurons. Such toxicity would severely limit potential for clinical use in the treatment of brain cancers.  
For this study, healthy male and female C57BL/6 mice were administered PAC-1 orally at a dosage 
of 50 mg/kg (as an aqueous suspension) daily for 14 consecutive days. Mice maintained normal behavior 
and body weights throughout the duration of the study, and no clinically observable signs of neuroexcitation 
were detected. Detailed pathologic assessment of brain tissues from male and female C57BL/6 mice also 
did not identify histologic evidence of neuronal inflammation or damage (Figure 4.7D, H). Staining of brain 
tissues for cleaved caspase-3 from mice receiving oral gavage of PAC-1 at 50 mg/kg once daily for 14 
consecutive days did not demonstrate cleaved caspase-3 staining within neuronal cell bodies (Figure 4.7). 
Figure 4.7. In vivo safety of orally-dosed PAC-1. (A) Murine T-cell lymphoma cells treated with staurosporine serve 
as positive control for cleaved caspase-3 immunohistochemical staining, while (B) incubation of primary antibody 
with blocking peptide serve as negative control for cleaved caspase-3 staining. (C) Representative H&E staining of 
mouse brain tissue from untreated control mice. (D) Representative H&E staining of mouse brains from mice treated 
with oral PAC-1 (50 mg/kg) daily for 14 days. (E) Representative cleaved caspase-3 staining of mouse brain tissue 
from untreated control mice. (F) Representative cleaved caspase-3 staining of mouse brains from mice treated with 
oral PAC-1 (50 mg/kg) daily for 14 days. (G) Negative control staining with primary cleaved caspase-3 antibody with 
blocking peptide in brain tissue from untreated control mice and (H) mice treated with oral PAC-1 (50 mg/kg) daily 
for 14 days. Asterisks denote neuronal cell bodies, and ventricular compartment with associated ependymal cells 
indicated with black arrow. Experiment and analysis performed by Timothy M. Fan.  
A
B
C E G
D F H
* * *
* * *
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4.3.2 PAC-1 is efficacious as a single agent in rodent glioblastoma models 
Cell culture experiments demonstrated that PAC-1 was efficacious as a single agent across a panel 
of brain cancer cell lines, including 9L rat glioblastoma cells (72 h IC50 of 5.7 ± 0.5 µM).  Preliminary 
investigations of the single agent efficacy of PAC-1 in vivo were initiated in the highly aggressive syngeneic 
9L rat glioblastoma model. In this experiment, the rats received PAC-1 (50 mg/kg, oral, as an aqueous 
suspension) from day 5 to day 9, and day 12 to day 16, for a total of 10 doses. The median survival in 
control 9L animals was 11.5 days compared to 20 days in PAC-1 treated rats. The ten doses of PAC-1 
provided a 73% increase in median survival suggesting a high anti-glioblastoma activity for PAC-1 as a 
single agent (Figure 4.8A). 
Figure 4.8. Oral PAC-1 is efficacious as a single agent in an intracranial model of glioblastoma. (A) PAC-1 improved 
survival of 9L rats by 73% (p < 0.001). Rats received 10 oral doses (50 mg/kg, in an aqueous oral suspension, days 5-
9 and 12-16), indicated by the blue horizontal line. The median survival of control animals was 11.5 days, compared 
to 20 days in PAC-1 treated animals. 8 rats per group. (B) PAC-1, administered in a gelatin capsules, improved survival 
of 9L rats by 350% (p =0.019), from 17 days to 59 days. Rats received 16 oral doses (50 mg/kg, solid packed into size 
9 capsules, days 3-18), indicated by the blue horizontal line. 5 rats per group. (C) Brains from control rats demonstrate 
extensive tumor formation. (D) Rats treated with PAC-1 (in capsules) demonstrate a significant anti-tumor response 
and almost complete eradication of tumor. The white arrow shows possible presence of histiocytes and hemosiderin. 
Experiment performed by the Gregory Riggins lab (JHU).  
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To simulate human delivery, the efficacy of PAC-1 was then evaluated when administered with 
PAC-1 administered as a solid in gelatin capsules. Rats with intracranial 9L glioblastoma were administered 
PAC-1 (50 mg/kg) in capsules once-a-day for 16 consecutive days beginning on day 3 post-tumor 
implantation. Rats treated with PAC-1 in capsules showed significantly improved survival; the median 
survival for rats treated with PAC-1 capsules (59 days) was 350% longer than for the untreated control rats 
(median survival = 17 days, p = 0.019; Figure 4.8B), and 40% of the animals survived until the end of the 
experiment (day 150). Hematoxylin and eosin staining demonstrated extensive tumor growth in control rats 
(Figure 4.8C), whereas the tumor was almost completely eradicated in rats treated with PAC-1 in capsules 
(Figure 4.8D). Only the brain tissue from PAC-1 treated rats demonstrated the presence of hemosiderin 
(marked arrow) and histiocytes suggesting a treatment effect in these brains.  
 
4.3.3 PAC-1 synergistically improves the efficacy of TMZ in vivo 
Inspired by the cell culture studies demonstrating the ability of PAC-1 to increase the activity of 
TMZ in 9L cells (Figure 4.5C and Figure 5), the combination was investigated in vivo. The ability of PAC-
1 to synergize with TMZ was evaluated in an intracranial 9L (TMZ sensitive, MGMT negative) syngeneic 
model of glioblastoma. In order to examine possible in vivo synergy between PAC-1 and TMZ, the PAC-1 
treatments were limited to 5 times, thereby minimizing its single agent activity. Rats were treated with 
water (vehicle control), PAC-1 as a single agent (50 mg/kg, oral, as an aqueous suspension, days 1-5), TMZ 
as a single agent (50 mg/kg, oral, days 5-9), and the combination of PAC-1 + TMZ. As shown in Figure 
4.9A, minimal dosing of PAC-1 did not alter animal survival (median survival of PAC-1 alone: 13.5 days, 
median survival of vehicle control rats: 14.5 days). TMZ improved the median survival to 20 days. 
Treatment with PAC-1 in combination with TMZ significantly improved the median survival (to 28 days) 
in compared to the control group (p < 0.0001) as well as TMZ only group (p = 0.007), demonstrating 
synergy between PAC-1 and TMZ.  
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In order to evaluate the exciting combination of PAC-1 and TMZ in a second and more clinically 
relevant model, an intracranial xenograft model with oncospheres was conducted. The cell line 020913 
(TMZ sensitive, MGMT negative) grows as oncospheres and forms gliomas that retain the original histo-
pathological and genetic features of the original tumor.27 These cells were used in a xenograft model in 
NOD SCID mice, thereby providing an opportunity for evaluation in a second species of animal. Mice were 
treated with a vehicle control, PAC-1 as a single agent (50 mg/kg, oral, in 10% PEG 400, five days a week 
for 6 weeks beginning on day 12), TMZ as a single agent (50 mg/kg, oral, five days a week for 3 weeks 
beginning day 26), and the combination of PAC-1 + TMZ (Figure 4.9B). Excitingly, the trends seen in 
previous models were observed in the sophisticated oncosphere model. Single agent PAC-1 mildly 
extended survival from 74 days (vehicle treated mice) to 91 days (p = 0.034). TMZ alone was slightly more 
effective, extending survival to 142 days. Use of PAC-1 in combination with TMZ substantially improved 
the median survival to 205 days (p < 0.0001 compared to vehicle, p = 0.0027 compared to TMZ alone).  
Figure 4.9. PAC-1 synergistically enhances the efficacy of TMZ in intracranial models of glioblastoma. (A) 
Combinations of PAC-1 and TMZ synergistically extend survival in intracranial 9L rat glioblastoma. PAC-1 (50 
mg/kg, in an aqueous oral suspension, days 1-5), did not improve survival as a single agent (median survival 13.5 days 
compared to 14.5 days in the control group), but did extend survival when used in combination with TMZ (TMZ alone 
median survival: 20 days, PAC-1 + TMZ median survival: 28 days). The combination of PAC-1 + TMZ extended 
survival to a statistically significant extent compared to control rats (p < 0.0001) and TMZ as a single agent (p = 
0.007). 8 rats per group. (B) Combinations of PAC-1 and TMZ synergistically extend survival in intracranial 
oncosphere-derived glioblastoma in SCID mice. PAC-1 (50 mg/kg, in 10% PEG 400, 5 days a week from day 12-52, 
shown with blue diagonal shading) improved survival from 74 days (control) to 91 days (p = 0.034). TMZ (50 mg/kg, 
5 days a week from day 26-44, shown with red diagonal shading) was more effective and improved survival to 142 
days. The combination of PAC-1 and TMZ was most effective, extending the median survival to 205 days (p = 0.0027 
compared to TMZ, p < 0.0001 compared to control). 5 mice per group. Experiment performed by the Gregory Riggins 
lab (JHU).  
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4.4 Evaluation of PAC-1 and TMZ in canine brain cancer patients 
4.4.1 Evaluation of feasibility and activity of PAC-1 and TMZ in a canine meningioma patient 
 As described earlier, in Chapters 1 and 3, murine models of cancer have been exceptionally useful 
in rapidly and systematically evaluating potential cancer treatment strategies in a controlled manner. 
However, many treatments have achieved success in murine models, but their activity and efficacy has 
failed to be replicated in human cancer patients. Reasons for this have been described earlier, but they center 
on the fact that murine tumor models rely upon rapidly growing, homogeneous tumors, that frequently 
demonstrate limited metastases, and occur in animals with a highly abbreviated life span compared to 
humans.28,29 Thus, the evaluation of anticancer strategies in pets with spontaneous cancers can complement 
induced murine models.30,31 Furthermore, as described in Chapter 3, canine cancer patients offer the 
opportunity to evaluate the feasibility of combining PAC-1 with a full-dose chemotherapeutic treatment. 
With the goals of evaluating the feasibility of PAC-1 in combination with full-dose TMZ, as well as 
anecdotally studying in vivo activity, the combination was evaluated in a canine patient with meningioma 
(Patient H). Meningiomas, like many canine cancers, display a breed-specific enrichment, in this case in  
moderate and long-nosed dog breeds (mesocephalic and ochocephalic dogs).32 As these dogs are extremely 
popular in the United States, there exists a large and clinically untreated patient population, enabling the 
opportunity for evaluation of treatments that could be directly translated into the comparatively smaller 
human meningioma patient population. As PAC-1 had demonstrated single agent activity against 
meningioma cell lines in culture (Table 4.1), we were eager to evaluate it in patients.  Furthermore, 
confirmation of feasibility of combining PAC-1 and TMZ treatments in meningioma patients would provide 
confidence to test the combination in the rarer canine glioblastoma population.  
 Patient H presented with cluster seizures that were determined by MRI to be the result of a large 
(~4 cm3) meningioma (Figure 4.10A). In both humans and canines, meningiomas are treated primarily via 
surgical resection.33 Upon disease recurrence patients are treated with further surgical resection and 
adjuvant radiotherapy. Unfortunately, surgical resection is not possible in all cases. No chemotherapeutic, 
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including TMZ, has shown efficacy in the treatment of relapsed or recurrent human or canine 
meningiomas,34 likely due to high expression of MGMT in the majority of patients.35  Thus, they represent 
a significant unmet clinical need.34 Thus, although Patient H was to be treated with the combination of 
PAC-1 and TMZ (to enable an initial feasibility study), it was not expected that TMZ would be efficacious.  
 Patient H was treated with daily low dose oral PAC-1 (12.5 mg/kg, from days 1-21) with five doses 
of TMZ (100 mg/m2, oral, days 8-12), with 7 days off (Treatment scheme shown in Figure 4.10B). Patient 
H received two cycles of treatment and was analyzed by MRI for a change in tumor burden on day 56. 
Excitingly, calculations indicate that Patient H experienced a 45% reduction in tumor volume (false colored 
images of tumor shown in Figure 4.11). This reduction also relieved the symptoms caused by the presence 
of the large tumor as Patient H experienced an increased quality of life and cessation of seizures.  
 
Figure 4.10. Patient H presented with cluster seizures. (A) MRI revealed that Patient H had a meningioma with a 
volume of ~4 cm3. (B) Patient H was treated with two cycles of daily low-dose metronomic PAC-1 in combination 
with TMZ.  
A B
0Day 8
PAC-1 (12.5 mg/kg daily – 21 doses)
TMZ (100 mg/m2)
2112
7 days off
28
x 2 cycles
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Figure 4.11. Patient H, a canine with a large meningioma responded to treated with PAC-1 and TMZ. Volumetric 
reconstructions indicated a 45% reduction in tumor volume following the two cycles of treatment (described in Figure 
4.10B). False color (green) shows presence and size of tumor from each orientation. Treatment and clinical 
management supervised by Timothy M. Fan. Analysis and volumetric reconstructions performed by Dr. Steve Joslyn 
(UIUC).  
 
The activity observed in the treatment of Patient H’s meningioma is intriguing. As no 
chemotherapeutic had previously demonstrated efficacy in the treatment of meningioma,34  the combination 
of PAC-1 and TMZ could have tremendous clinical impact on non-surgically resectable, typically MGMT 
positive,35,36 meningiomas. Furthermore, as TMZ is not active as a single agent,37 it suggests two 
possibilities for the observed biologic effect: (1) the anticancer synergy between PAC-1 and TMZ was great 
enough to enable an antitumor effect to be observed, or (2) TMZ is not active in meningiomas and all 
efficacy was the result of PAC-1 as a single agent. As meningiomas predominantly express the DNA repair 
enzyme MGMT,35,36 thereby severely limiting the clinical utility of TMZ, the second option may be more 
likely. Due to the popularity in mesocephalic (moderate length nose) and ochocephalic (long-nosed) breeds 
as family-owned pets in the United States and the strong association between cranio-facial morphology and 
brain cancer type,32 canines with spontaneous meningiomas represent a large and clinically untreated 
population to further evaluate the observed efficacy in a controlled clinical trial. Such a trial would enable 
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differentiating between activity derived exclusively from PAC-1 as a single agent and activity resulting 
from the synergistic cell death induced by PAC-1 in combination with TMZ.  
 
4.5 Conclusions  
4.5.1 PAC-1 is active as a single agent, and synergizes in combination, for the treatment of 
glioblastoma and meningioma 
 Brain cancers, particularly glioblastoma, are among the most aggressive and lethal. As cancer 
survival steadily increases for many of the most common cancers, glioblastoma remains exceptionally 
deadly, with a median patient survival of < 15 months.6,7 There exists significant clinical need for novel 
therapeutics with activity in brain cancers, particularly those expressing the DNA repair enzyme MGMT. 
PAC-1 is a BBB permeant small-molecule, capable of initiating apoptosis in cancer cells regardless of 
MGMT status and therefore represents an exciting opportunity. In two murine models of glioblastoma PAC-
1 demonstrated a significant extension in median survival. Furthermore, the known ability of PAC-1 to 
synergize and enhance the activity of cytotoxic chemotherapeutics suggested that it might be capable of 
synergistically enhancing the activity of the standard-of-care drug TMZ. As described in this chapter, the 
combination of PAC-1 and TMZ was indeed synergistic, significantly extending survival in two orthotopic 
models of glioblastoma.  
Excitingly, when a canine patient with naturally occurring meningioma was treated with PAC-1 + 
TMZ, she experienced a significant improvement in quality of life, as well as a 45% reduction in tumor 
burden. Given the rapid lethality of many brain cancers, the quality of life of the patient is of high 
importance clinically. Based upon the synergistic activity observed in the murine models and the feasibility 
of treating a large mammal with the combination, it is expected that a Phase IB trial in human glioblastoma 
patients will be conducted in the near future, combining PAC-1 with the adjuvant dosing phase of TMZ. 
Importantly, because PAC-1 is capable of inducing apoptosis regardless of MGMT status, it is possible that 
it may be capable of increasing survival in the patient population with the poorest prognosis.  
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Use of PAC-1 for the treatment of brain cancers is enabled by its ability to penetrate the BBB.22 
Additionally, metastases of diverse cancers to the brain represent a leading cause of mortality,38 due to the  
lack of options for therapy beyond radiation and surgical resection. As such, PAC-1 may have significant 
potential for the treatment of diverse metastatic diseases. However, as previously mentioned, this BBB 
penetration can be accompanied by transient and non-life limiting neuroexcitation following IV or IP 
administration of high doses of the drug.21 These side effects can be mitigated through oral dosing, but are 
still sufficiently undesirable to suggest design of a compound that does not penetrate the BBB for the 
treatment of non-CNS invasive cancers. As such, efforts have been made to design various non-BBB 
analogues of PAC-1, and one such compounds, S-PAC-1, was shown to be efficacious in a canine 
lymphoma trial.21 Furthermore, the metabolically stable PAC-1 analogues39 are also predicted to be non-
BBB permeable.  Unfortunately, in head to head comparisons, no agent has been capable of displaying 
equal or greater potency than PAC-1 in subcutaneous murine tumor models. Reasons for this are unknown, 
but could be due to an altered distribution to tumor tissue or differing tumor cell penetration.  
Based upon the body of evidence demonstrating the activity of PAC-1 in murine tumor models and 
canine patients, and the lack of evidence of human patients experiencing even minor neuroexcitation, there 
exists no compelling rationale to support progression of a non-BBB permeable PAC-1 at this time. 
Furthermore, during IND-enabling toxicity studies, rats were treated with up to 1 g/kg of PAC-1 without 
demonstration of toxicity, suggesting the possibility of a species-dependent phenotype that might not be 
present in humans. Until PAC-1 has been demonstrated to induce a dose-limiting toxicity in human cancer 
patients, thereby preventing efficacious doses to be used, there exists no reason to actively pursue a non-
BBB permeable analogue.  
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4.6 Materials and methods 
Compounds and cell culture 
TMZ for animal studies was obtained from Johns Hopkins Pharmacy. TMZ for cell culture studies 
was purchased from Selleck. PAC-1 was synthesized as previously reported.40 
GBM oncosphere cells 020913 were a kind gift from Sara Piccirillo and Angelo Vescovi, 
Università degli Studi Bicocca-Millan, Italy. Other glioblastoma oncosphere cells JHH136, JHH 520 and 
JHH079 were generated from patients tissues obtained from Johns Hopkins Hospital using an IRB approved 
protocol. All the glioblastoma oncosphere cells were cultured in serum free medium supplemented with 
EGF (20 ng/ml) and FGF (10 ng/ml) (Peprotech, Rocky Hill, NJ). GBM cell line LN-382 was gifted by Dr. 
Erwin Van Meier at Emory University. 9L cells were a generous gift from Marvin Barker, MD, (University 
of California, San Francisco, Brain Tumor Research Center, San Francisco, CA). The serum grown/ 
adherent cell lines were grown in DMEM supplemented with 10% FBS and 1X Penicillin/Streptomycin. 
All the cells were maintained at 37˚ C in 5% CO2. 
 
Immunoblotting 
Protein lysates from freshly cultured cells (or cells treated as described in the text) was prepared 
using RIPA buffer (50 mM Tris base, 150 mM NaCl, 1% Triton-X 100, 0.5% Na-deoxychloate, 0.1% SDS, 
pH 7.4 with a 1:100 dilution of Protease Inhibitor Cocktail Set III), and clarified.  Protein content was 
normalized by BCA Protein Assay reagent (Pierce).  Samples were denatured, separated by SDS-PAGE (4-
20%) and transferred to a PVDF membrane for Western blot analysis. Antibodies against caspase-3 were 
obtained from Cell Signaling Technology (catalog # 9665, 9662). GAPDH antibody was obtained from 
Santa Cruz Biotech, CA. 
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Cell Proliferation, Apoptosis, and Clonogenic Survival Assays 
Glioblastoma cell proliferation was assessed using an AlamarBlue assay.41 The concentrations of 
PAC-1 used in IC50 determination were spread evenly between 100 µM and1 nM. DMSO was used as a 
vehicle control and the concentration of DMSO was limited to £1%.   
PAC-1 and TMZ were assessed in combination in U87, D54 and 9L cells.  Cells (1,875 per well) 
were treated for 72 h with a range of TMZ concentrations in the presence or absence of three concentrations 
of PAC-1.  At the conclusion of treatment cell growth and viability was assessed by Alamar Blue.   
The ability of PAC-1 and TMZ combinations to induce apoptosis was assessed by Annexin V-
FITC/propidium iodide staining and flow cytometry.  50,000 9L cells were plated in 6-well plates and 
treated with combinations of PAC-1 and TMZ for 48 hours.  At the conclusion of treatment the entire 
contents of each well was transferred to flow cytometry tubes, pelleted, and suspended in 450 µL of 
Annexin V-FITC binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, 1% BSA, pH 7.4), 
premixed with Annexin V-FITC and propidium iodide dyes.  Staining was assessed by flow cytometry 
(10,000 events recorded per sample).   
PAC-1 and TMZ combinations were assessed for their ability to induce procaspase-3 and PARP 
cleavage. 50,000 9L cells were plated in 6-well plates and treated with combinations of PAC-1 and TMZ 
for 48 hours.  At the conclusion of treatment then entire contents of each well was transferred to eppindorf 
tubes, pelleted, and lysed on ice in RIPA buffer (50 mM Tris base, 150 mM NaCl, 1% Triton-X 100, 0.5% 
Na-deoxychloate, 0.1% SDS, pH 7.4 with a 1:100 dilution of Protease Inhibitor Cocktail Set III), and 
clarified.  Protein content was normalized by BCA Protein Assay reagent (Pierce).  Samples were 
denatured, separated by SDS-PAGE (4-20%) and transferred to a PVDF membrane for Western blot 
analysis of procaspase-3 (Cell Signaling #9662) and PARP (Cell Signaling #9542).  Blots were stripped 
and re-probed for β-actin (Cell Signaling #4970) as a loading control. The ability of PAC-1 and TMZ 
combinations to alter clonogenic survival capacity was assessed in 9L cells.  250 cells were plated and 
allowed to adhere for 48 hours prior to treatment with combinations of PAC-1 and TMZ for 12 hours. 
Media was then replaced, plates were sealed with a gas permeable membrane and cells were allowed to 
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grow and form colonies for 7 days.  At the conclusion of colony growth media was removed, cells were 
washed with PBS, stained with 0.05% crystal violet in 6% glutaraldehyde for thirty minutes prior to 
counting of colonies.   
 
Assessment of Cleaved Caspase-3 Activation in Normal Brain Tissue 
Experimental procedures were reviewed and approved by the University of Illinois Institutional 
Animal Care and Use Committee. Mice were treated with oral PAC-1 (50 mg/kg) for 14 days, then 
sacrificed. Cleaved caspase-3 immunohistochemistry was performed on brain tissues to characterize any 
potential for off-target blood-brain barrier penetrant side effects, specifically apoptosis induction of normal 
bystander neurons or glial cells.  Processed brain slides were deparaffinized in xylene and rehydrated in 
alcohol. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol for 15 
minutes, followed by 2 rinses in IHC wash buffer (Biogenex, San Ramon CA) for 5 minutes.  Slides were 
placed in citrate buffer, pH 6, and put into the Decloaker (Biocare Medical, Concord, CA) with deionized 
water.  Slides were cooled in citrate buffer for 2 minutes, and then placed in wash buffer.  Using an 
automatic immunostainer (i6000, Biogenex), non-specific staining was minimized by blocking for 15 
minutes with avidin and biotin.   Slides were then incubated with normal goat serum for 20 minutes at room 
temperature, then incubated with cleaved caspase-3 primary antibody (Cell Signaling, #9661; 1:1250 
dilution) at 4°C for 30 minutes, washed, and then incubated with Supersensitive rabbit link (BioGenex) for 
20 minutes at room temperature.  Slides were again washed and incubated with Supersensitive HRP 
Reagent (BioGenex) for 20 minutes at 22-25°C. The reaction was developed using DAB substrate for 5 
minutes and the slides were then counterstained with Mayer’s hematoxylin.  A murine T-cell lymphoma 
(EL4) cell pellet treated with staurosporine and served as a positive control.  
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9L glioblastoma syngeneic model and glioblastoma oncosphere xenograft model  
All the drug efficacy studies in rodents were approved by the Johns Hopkins Animal Care and Use 
Committee.  
 The 9L model was conducted as described elsewhere.42,43 Briefly, 9L cells were passaged in the 
flank of F344 rats every 3 to 4 weeks.  Tumors were excised from carrier animals, and cut into 1mm3 
pieces and place in sterile 0.9% saline on ice.  The excised tumor was then intracrannially implanted into 
female rats, weight 150-200 g.  Rats were anesthetized and heads were shaved and prepared using 
pvodione-iodine.  A midline scalp incision was made and the coronal and sagittal sutures were identified. 
Using an electric drill, a 3 mm burr hole was made 3 mm lateral to the sagittal suture and 5 mm posterior 
to the coronal suture. The dura was incised sharply and a small amount of cortex and white matter was 
removed with gentle suction.  The excised tumor piece was placed in the cavity. After implantation of 
tumor, the skin was closed with surgical staples. Animals were closely monitored for signs of toxicity, 
including failure to thrive, weight loss, and neurologic deficits. 
For the oncospheres model, NOD SCID mice were anesthetized and a small incision in the skin 
over the cranium was made. A hole was made 1 mm lateral of midline and 1 mm lateral of Bregma over 
the parietal lobe using a surgical drill as described elsewhere.43 After drilling the hole, the animal was placed 
in a stereotactic frame and 360,000 020913 cells were implanted at a depth of 2.5 mm using a Hamilton 
syringe. After implantation, the incision was closed with surgical staples and the animals were allowed to 
recover. Animals were closely monitored for signs of toxicity, including failure to thrive, weight loss, and 
neurologic deficits. 
 
Statistical analysis 
The IC50 values were calculated using Graphpad prism 5.0 or TableCurve. Survival curves were 
made using Graphpad prism 5.0 and log rank test was used to determine the significance. A p value of less 
than 0.05 was regarded as statistically significant. 
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Chapter 5. Development of a small-molecule tool for the rapid induction of 
intrinsic pathway apoptosis  
 
Portions of this chapter are reproduced with permission from literature (Palchaudhuri, R.; 
Lambrecht, M. J.; Botham, R. C.; Partlow, K. C.; Van Ham, T. J.; Putt, K. S.; Nguyen, L. T.; Kim, 
S.-H.; Peterson, R. T.; Fan, T. M.; Hergenrother, P. J. Cell Reports 2015, 13, 2027-2036).  
 
5.1 Introduction 
5.1.1 Small-molecules capable of initiating apoptosis are important for the study of disease 
and have potential for development into therapeutics 
Small-molecules have been indispensable to the study of apoptosis, and the exploitation of 
apoptosis for the treatment of cancer.1-3 As described in Chapters 1 and 3, apoptosis is the primary 
mechanism by which cancer chemotherapeutics exert their activity. Furthermore, even non-clinically useful 
natural products and synthetic small-molecules have proved valuable for the study of apoptosis and 
identification of novel targets for manipulating cellular processes for the treatment of disease. It was with 
these goals that the University of Illinois Heritage Library small-molecule collection was screened for the 
capacity to kill HL-60 human leukemia cell lines during a 24 h treatment with 20 µM compound.  
The small-molecule shown in Figure 5.1A was identified in the screen and subsequently named 
Raptinal based upon the unparalleled speed with which it was able to kill cells.4 This rapid cell death was 
observed to occur within minutes to h of treatment with 10 µM compound and displayed the morphological 
features of apoptosis, including extensive blebbing (Figure 5.1C, 5.1D) and protection with the pan-caspase 
inhibitor Q-VD-OPh (Figure 5.1E). Importantly, this challenged a long held belief that apoptosis required 
several h following the initial pro-apoptotic stimulus (due to rate-limiting steps upstream of cytochrome c 
release, including transcription/translation and cell-cycle dependent responses).5-7 Inspired by the utility 
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PAC-1 as a small-molecule resource for studying stem cell differentiation,8 the role of caspase-3 in 
cardiomyocyte hypertrophy,9 and other biological processes,10,11 we believed that extensive characterization 
of Raptinal could enable it to become the new standard pro-apoptotic control compound for cell biology 
studies. Furthermore, the speed with which Raptinal acts could enable studies that were not previously 
possible, due to minimizing complications from cell cycle status, transcriptional responses and secondary 
unrelated events. As such, Raptinal would have potential for enabling new studies in many areas of human 
health, including cancer,12 heart disease,13 and neurodegeneration.14 Thus, the goal of my work on Raptinal 
was to characterize its potential as a small-molecule tool compound for the study of apoptosis by 
determining whether it rapidly induced classical apoptosis with consistent and predictable activity across 
many cell lines. Furthermore, by using structurally related analogues and dialdehyde containing natural 
products, I sought to characterize how unique the speed of Raptinal-induced cell death was.  
 
 
Figure 5.1. Raptinal induces rapid caspase-dependent apoptosis. (A) Structure of Raptinal. (B-E) Light microscopy 
images of U-937 cells treated with 10 µM Raptinal for 30 minutes (C) and 60 minutes (D) show cellular blebbing that 
is inhibited by the pan-caspase inhibitor Q-VD-OPh (E, 50 µM). Scale bar indicates 20 µm. 
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5.2 Characterization of Raptinal-induced cell death 
5.2.1 Capacity for rapid induction of cell death is limited within a library of small-molecules 
structurally related to Raptinal  
 The structure-activity relationship (SAR) of Raptinal was explored using a small library of 
synthesized derivatives and a collection of commercially available dialdehyde containing small-molecules 
(Figure 5.2). The dialdehyde motif was found to be essential for potent activity (24 h IC50 < 10 µM) within 
the Raptinal scaffold (S1-S11). However, unrelated dialdehyde containing small-molecules (S12-S15) did 
not universally retain activity, suggesting that the activity of Raptinal within a cell was specific to a protein 
target or set of targets.  
 
 Figure 5.2. The IC50 values for Raptinal and derivatives after 24 h treatment of U-937 cells. Data represent the mean 
± SD from 3 independent experiments. Compounds synthesized by Michael Lambrecht.  
 
Related active compounds (24 h IC50 < 10 µM) were further examined by Annexin V-FITC and 
propidium iodide (PI) staining with flow cytometry for their ability to replicate the speed of cell death 
induced by Raptinal (Figure 5.3). Interestingly, both of the tetrahalogenated compounds (chloro-Raptinal, 
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S11, and bromo-Raptinal, S12) demonstrated significantly slower induction of apoptosis than the parental 
Raptinal. This could have been related to the lower concentration of compound used in relation to the 24 h 
IC50 value determined in Figure 5.2 (Raptinal: 0.7 µM, compared to chloro-Raptinal: 4.6 µM and bromo-
Raptinal: 6.5 µM), the tetrahalogenated compounds could have possessed decreased cell permeability, or 
the halogen substituents could have altered interactions with the protein target(s).  
 
Figure 5.3. Time course analysis of apoptosis induced by Raptinal and other active dialdehyde containing small 
molecules. U-937 cells were treated with 10 µM compounds and viability was assessed by Annexin V-FITC and 
propidium iodide staining with flow cytometry. Data points represent the mean ± SD from 3 independent experiments. 
Structures are shown in Figure 5.2. Compounds synthesized by Michael Lambrecht.  
 
Conversely, the dialdehyde natural product polygodial demonstrated remarkable similarity with 
Raptinal in the timing of cell death (20 h timecourse shown in Figure 5.3, 4 h timecourse shown in Figure 
5.4). Use of Annexin V-FITC and PI stain enabled examination of the timing of phsophatidyl serine 
exposure (as visualized with Annexin V-FITC) and loss in membrane integrity (as visualized with PI) for 
the two compounds. When the treatments were compared, the transition from Annexin V (-) / PI (-) to 
Annexin (+) / PI (-) was observed to be much cleaner in the Raptinal treated cells than those treated with 
polygodial. PI (+) cells appear within 30 to 60 minutes following treatment with polygodial, whereas 
Raptinal treatment only yielded PI (+) cell populations following progression through a significant Annexin 
(+) / PI (-) population. This suggests preliminarily that they may be acting through entirely different or only 
overlapping mechanisms. Further characterization with small-molecule protectants and genetic knock-
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down of apoptotic proteins would provide further information regarding the similarities and differences of 
death induced by these two molecules.  
 
 
Figure 5.4. Analysis of cells treated with Raptinal or polygodial. U-937 cells were treated with 10 µM compound and 
assessed by Annexin V-FITC and PI staining with flow cytometry. (A) Time course analysis until complete cell death 
induced by 10 µM Raptinal or polygodial. Data points represent the mean ± SD from 3 independent experiments. 
Same data as shown in Figure 5.3. (B) Annexin V-FITC and PI stained cell populations demonstrate that Raptinal and 
polygodial differ in the timing inducing loss of membrane permeability. Structures are shown in Figure 5.2. 
Compounds synthesized by Michael Lambrecht. 
 
 
5.2.2 Raptinal-induced cell death is consistent across a panel of cell lines 
 In order for a small-molecule tool to be useful as a cell biology resource, it must possess consistent 
activity across a variety cell lines. The 24 h IC50 value was thus established in a small panel of normal and 
cancer cell lines (Table 5.1). Raptinal displayed consistent potency across the cell lines, with an IC50 of ~1 
µM in all cancer cells lines and ~3 µM in the cell lines derived from non-cancerous tissues. The slight 
difference in potency between normal and cancer cell lines is likely due to the fact that cancerous cells are 
typically closer to the apoptotic threshold than normal cells.15 This effect is exploited in vivo and is 
responsible for the therapeutic window of many cancer chemotherapeutics.16,17   
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Table 5.1. Raptinal toxicity in various cell lines. The IC50 values of Raptinal against normal and cancer cell lines was 
assessed after a 24 h incubation. Data represent the mean ± SD from three independent experiments.  
 
 
 
 
 
 
 
5.2.3 Raptinal rapidly induces apoptosis in adherent cell lines  
 Adherent cell lines are notoriously more resistant to common pro-apoptotic small-molecules in 
comparison to suspension cell lines. This resistance is the primary reason product sheets for methods to 
study apoptosis utilize suspension cell lines. Therefore, in order for Raptinal to be generally useful to cell 
biologists it must be capable to inducing apoptosis with comparable or greater speed than other commonly 
used rapid initiators of cell death. In a panel of >20 cytotoxins evaluated in U-937 cells, Raptinal was 
markedly the fastest inducer of apoptosis.4  Staurosporine and 1541B were the next fastest agents.  To assess 
the consistency of Raptinal’s speed to apoptosis across other cell lines, we examined the ability of Raptinal 
to induce apoptosis relative to staurosporine and 1541B in a small panel of adherent cell lines. We 
determined both the timing of cell death induced by these agents, as well as compared the extent of apoptotic 
markers (cleavage of PARP-1 and procaspase-3) by Western blot (Figure 5.5). Raptinal was consistently 
the fastest small-molecule inducer of apoptosis across the panel. Interestingly, staurosporine and 1541B 
were less consistent in uniformly inducing apoptosis within the experimental time course, and in many 
cases never achieved 100% cell death within the 24 h analysis. Although staurosporine was the second 
fastest inducer of apoptosis in HOS, SK-MEL-5 and MIA PaCa-2 cells, it was less active in H1993 cells, 
requiring > 15 h to induce >50% cell death.  
 
 
 
Cell line Cell type Average IC50 (µM) 
HFF-1 Human foreskin fibroblast 3.3 ± 0.2 
MCF10A Human breast tissue 3.0 ± 0.2 
BT-549 Human breast cancer 1.3 ± 0.4 
MDA-MD-436 Human breast cancer 1.1 ± 0.1 
143B Human osteosarcoma 1.2 ± 0.5 
HOS Human osteosarcoma 1.0 ± 0.1 
H460 Human lung cancer 1.1 ± 0.1 
H1993 Human lung cancer 1.2 ± 0.1 
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Figure 5.5. Raptinal induces apoptosis in adherent cell lines more rapidly than 1541B or staurosporine. (A) Time 
course analysis of adherent cell viability upon treatment with Raptinal, 1541B, and staurosporine (all tested at 10 µM). 
Annexin V-FITC and PI staining with flow cytometry. Data points represent the mean ± SD from 3 independent 
experiments. (B) Immunoblots of adherent HOS, H1993, SK-MEL-5 and MIA PaCa-2 cells show cleavage of PARP-
1 and activation of procaspase-3 by 10 µM Raptinal but not other cytotoxins (all tested at 10 µM) after 2 h. 
 
5.2.4 Raptinal induces rapid apoptosis, without markers of alternative cell death pathways 
 In order for a pro-apoptotic tool to have value in cell biology, it must be capable of eliciting its 
desired activity without perturbing other, and unrelated, cellular processes. Staurosporine, a broad spectrum 
kinase inhibitor has been the literature standard pro-apoptotic control compound for decades. Its 
employment has enabled identification of fundamental regulators of the apoptotic pathway,18 CAD/ICAD,19 
AIF,20 and identification of cellular caspase protein substrates.21-23 Unfortunately, activation of the apoptotic 
pathway through broad spectrum kinase inhibition possesses inherent complications. For example, 
staurosporine was used in a proteomic study to identify a possible relationship between protein 
phosphorylation status and being a substrate for caspase cleavage during apoptosis.22 Although the authors 
argued that staurosporine-induced apoptosis was rapid enough to not alter the phosphorylation status of 
proteins, its use of a kinase inhibitor calls into question the reliability of the findings. Furthermore, 
staurosporine is a relatively expensive small-molecule ($100/mg), is light-sensitive, and is prone to 
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degradation. These characteristics decrease its experimental reproducibility. Therefore, there exists a great 
need for a small-molecule capable of cleanly inducing rapid apoptosis, that is, without activation of other 
cellular pathways, to enable further studies of this critical cellular process. Thus, Raptinal was evaluated 
for the capacity to induce pyroptosis, necroptosis and ferroptosis. As described below, cell death induced 
by Raptinal did not induces these cellular processes, and appeared consistent with clean mitochondrial-
mediated intrinsic pathway apoptosis.  
 Pyroptosis, or pyronecrosis, is a caspase-1 dependent inflammatory cell death process.24 Pyroptosis 
can be stimulated by various pathological stimuli including stroke, heart attack and microbial infections. 
Pyroptosis induces nuclear fragmentation, pore formation and release of cellular contents. In order to 
investigate a role of pyroptosis and caspase-1 in Raptinal-induced cell death, U-937 cells were treated with 
10 µM Raptinal and monitored by Western blot for cleavage of procaspases-1, 3 and 9, and, as marker of 
apoptosis, cleavage of PARP-1 (Figure 5.6). Consistent with mitochondrial-mediated intrinsic pathway 
apoptosis, procaspase-9 was cleaved to caspase-9 first. Active caspase-9 (as part of the apoptosome) was 
likely responsible for cleavage of procaspase-3 to caspase-3. Low levels of cleaved caspase-3 were 
accompanied by cleavage of PARP-1, a sensitive marker for active caspase-3 within a cell. Near complete 
cleavage of procaspase-3 was apparent by 40 minutes post-treatment. In contrast, caspase-1 bands were 
never observed, even with significant over-exposure of the blot. Furthermore, cleavage of procaspase-1 
bands was extremely limited over the course of experiment. Investigations at later time points would have 
had limited value given that the flow cytometry analysis (Figures 5.3 and 5.4) demonstrated that U-937 
cells treated with 10 µM Raptinal are fully apoptotic within 1-2 h.  
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Figure 5.6. Raptinal induced apoptosis does not include caspase-1 dependent pyroptosis. U-937 cells treated with 10 
µM Raptinal and monitored by immunoblotting demonstrate substantial cleavage of procaspase-9 to caspase-9 within 
20 minutes and cleavage of procaspase-3 to caspase-3 within 20 minutes. Evidence of caspase-3 activity (in the form 
of cleavage of PARP-1) appears within 20 minutes. No caspase-1 bands were present and limited procaspase-1 
cleavage was observed.   
 
 Raptinal-induced cell death was next investigated for involvement of necroptosis. Necroptosis is a 
caspase-independent form of programmed necrosis.25 Typically necroptosis is stimulated through the 
TNFR1 receptor (by TNFa). TNFR1 stimulation triggers key events, including activation of RIPK1 and 
recruitment of RIPK3 to form the necrosome. The necrosome phosphorylates MLKL, a process which 
drives oligomerization and insertion of the complex into the cellular membranes. Necroptosis can be 
prevented with an inhibitor of RIPK1, necrostatin-1 (Figure 5.7A). Key requirements for defining cell death 
as occurring through necroptosis include protection with necrostatin-1 and observation of phosphorylation 
of MLKL. To investigate whether or not Raptinal-induced cell death could be prevented with necrostatin-
1, U-937 cells were pre-treated for 2 h with necrostatin-1 and then exposed to 10 µM Raptinal for 2 h. Cells 
were assessed by Annexin V-FITC and PI staining for viability. As expected, a 2 h treatment with Raptinal 
reduced cell viability by >80%. Pre-treatment with necrostatin-1 conferred minimal protection, providing 
evidence that necroptosis is not involved in Raptinal-induced cell death (Figure 5.7B). To further 
investigate the potential for overlap with the necroptosis cell death pathway, cells were examined for 
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phosyphoylation of MLKL. As seen in Figure 5.7C, MLKL was not phosphorylated in Raptinal-treated 
cells. This lack of phosphorylated MLKL is in contrast to cells that were triggered to undergo necroptosis 
by stimulation of TNFR1 with TNFa, under conditions of caspase inhibition (with pan caspase inhibitor 
Q-VD-OPh). 
 
Figure 5.7. Raptinal induced apoptosis does not include elements of necroptosis. (A) Structure of necrostatin-1. (B) 
U-937 cells were pre-treated with 30 µM necrostatin-1 and then treated with 10 µM Raptinal. Minimal (<15%) 
protection was observed. Data points represent the mean ± SD from 3 independent experiments. (C) U-937 cells 
treated with 10 µM Raptinal do not show phosphorylation of MLKL, whereas cells induced to undergo necroptosis 
(with 50 µM Q-VD-OPh, 20 µg/ml cycloheximide and 10 ng/ml TNFa), demonstrate MLKL phosphorylation within 
1 h of treatment with TNFa.  
 
 A relatively recently discovered form of programmed cell death is ferroptosis. Ferroptosis, named 
for its iron dependence, was identified as the mode-of-action of a class of compounds capable of eliciting 
cell death specifically in RAS mutant tumor cells.26 Ferroptosis can be identified via protection with the 
small-molecule ferrostatin-1 (Figure 5.8A). To examine a possible role for ferroptosis in Raptinal-induced 
cell death, U-937 cells were pre-treated for 2 h with ferrostatin-1 and then exposed to 10 µM Raptinal for 
2 h. Cells were assessed by Annexin V-FITC and PI staining for viability. As expected, a 2 h treatment with 
Raptinal reduced cell viability by >80%. Similar to cell death induced by H2O2, rotenone and 
staurosporine,26 pre-treatment with ferrostatin-1 conferred <10% protection, providing evidence that 
ferroptosis is not involved in Raptinal-induced cell death (Figure 5.8B).  
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Figure 5.8. Raptinal induced apoptosis does not include elements of ferroptosis. (A) Structure of ferrostatin-1. (B) U-
937 cells were pre-treated with 2 µM ferrostatin-1 and then treated with 10 µM Raptinal. Minimal (<10%) protection 
was observed. Data points represent the mean ± SD from 3 independent experiments. 
 
5.2.5 Raptinal does not directly activate procaspase-3 in vitro 
 Given the exceptional and unprecedented speed with which Raptinal is capable of inducing 
apoptosis and activating executioner caspases, it was important to determine whether Raptinal had a direct 
effect on the activation of procaspase-3. As shown in Figure 5.9, even treatments with 100 µM Raptinal for 
4 h, did not alter the activity of recombinant expressed procaspase-3.  As expected, the small-molecule 
1541B27 induced activation of procaspase-3.   
Figure 5.9. Raptinal, unlike 1541B, does not directly activate recombinant procaspase-3 in vitro. 250 nM procaspase-
3 was treated with increasing concentrations of Raptinal (0, 10, 25, 50 and 100 µM) and 25 µM 1541B, and assessed 
for activity over time. Experiment performed in caspase activity buffer (50 mM HEPES, 50 mM KCl, 0.1 mM EDTA, 
10 mM DTT, 0.01% Triton X-100, pH 7.4) and activity assessed by cleavage of Ac-DEVD-AFC (50 µM) at designated 
time points.  
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5.3 Use of Raptinal as a tool to study apoptosis 
 
5.3.1 Investigations of the role of mitochondrial function in time and extent of apoptosis  
 The mitochondria are critical to intrinsic pathway apoptosis. Upstream of the mitochondria, the 
ratio of pro- and anti-apoptotic Bcl-2 proteins can determine whether or not a cancer cell treated with 
chemotherapeutics will die. Translocation and oligomerization of pro-apoptotic Bcl-2 proteins Bax and Bak 
is critical for the release of cytochrome c from the mitochondria and subsequent apoptosome formation. 
Using Raptinal, we were interested in investigating the role of mitochondrial function in rapid apoptosis. 
For these studies, a panel of small-molecule inhibitors that target the mitochondria were investigated, 
including inhibitors of respiration, the electron transport chain, and components of the mitochondrial 
transition pore. The pan-caspase inhibitor Q-VD-OPh was included as a positive control for protection. 
Cells were pretreated with the putative protective agents for 2 h, at optimized concentrations, and 
subsequently incubated with Raptinal (10 µM) for an additional 2 h, at which point cell viability was 
assessed by Annexin V-FITC and PI staining in order to identify agents critical to rapid apoptosis induction. 
Excitingly, several of the compounds that affect mitochondrial function were able to afford significant to 
quantitative protection from Raptinal (Figure 5.10A). DIDS, a covalent inhibitor of the voltage-dependent 
anion channel (VDAC), afforded significant protection from apoptosis.28,29 A mitochondrial respiration 
uncoupler (FCCP), electron transport chain inhibitors of complex I (rotenone), complex III (antimycin A), 
complex IV (sodium azide and potassium cyanide), and the ATP synthase inhibitor (oligomycin A) all 
provided significant to quantitative protection. Interestingly, complex II inhibition by TTFA or atpenin A5 
did not confer significant protection in contrast to complex I, III, and IV inhibition.  
 To further study the role of mitochondrial voltage-dependent anion function and respiration in 
protection from cell death, cytochrome c release at 1 and 2 h was evaluated in the presence of mitochondrial 
inhibitors. Immunoblots of mitochondrial and cytosolic fractions revealed that the small molecules that 
afforded protection in Figure 5.10A were able to delay Raptinal-induced cytochrome c release and 
subsequent caspase-9 activation (Figure 5.10B, C). These results are consistent with previous suggestions 
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that proton transport may be required for Bax-mediated mitochondrial outer membrane permeabilization.30 
However, when cells pre-treated with mitochondrial inhibitors were monitored for Raptinal-induced 
executioner caspase-3/-7 activity for up to 6 h, it appeared that these inhibitors of mitochondrial function 
were simply delaying the onset on apoptosis, rather than preventing it from occurring (Figure 5.10D). This 
may be due to the critical role of mitochondrial respiration in cell viability and that insufficient levels of 
mitochondrial poisons were able to be used. However, utilization of a variety of small molecule modulators 
in combination with rapid induction of the intrinsic pathway by Raptinal has helped to further validate the 
importance of voltage-dependent anion channel, coupled mitochondrial respiration, electron transport chain 
function, and ATP synthase activity in apoptosis induction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Rapid Raptinal-induced apoptosis requires functional mitochondria. (A) U-937 cells pre-treated with 
potential cyto-protective inhibitors mitochondrial function were treated with 10 µM Raptinal for 2 h, and protection 
from Raptinal was assessed by Annexin V-FITC and PI staining with flow cytometry. Data points represent the mean 
± SD from 3 independent experiments. *p values <0.05. Experiment performed by Rahul Palcaudhuri and Michael 
Lambrecht. (B-C) Protective mitochondrial agents retard cytochrome c release and caspase-9 activation in U-937 cells 
evaluated after 1 h (B) or 2 h (C) treatment with 10 µM Raptinal. (D) Protective mitochondrial agents retard 
executioner caspase-3/-7 activity in U-937 cells evaluated for 6 h following treatment with 10 µM Raptinal.  
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5.4 Conclusions 
 
5.4.1 Raptinal as a pro-apoptotic small-molecule tool for cell biology studies 
 As described in this chapter, Raptinal is a small-molecule capable of inducing apoptosis in many 
different cell lines within 1-2 h, and even faster in most suspension cell lines. Raptinal induced apoptosis 
occurs with exposure of phosphatidyl serine prior to loss in membrane integrity (Figure 5.4) and does not 
present with markers of pyroptosis (Figure 5.6), necroptosis (Figure 5.7) or ferroptosis (Figure 5.8). 
Furthermore, it is consistently the fastest agent to induce apoptosis, even in cell lines that are more resistant 
to other stimuli (Figure 5.5). Based upon the extensive characterization, the consistent and predictable 
activity, and the ease of synthesis, we envision Raptinal being quickly adopted as a new control compound 
for cell biology studies.  
 
5.4.2 Use of Raptinal for the clinical management of cancer 
 Initiation of intrinsic pathway apoptosis is the primary mechanism by which cancer 
chemotherapeutics achieve their activity. However, these agents vary greatly in their potency and timing of 
apoptotic induction. Raptinal was determined to initiate apoptosis with unparalleled speed in comparison 
to a panel of 25 clinical and pre-clinical cytotoxic agents.4 As such we believe that Raptinal might be 
particularly useful for the treatment of cancer in instances where a given concentration (10 µM) could be 
maintained for a period of 1-2 h. Extensive studies in vitro have shown this to be sufficient to achieve near 
complete cell death in the time immediately following the treatment. One such opportunity occurs in the 
treatment of non-muscle invasive bladder cancers (NMIBC).31 NMIBC patients undergo surgical resection 
of the tumor, followed by a localized chemotherapeutic treatment. The patient arrives for chemotherapy in 
a relatively dehydrated state and their bladder is filled via catheter with a solution of the chemotherapeutic 
(typically 40 mg mitomycin C in 20 ml saline) for 2 h, after which the bladder is drained. Although mild 
dilution occurs over the time period, the patients are treated with ~6 mM mitomycin C for 2 h. Given the 
enhanced speed of apoptosis induced by Raptinal over mitomycin C (time to 50% cell death with 10 µM 
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compound is ~20 h, compared to 1.5 h with Raptinal), we believe that Raptinal might have an opportunity 
to greatly improve therapeutic outcomes in NMIBC patients.  
 A second situation of localized chemotherapeutic delivery occurs with polymer wafers, 
impregnated with chemotherapeutic, and placed at the site of tumor surgical resection. An example of these 
were described in Chapter 4: Gliadel wafers, impregnated with the nitrosourea carmustine, and placed at 
the site of glioblastoma surgical resection.32 Carmustine was originally selected for use in the wafers based 
upon demonstration of mild activity in the treatment of glioblastoma, an exceptionally short half-life, and 
severe toxicity during systemic delivery.33 However, although Gliadel wafers are able to provide extended 
delivery of the chemotherapeutic, they are only mildly effective in patients. In addition to being able to 
initiate cell death faster than both chemotherapeutics used in the treatment of glioblastoma (carmustine and 
temozolomide), Raptinal is also more potent following short (24 h), intermediate (72 h) and long (7 day) 
treatments (as shown in Figure 5.11). This suggests that creation of polymer wafers impregnated with 
Raptinal could be more effective in the treatment of glioblastoma than currently used chemotherapeutics.  
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Figure 5.11. Raptinal is more potent at killing glioblastoma cells following short (24 h), intermediate (72 h) and long 
(7 day) treatments than clinically used chemotherapeutics carmustine (BCNU) and temozolomide (TMZ). (A-C) 
Treatment of U87 human glioblastoma cells with Raptinal, BCNU or TMZ for 24 h (A), 72 h (B) or 7 days (C). (D-
F) Treatment of T98G human glioblastoma cells with Raptinal, BCNU or TMZ for 24 h (A), 72 h (B) or 7 days (C). 
Data points represent the mean ± SD from 3 independent experiments. 
 
As described in the two examples above, we believe that Raptinal might be most clinically useful 
in contexts where its unique ability to induce rapid cell death could be exploited. Although many cellular 
modes of resistance can limit the ability of a pro-apoptotic chemotherapeutic to be efficacious in vivo, >24 
cell lines have been treated with Raptinal and all have been susceptible. As such, we believe that with the 
appropriate administration routes, Raptinal could be extremely useful in the clinical management of cancer.   
 
5.5 Materials and methods 
 
Cell culture conditions  
All cells were grown in RPMI 1640, DMEM or EMEM media supplemented with 10% FBS, 1% 
penicillin-streptomycin and incubated at 37 ºC in 5% CO2, 95% humidity incubator. 
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Reagents for Biological Experiments  
 
All immunoblotting antibodies (for human PARP-1, caspase-3, caspase-8, caspase-9, caspase-1, 
cytochrome c, phosphor-MLKL, actin and cox IV) were purchased from Cell Signaling Technologies. Full-
length recombinant Bid was purchased from R&D Systems. Human TNFα was purchased from PeproTech. 
Annexin V-FITC conjugate was obtained from Southern Biotech. Propidium iodide, sulforhodamine B, 
staurosporine, rotenone, antimycin A, oligomycin A, potassium cyanide, sodium azide, TTFA, FCCP, 
DIDS, cyclosporine A, sodium fluoride, and cycloheximide were obtained from Sigma Aldrich. Q-VD-
OPh was obtained from Calbiochem. Atpenin A5 was purchased from Cayman Chemical. MTS was 
purchased from Promega Inc.  
 
MTS assay for suspension cells  
Serial dilutions of compound in 100% DMSO were added in triplicate (2 µL to each well) to empty 
wells of a 96-well plate. U-937 suspension cells in RPMI 1640 media were added to 96-well plates (198 
µL containing 4 x 104 cells) and the cells incubated for 24 h. A solution containing the soluble tetrazolium 
salt ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner 
salt; MTS) and the electron coupling reagent, phenazine methosulfate (PMS) was prepared according to the 
manufacturer’s instructions (Promega) and 20 µL added to each well. The plates were incubated at 37 ºC 
for 15-45 min and the absorbance at 490 nm was measured using a SpectraMax Plus 384 well plate reader 
(Molecular Devices, Sunnyvale CA). The mean IC50 values and standard deviations were determined from 
three independent experiments.  
 
Sulforhodamine B assay for adherent cells  
Serial dilutions of compound in 100% DMSO were added in triplicate (2 µL to each well) to empty 
wells of a 96-well plate. Adherent cells (MCF10A, HFF-1, BT-549, MDA-MB-436, 143B, HOS, H460, 
H1993) cells were added to each well (5 x 103 cells in 198 µL of RPMI 1640, DMEM or EMEM media). 
The plates were incubated for 24 h. The media was removed from the plate and ice-cold trichloroacetic acid 
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(100 µL of 10% w/v trichloroacetic acid) was added to the plates which were then incubated at 4 ºC 
overnight to fix the cells. The trichloroacetic acid was removed and the wells washed with 200 µL of de-
ionized water 5 times. Sulforhodamine B (200 µL of 0.04 % sodium salt dissolved in 1% acetic acid) was 
added to each well and the plates incubated at room temperature for 30 min. Excess sulforhodamine B was 
removed by washing the plates 5 times with 1% acetic acid. The bound dye was released by the addition of 
unbuffered Tris-base (200 µL of 10 mM solution) and after a 30 min incubation at room temperature the 
absorbance at 510 nm was measured (Molecular Devices SpectraMax Plus 384 plate reader). The mean 
IC50 values and standard deviations were determined from three independent experiments. 
 
Immunoblotting  
U-937 cells (3 x 106 cells in 2 mL RPMI) were treated with compound (1% final DMSO v/v) for 
the appropriate period of time. After centrifugation and washing with PBS, cells were lysed with RIPA lysis 
buffer containing protease cocktail inhibitor III (Calbiochem) and cell debris removed by centrifugation 
(16000xg 5 min). The lysate concentrations were normalized after determination of protein concentration 
by the Bradford assay and whole cell lysate (40-60 µg) was resolved by 4-20% gradient SDS-PAGE gel 
electrophoresis at 120 V for 70 min after which proteins were transferred onto PVDF membranes (60 V for 
2 h) and blocked in 5% BSA or fat-free milk in TBST (as per primary antibody manufacturer’s instructions) 
overnight at 4 ºC. The membranes were blotted for molecules of interest with primary antibody (1:1000 in 
2% BSA or milk in TBST) overnight at 4 ºC. The bound primary antibodies were detected using appropriate 
secondary HRP conjugated antibodies (1:5000 in TBST) for 1 h at room temperature and visualized by 
ECL autoradiography or with an Image Quant LAS 4010. The membranes were stripped in acidic methanol, 
blocked and re-probed as necessary.  
 
Induction of Necroptosis and Observation of Phospho-MLKL by Immunoblot  
U-937 cells (1 x 106 cells in 1 mL RPMI) were pre-treated with Q-VD-OPh (50 µM) for 30 minutes. 
Cells were then treated with TNFα (10 ng/ml) in the presence of cycloheximide (20 µg/ml) for (1% final 
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DMSO v/v) for the appropriate period of time. After centrifugation and washing with PBS, cells were lysed 
with RIPA lysis buffer containing protease cocktail inhibitor III (Calbiochem) and Phosphatase Inhibitor 
IV (BioVision). Samples were further processed for immunblot analysis as described above.  
 
Cell morphology by light microscopy  
Phase contrast images of U-937 cells treated with 10 µM Raptinal were taken with an Olympus 
DP-21 microscope digital camera. The cells were kept warm between images by returning the plate to the 
37°C incubator. 
 
In vitro activation of procaspase-3  
Procaspase-3 was expressed as described previously and purified with Qiagen nickel-NTA resin.34 
Increasing concentrations of Raptinal (0, 10, 25, 50 and 100 µM) and 25 µM 1541B were assessed for their 
capacity to enhance the activity of procaspase-3 over time. 250 nM procaspase-3 was treated with 
compounds in caspase activity buffer (50 mM HEPES, 50 mM KCl, 0.1 mM EDTA, 10 mM DTT, 0.01% 
Triton X-100, pH 7.4) and activity was assessed by cleavage of Ac-DEVD-AFC (50 µM) at designated time 
points.  
 
Protection assays using small molecule inhibitors  
For protection assays, U-937 cells (0.5 x 106 cells/mL) were pretreated with the prospective 
protective agents for 2 h at the following concentrations: Sodium fluoride (1 mM), cyclosporine A (10 µM), 
oligomycin A (10 µM), FCCP (10 µM), TTFA (1 mM), atpenin A5 (1 µM), rotenone (200 µM), potassium 
cyanide (1 mM), sodium azide (1 mM) antimycin A (100 µM), sodium pyruvate (5 mM), DIDS (2 mM), 
and Q-VD-OPh (50 µM). The cells were then co-treated with Raptinal at 10 µM for 1 or 2 h prior to analysis 
by propidium iodide/FITC-annexin V staining and flow cytometry or immunoblot analysis for cytochrome 
c release and procaspase-9 activation. 
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Cytochrome c release by immunoblot  
U-937 cells (3 x 106 cells in 2 mL RPMI) were treated protectants as described above. Cells were 
centrifuged (1000xg. 2 min), washed with ice-cold PBS and resuspended in cold 50 µL digitonin 
permeabilization buffer (75 mM NaCl, 1 mM Sodium phosphate monobasic, 8 mM sodium phosphate 
dibasic, 250 mM sucrose, 190 µg/mL digitonin, protease cocktail inhibitor, pH 7.5) and placed on ice for 5 
min. Cell permeability (> 95%) was confirmed by trypan blue. The permeabilized cells were centrifuged 
(14000xg, 5 min) and 40 µL of supernatant (cytosolic fraction) was saved. The pellet (mitochondrial 
fraction) was washed in 200 µL digitonin permeabilization buffer and lysed in 50 µL RIPA lysis buffer. 
After normalizing samples for protein concentration, ~40 µg of cytosolic and mitochondrial protein was 
resolved by electrophoresis on 4-20% SDS-PAGE gels and immunoblotted for caspase-9 and cytochrome 
c respectively. Cytosolic immunoblots were re-probed for actin while mitochondrial immunoblots were re-
probed with cox IV to confirm equal loading.  
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